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Abstract 
 
 
Background: The prevalence of diabetes is increasing worldwide, and Indonesia is 
among the top ten countries with the highest number of people with diabetes. The 
Indonesian Government has included diabetes as a national health priority area. 
Starting in 2014, Jaminan Kesehatan Nasional – JKN (National Health Insurance) 
will be implemented to provide subsidised healthcare for the entire population. While 
Indonesia has a major deficiency in its health workforce, optimising the use of its 
current healthcare resources, including community pharmacists, will be paramount in 
improving access to appropriate diabetes care.  
 
Objectives: This study aimed to evaluate community pharmacy-based services for 
type 2 diabetes patients with regard to current practice, views on community 
pharmacists’ roles, and factors essential to further service development for these 
patients. This was used to develop a model of services for type 2 diabetes patients 
within the Indonesian community pharmacy setting.  
 
Methods: Questionnaire surveys and interviews (a qualitative approach) were used 
to obtain data from three main stakeholder groups, i.e. pharmacists, patients and 
doctors.  
 
The pharmacist survey - A questionnaire was administered to pharmacists from a 
random sample of 400 community pharmacies in Surabaya, Indonesia. Current 
practice and views on future roles were rated using Likert scales, while an open-
ended question was used to identify priority roles. Logistic regression models were 
employed to identify characteristic factors associated with current practice. SPSS 
version 19.0 was used to assist with data analysis. 
 
The patient survey – A questionnaire survey was conducted in ten community 
pharmacies (each with more than 50 diabetic patients per month) that were 
purposefully selected to include different geographical areas and socio-economic 
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levels within Surabaya, Indonesia. Each pharmacy was requested to recruit 
approximately 20 patients when they were seeking oral antidiabetic medications. 
Usage of pharmacy services was identified using binary responses (‘yes’/’no’) and 
views on pharmacists’ roles were rated using Likert scales, while an open-ended 
question was used to identify priority roles. Logistic regression models were 
employed to identify characteristic factors associated with patient views of 
pharmacists’ roles. SPSS version 19.0 was used to perform the analysis. 
 
The qualitative study – In depth face-to-face interviews were conducted with ten 
doctors and ten pharmacists in Surabaya, Indonesia. They were purposefully selected 
to include a broad variety of practice settings within the sample. A semi-structured 
interview guide was used to explore current practice, views on pharmacists’ roles 
and factors contributing to the development of pharmacy-based services for type 2 
diabetes patients. Nvivo version 9 was used to facilitate thematic content analysis of 
the data.   
 
Results:  
The pharmacist survey - A response rate of 60% (240/400) was achieved. 
Community pharmacies mainly provided basic services of dispensing (100%) and 
education on directions for use of medications (72.6%). All community pharmacists 
viewed dispensing as part of their roles, and more than half of the pharmacists 
believed that they should provide services beyond dispensing. Services perceived as 
priorities included: education related to medications [i.e. directions for use (58.6%), 
common/important adverse effects (25.7%)], lifestyle education [i.e. exercise 
(36.5%), diet (47.7%)], and monitoring compliance with medications (27.9%). 
Facilitators for providing some services beyond dispensing included pharmacists’ 
positive views, diabetes training, high pharmacist availability, higher number of 
diabetes customers, being set within a doctor’s clinic, or availability of a counselling 
area/room, while low pharmacist availability acted as a barrier. 
 
The patient survey – A total of 196 pharmacy clients with type 2 diabetes responded. 
Community pharmacies were mainly utilised for the basic services of dispensing 
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(100%) and education on directions for use of medications (79.6%). Almost all 
patients viewed dispensing as a part of community pharmacists’ roles. There were 
mixed responses towards pharmacists providing services beyond dispensing. 
Services perceived as priorities included: education related to medications [i.e. 
directions for use (64.5%), storage requirements (26.6%), common/important 
adverse effects (25.5%)]; and monitoring compliance with medications (37.3%). 
Patients who had higher incomes or who were working were less supportive; 
whereas patients who had previously used a service, those with other risk factors for 
complications or having poor/unknown glycaemic control were more supportive of 
pharmacists providing some services beyond dispensing. 
 
The qualitative study – The data were saturated after the eighth interview with both 
pharmacist and doctor groups. Community pharmacists mainly supplied medicines 
(with limited labelling), with some providing services beyond dispensing, (mainly 
basic information on how to use medications). There was strong agreement between 
pharmacists and doctors about a pharmacist’s dispensing role (with improved 
labelling) and education related to medications (i.e. directions for use). A lower level 
of agreement between pharmacists and doctors was reported regarding prescription 
review (clinical aspects); education related to medications (i.e. common/important 
adverse effects) and healthy living (i.e. exercise and diet); and the monitoring of 
medication compliance and treatment outcomes (i.e. inquiring about patients’ 
glycaemic control and problems). Factors influencing the development of pharmacy-
based services included: pharmacist − positive views (facilitator) and perceived lack 
of competence (barrier); relationships with doctors and patients – lack of support and 
accessibility (barriers); pharmacy environment − business orientation (barrier), lack 
of staff and poor pharmacist availability (barriers), and availability of supporting 
resources, such as counselling areas/rooms, procedures/protocols and IT systems for 
labelling and patient records (facilitators); and external environment − a health 
system to support pharmacist roles, remuneration, marketing and professional 
assistance (facilitators). 
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Based on the surveys and qualitative data, a two-level system of pharmacy services 
was suggested: (i) basic services – dispensing, prescription review, patient education 
(medication and healthy living), and monitoring at the time of repeat dispensing; and 
(ii) advanced services (e.g. medication use reviews) that can be developed to further 
expand pharmacists’ professional roles. 
 
 
Conclusions: 
Collaboration between the Government and Ikatan Apoteker Indonesia – IAI 
(Indonesian Pharmacists Association) will be required to integrate the developed 
model of pharmacy services into the health system (under the new JKN), thus 
optimising the current under-utilisation of community pharmacists. Pharmacists 
should be immediately available at all opening hours or for defined advertised 
periods. Initially, it is important for IAI to facilitate the implementation of IT systems 
for labelling and patient records as well as the development of appropriate training 
and professional standards, procedures and other materials. In addition, an 
appropriate remuneration system should be established to create a stable environment 
for community pharmacies to remain viable. Improving the professional environment 
and facilities to deliver the developed model of services will enable piloting of its 
feasibility and effectiveness within the context of the Indonesian health system. 
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Riskerdas Riset Kesehatan Dasar (National Basic Health Research) 
SJSN  Sistem Jaminan Sosial Nasional (National Social Security System) 
SMBG  self-monitoring of blood glucose 
THE  total health expenditure 
UK  United Kingdom 
USA  United States of America 
WDF   World Diabetes Foundation 
WHO  World Health Organisation 
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1.1  Background 
 
 
1.1.1   Type 2 diabetes: The burden in Indonesia 
 
The prevalence of diabetes is increasing worldwide, mostly in developing countries. 
Indonesia is among the top ten countries with the highest number of people with 
diabetes. Using the International Diabetes Federation (IDF) Diabetes Atlas update 
data in 2013,1 it has been estimated that 8.5 million people in Indonesia were living 
with diabetes, and this is expected to increase to 14.1 million by 2035.  Based on the 
DiabCare Asia 2008 study, type 2 diabetes is the most common form of diabetes in 
Indonesia, affecting 97.5% of people diagnosed with diabetes.2 
 
Many Indonesians with type 2 diabetes are undiagnosed;3 and, while the vast 
majority of those diagnosed receive treatment, only a minority – less than 20%2 – 
achieve treatment goals (HbA1c <6.5%). Undertreated diabetics have a higher risk of 
having a range of microvascular (i.e. neuropathy, retinopathy, nephropathy) and 
macrovascular (i.e. cardiovascular diseases – CVDs) complications,4 which may lead 
to disability, as well as loss of life and productivity. It was estimated that in 2010, 
non-communicable diseases (NCDs) accounted for 63% of all deaths in Indonesia, 
and about half of those were due to diabetes and CVDs (some of which might relate 
to diabetes). Acknowledging the significant health and socio-economic burden of 
diabetes, the Indonesian Government has included NCDs and diabetes as a national 
health priority area.5 
 
It has been suggested that key barriers to appropriate diabetes care are the lack of 
awareness, accessibility and affordability; and all are interconnected and lead 
directly to another key barrier, which is poor quality diabetes care.6 It has been 
reported that Indonesia has a major deficiency in its health workforce, contributing to 
the poor access to diabetes care. In 2007, the doctor:population ratio was 
21:100,000;7 and in terms of specialists, in 2013, there were only approximately 
3,000 internal medicine specialists and 64 endocrinologists in the entire country.6 
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This ratio was lower than in most other East Asian and Pacific region countries; and 
was much lower than in developed countries such as the UK, the USA and Australia 
with more than 200 doctors per 100,000 population.7 Moreover, due to the lack of 
adequate expertise and equipment at the primary care levels, the majority of patients 
diagnosed with diabetes prefer to use secondary and tertiary care levels (e.g. 
hospital-based facilities),2, 8 causing an unnecessary burden at these levels as well as 
higher health costs and, as such, further contributing to poor accessibility to 
appropriate care. 
 
Starting in 2014, the Indonesian Government will gradually establish Jaminan 
Kesehatan Nasional – JKN (National Health Insurance) to provide affordable 
healthcare to the entire population.9, 10 In consideration of the high rate of diabetes in 
Indonesia, the implementation of this national health coverage is expected to cause a 
surge in the demand for diabetes care. Thus, strengthening the referral system and 
optimising the use of primary care resources, including pharmacists and other 
healthcare workers (e.g. nurses, diabetes educators), will be paramount in improving 
access to appropriate diabetes care. 
 
 
1.1.2   Type 2 diabetes: Community pharmacy-based services in Indonesia 
 
Since the introduction of the concept of Pharmaceutical Care in the eighties, this 
initiative has been a dominant form of community pharmacy practice around the 
world.11 Pharmaceutical care places emphasis on rational and evidence-based 
pharmacotherapy, thus focusing on improving the patient’s quality of life.12 With 
regard to type 2 diabetes, extensive studies have indicated potential benefits of 
community pharmacy-based interventions (e.g. patient education/counselling and 
monitoring) on patient outcomes.13, 14-22 
 
In 2006, pharmaceutical care was included within Indonesian legislation (Ministry of 
Health Decree No. 1027/MENKES/SK/IX/2004: Standards for Pharmaceutical Care 
in Community Pharmacies).23 These standards emphasise the need for community 
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pharmacists to be more involved in the care of patients with chronic diseases, 
including type 2 diabetes. Only a few studies have been conducted to evaluate 
community pharmacy practice in Indonesia;24-28 all have focused on general aspects 
of care rather than on diabetes services.  
 
At the international level, pharmaceutical care has been practised in varying forms 
and degrees.11, 29 Studies regarding community pharmacy practice in the area of 
diabetes, however, have been limited to developed countries.30-35 Developed 
countries, however, may have different community pharmacy systems, settings, 
staffing structures, remuneration and funding streams, health systems, levels of 
support and pharmacist roles than developing countries such as Indonesia. For 
example, unlike in developed countries, community pharmacies in Indonesia have 
limited roles within the Government insurance plans; they can be owned by a 
pharmacist and/or a non-pharmacist (a pharmacist manager is required to be legally 
responsible for the pharmacy practice); and they usually do not have computerised 
dispensing/patient record systems. Thus, questions remain about translating findings 
from developed countries to diabetes practice in Indonesia. To our knowledge, this is 
the first study designed to develop a model of community pharmacy-based services 
for patients with type 2 diabetes within the Indonesian setting. 
 
 
1.2   Objectives 
 
The main objectives of this thesis are: 
1. To evaluate data on current community pharmacy-based services for type 2 
diabetes patients 
2. To explore stakeholder (pharmacist, patient and doctor) views on the roles of 
community pharmacists in type 2 diabetes care 
3. To explore factors associated with the development of community pharmacy-
based services for type 2 diabetes patients 
4. To develop a model of community pharmacy-based services for type 2 diabetes 
patients within the Indonesian setting, based on current practice and stakeholder 
views.  
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1.3   Significance 
 
The results of this study will provide the basis for an Indonesian model of diabetes 
care in community pharmacies. It is intended that the model will be a framework 
used to design and implement support in the development of community pharmacy 
professional practice in Indonesia, particularly in the area of type 2 diabetes.  
 
In light of the high rate of diabetes and the lack of health workers in Indonesia, the 
model will be valuable in enabling the inclusion of community pharmacies within the 
health care system, thus strengthening its ability to provide appropriate primary 
health care for patients with type 2 diabetes. 
 
 
1.4   Thesis organisation 
 
This thesis presents three related study reports on community pharmacy-based 
services for type 2 diabetes in the Indonesian setting: 
 
• Chapter 3 presents a survey of community pharmacists. This provides data on 
pharmacy- and pharmacist-related characteristics, services provided for type 2 
diabetes patients, and pharmacists’ views on their roles in diabetes care.  This 
study also investigated pharmacist/pharmacy characteristics and their 
relationships to provision of services. 
 
• Chapter 4 presents a survey of pharmacy clients with type 2 diabetes. This 
chapter summarises patients’ characteristics and their views on the roles of 
community pharmacists in type 2 diabetes care. Also presented is an evaluation 
of patient characteristics associated with positive views towards community 
pharmacist contributions. 
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• Chapter 5 presents a qualitative study (interviews) of the main diabetes care 
providers, i.e. community pharmacists and doctors. This provides rich data 
regarding type 2 diabetes care practice, expected roles of community 
pharmacists, and factors affecting the development of community pharmacy-
based services for type 2 diabetes patients.  
 
Each of these chapters comprises the specific objectives and methodology of the 
particular study, as well as the results, discussion and key findings.   
 
Chapter 6 presents general discussion that integrates the findings of the three related 
studies to address the first three main objectives. Consequently, this satisfies the 
fourth main objective, which was to develop a model of community pharmacy-based 
services for type 2 diabetes patients (see Table 1.1).  
 
 
Table 1.1   Thesis organisation 
 
Objectives Chapters 
1. Current community pharmacy-based 
services for type 2 diabetes patients 
Chapter 3: Survey of community pharmacists 
Chapter 4: Survey of type 2 diabetes patients 
Chapter 5: Qualitative study (interviews) of  
doctors and community pharmacists  
 
 Chapter 6: General discussion (integrated findings) 
2. Views on community pharmacists’ roles 
in type 2 diabetes care 
Chapter 3: Survey of community pharmacists 
Chapter 4: Survey of type 2 diabetes patients 
Chapter 5: Qualitative study (interviews) of 
doctors and pharmacists 
 
 Chapter 6: General discussion (integrated findings) 
3. Factors associated with the development 
of community pharmacy-based services 
for type 2 diabetes patients 
Chapter 3: Survey of community pharmacists 
Chapter 4: Survey of type 2 diabetes patients 
Chapter 5: Qualitative study (interviews) of  
doctors and community pharmacists 
 
 Chapter 6: General discussion (integrated findings) 
4. Model of community pharmacy-based 
services for type 2 diabetes patients 
Chapter 6: General discussion (integrated findings) 
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1.5   Ethical issues 
 
The data collection instruments and methodology used in this study were approved 
by the Human Research Ethics Committee of Curtin University (PH-09-11 and PH-
03-12) as well as Ikatan Apoteker Indonesia – IAI (Indonesian Pharmacists 
Association) (001/SK/BPD-IAI/SURABAYA/2010). Copies of the ethical approvals 
from Curtin University have been included in Appendices 1 and 2, while the 
approval from IAI has been included in Appendix 3. 
 
 
1.5.1   Confidentiality   
Confidentiality was an ethical issue for this study, in particular because participants 
shared information about their pharmacies or their organisations that was not 
necessarily public knowledge, as well as their own personal opinions and 
experiences.  All data collected for this study were kept strictly confidential.  The 
participants’ names were not used at any stage of the research process.  The 
participants were identified by a unique study identifier code to ensure privacy, and 
the names of persons identified in the questionnaire or interview transcripts were 
removed.  All the data were kept on a secure computer and access to the computer 
was by specific passwords known only to the principal investigator.  The completed 
questionnaires, transcriptions and audio recordings were stored in a secure locked 
cabinet at the School of Pharmacy, Curtin University. No information was released 
or printed that disclosed anyone’s personal identity.  Participant quotes used in this 
report contained no personal identifiers. Quotations were identified generically by 
indicating the type of interviewee (pharmacist or doctor) and number, e.g. 
Pharmacist 5.  
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1.5.2   Informed consent   
Participants were provided with information about the study. They were made aware 
that the participation was voluntary and they might withdraw from the study at any 
time without any adverse consequences. Written informed consent was obtained 
from all who agreed to participate. Information sheets and consent forms were 
provided in Bahasa Indonesia. (These are further explained in Chapters 3 to 5.) 
 
 
1.5.3   Compensation   
The interview participants were reimbursed for their time with a cash payment. This 
is further explained in Chapter 5. 
 
 
1.5.4   Conflicts of interest   
There were no known or anticipated conflicts of interest among the researchers 
involved in this project. 
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CHAPTER 2 
Literature review
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2.1  Diabetes   
2.1.1   Overview 
 
Diabetes is a chronic disease characterised by high levels of glucose in the blood 
(hyperglycaemia). There are three main types of diabetes: 
 
• Type 1 diabetes  
Type 1 diabetes was previously known as Insulin Dependent Diabetes Mellitus 
(IDDM).36 The disease can occur at any age, although onset mostly occurs in 
children and young adults.37 
  
• Type 2 diabetes  
This type of diabetes was known previously as Non-Insulin Dependent Diabetes 
(NIDDM).36 Although it mostly occurs in people aged over 40 years, the disease 
also is becoming increasingly prevalent in younger age groups.38, 39 
 
• Gestational diabetes  
This type of diabetes affects a woman during pregnancy. The condition usually 
disappears once the baby is born. However, a history of gestational diabetes 
increases a woman's risk of developing type 2 diabetes later in life.37  
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Diabetes is an independent risk factor for both macrovascular diseases (due to the 
damage to larger blood vessels) and microvascular diseases (due to damage to small 
blood vessels): 
  
• Macrovascular complications 
- Cardiovascular diseases: 50% or more of people with diabetes die of 
cardiovascular disease (primarily heart disease and stroke).4  
 
• Microvascular complications 
- Neuropathy (peripheral nerve dysfunction): 80% of amputations occur 
after foot ulceration and injury, which can be a result of diabetic 
neuropathy.40  
- Retinopathy (eye damage): 1% of global blindness can be attributed to 
diabetes.41 
- Nephropathy (kidney damage): diabetes is among the leading causes of 
kidney failure.4 
 
These complications are often the cause of death among people with diabetes. It was 
reported that the overall risk of death among people with diabetes is at least double 
that of their peers without diabetes.42  
 
 
2.1.2   Type 2 Diabetes  
Type 2 diabetes is the most common form of diabetes, affecting approximately 90% 
of people with diabetes worldwide.43 The DiabCare Asia 2008 study reported that 
type 2 diabetes accounted for 97.5% of Indonesians diagnosed with diabetes.2   
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2.1.2.1   Pathophysiology of type 2 diabetes 
 
The pathophysiology of type 2 diabetes is characterised by two major features: the 
gradual fall in pancreatic ß-cell function (impaired insulin secretion) within a 
background of insulin resistance.37, 44, 45 Insulin normally reduces glucose output by 
the liver and enhances glucose uptake by skeletal muscle. Decreased insulin 
secretion will reduce insulin-signalling in its target tissues. Insulin resistance 
pathways affect the action of insulin in each of the major target tissues, leading to 
hyperglycaemia. In turn, the raised concentrations of glucose in the bloodstream feed 
back to worsen both insulin secretion and insulin resistance.44, 45 
 
Various genetic and environmental factors are reported to contribute to the 
development of type 2 diabetes.44, 45 It is reported that a family history of diabetes is 
associated with a higher risk of developing the disease. Its pathogenesis is assumed 
to involve genetic abnormalities in the molecules related to the regulatory system of 
glucose metabolism; to date these genetic abnormalities have been able to explain 
about 30% of genetic factors responsible for type 2 diabetes.44 In addition to genetic 
factors, environmental factors related to an increase of visceral fat, such as ageing, 
obesity, insufficient energy consumption (lack of physical activity), alcohol drinking, 
and smoking have been reported to be associated with type 2 diabetes.44, 45 
 
 
Figure 2.1  Pathophysiology of type 2 diabetes (Stumvoll et al., 2005)45 
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2.1.2.2   Treatment of type 2 diabetes 
 
Treatment plans for patients diagnosed with type 2 diabetes should be formulated as 
a collaborative therapeutic alliance among the patient and family, the doctor and 
other members of the health care team.37, 46 The plan should aim to improve quality 
of life and reduce the progression of complications to prevent premature death.46 
Thus, multiple interventions are needed, not only to control hyperglycaemia, but also 
to control other risk factors for complications (such as overweight/obesity, 
hypertension, dyslipidaemia and smoking). The cornerstone of the interventions is 
the inclusion of: 
 
• Diet 
Diet management involves controlling weight and the introduction of a healthy 
eating plan.36 Diet plays an important role in preventing and controlling blood 
glucose, and is an essential component of an overall healthy lifestyle.36, 37, 46 
 
• Physical activity 
Increasing physical activity improves glucose control, reduces cardiovascular 
risk factors and contributes to weight loss.37 The recommendation from 
Perkumpulan Endokrinologi Indonesia – PERKENI (Indonesian Society of 
Endocrinology) is  ≥150 minutes per week of moderate-intensity physical activity 
(50-70% of maximum heart rate), spread over at least 3 days per week.46  
 
• Medications 
If a trial of healthy lifestyle practices for six weeks or more is unsuccessful in 
controlling blood glucose in a person with type 2 diabetes, oral antidiabetic drugs 
(see Table 2.1) and/or insulin can be used.36, 46 Insulin may be needed at an early 
stage of the condition when treatment is being started (when the so-called 
‘primary’ failure of oral antidiabetic drugs suggests the patient actually has type 
1 diabetes) or when the patient has later become refractory to oral antidiabetic 
drugs (which is the so-called ‘secondary’ failure consistent with the progression 
of type 2 diabetes).36 
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• Self-management education and support 
Education and support is required to facilitate the development of patient 
knowledge, skills and abilities necessary for diabetes self-care.37  This ongoing 
education/support should focus on assisting patients’ behavioural changes, 
including: healthy lifestyle (e.g. physical activity, healthy eating, smoking 
cessation, weight management); disease self-management (e.g. medication taking 
and management, self-monitoring of blood glucose); and prevention of diabetes 
complications (e.g. self-monitoring of foot health, active participation in 
screening for eye, foot and renal complications).37, 46   
 
 
Table 2.1   Oral antidiabetic medications46-48 
 
Medication Mechanism of action 
Well-validated  
Metformin Metformin is the only biguanide available; its major effect is to 
decrease hepatic glucose production and insulin resistance. 
Sulfonylureas 
(e.g. gliclazide, glimepiride) 
Sulfonylureas lower glycaemia by enhancing insulin secretion. 
Less well-validated  
Thiazolidinediones 
(e.g. rosiglitazone, pioglitazone) 
Thiazolidinediones are peroxisome proliferator–activated receptor γ 
modulators which regulate genes involved in lipid and glucose 
metabolism; they reduce hepatic glucose production and insulin 
resistance. 
GLP-1 analogues  
(e.g. exenatide) 
GLP-1 is a naturally occurring peptide produced by the L-cells of the 
small intestine, increasing glucose-dependent insulin secretion and 
supressing inappropriate glucagon secretion.  
Other therapies  
α-Glucosidase inhibitors  
(e.g. acarbose) 
Acarbose delays absorption of carbohydrates by inhibiting α-
glucosidase enzymes in the small intestine and, thus, reduces 
postprandial hyperglycaemia. 
Glinides  
(e.g. repaglinide, nateglinide) 
Like the sulfonylureas, the glinides stimulate insulin secretion, 
although they bind to a different site within the sulfonylurea receptor. 
 DPP-4 inhibitors 
(e.g. sitagliptin) 
DPP-4 inhibitors are small molecules that enhance the effects of GLP-
1 and GIP, increasing glucose-dependent insulin secretion and 
suppressing glucagon production. 
SGLT2 inhibitors 
(e.g. dapagliglozin, canagliflozing) 
This class of drug reduces glucose reabsorption in the kidney and 
lowers plasma glucose, independent of changes in insulin 
concentrations or peripheral insulin resistance. 
Abbreviations: DPP-4, dipeptidyl peptidase four inhibitors; GLP-1, glucagon-like peptide-1; GIP, glucose-
dependent insulinotropic peptide; SGLT2, Sodium-glucose co-transporter 2 
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Goals for optimum diabetes treatment are summarised in Table 2.2. As 
hyperglycaemia defines diabetes, glycaemic control is fundamental to the 
management of diabetes. The American Diabetes Association (ADA) has 
recommended a goal of HbA1c ≤7.0%;37 more stringent HbA1c goals (such as 
<6.5%) have been suggested by the American Association of Clinican 
Endocrinologists (AACE) to further lower the risk of complications.49 However, this 
target should be individualised based on age, presence and absence of complications, 
and life expectancy.49  
 
 
Table 2.2   Goals for optimum diabetes treatment (PERKENI, 2006 & 2011)46, 50 
 
 Good Fair Poor 
BGL fasting 80–100 mg/dL  
(4.5–5.5 mmol/L) 
100–125 mg/dL  
(5.5–7.0 mmol/L) 
≥126 mg/dL  
(7.0 mmol/L) 
BGL postprandial 80–144 mg/dL   
(4.5–7.9 mmol/L) 
145–179 mg/dL  
(8.0–9.9 mmol/L) 
≥180 mg/dL  
(10.0 mmol/L) 
HbA1c <6.5%  6.5 – 8.0% >8% 
Total cholesterol <200 mg/dL  
(5.2 mmol/L) 
200–239 mg/dL  
(5.2–6.1 mmol/L) 
≥240 mg/dL  
(6.2 mmol/L) 
HDL-C >40 mg/dL (1.1 mmol/L) 
(male)  
  
 >50 mg/dL (1.3 mmol/L) 
(female) 
  
LDL-C <100 mg/dL (2.6 mmol/L) 
(without presence of risk factors) 
<70 mg/dL (1.8 mmol/L) 
(with presence of risk factors)  
100–129 mg/dL 
(2.6–3.3 mmol/L) 
≥130 mg/dL  
(3.4 mmol/L) 
Triglycerides <150 mg/dL  
(1.7 mmol/L) 
150–199 mg/dL 
 (1.7–2.2 mmol/L) 
≥200 mg/dL  
(2.3 mmol/L) 
BMI 18.5–23 kg/m2 23 – 25 kg/m2 >25 kg/m2 
Blood pressure 130/80 mmHg 130-140/80-90 mmHg >140/90 mmHg 
Abbreviations: BGL, blood glucose levels, HbA1c, glycosylated haemoglobin; HDL-C, (high-density 
lipoprotein) cholesterol; LDL-C, (low-density lipoprotein) cholesterol; BMI, body mass index = weight (kg) 
divided by height2 (m2) 
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2.1.2.3   Health care for type 2 diabetes 
 
A detailed assessment should be performed at initial diagnosis to include appraisal of 
diabetes complications and risk factors for complications. This will provide a basis 
for continuing care that includes a treatment plan, treatment administration, 
monitoring and review (see Figure 2.2 and Table 2.3).  
 
 
Figure 2.2   Model of care for type 2 diabetes patients in primary care36, 37, 46, 51 
 
 
Initial Assessment 
• Medical history 
• Physical examination  
• Laboratory evaluation  
 
 
Treatment Plan 
• Individualised treatment targets 
• Individualised treatment plan  
- diet, exercise and antidiabetic agents 
- prevention/treatment of  complications  
• Patient education 
Treatment administration 
• Medications prepared  
• Appropriate labels provided  
• Patient educated 
Monitoring 
• Monitor compliance with treatment plan 
• Monitor treatment outcomes 
• Monitor adverse treatment effects 
• Monitor patient comprehension and continuing 
educational needs 
Review 
• Review of treatment plan  
• Consider:  
- adjust treatment plan 
- adjust education 
- refer  
Type 2 diabetes patient 
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Table 2.3   Tabulation of the processes in the model of care for type 2 diabetes 
patients in primary care36, 37, 46, 51, 52 
 
Stage Activity Component 
Initial 
Assessment 
History-taking • Specific symptoms of glycosuria/hyperglycaemia 
• Predisposition to diabetes: e.g. age, family history, obesity,  
lifestyle issues (e.g. smoking, diet, alcohol, physical activity, 
occupation) 
  • Risk factors for complications: personal or family history of 
cardiovascular disease, overweight/obesity, smoking, 
hypertension, dyslipidaemia 
  • Symptoms of complications: e.g. cardiovascular symptoms, 
neurological symptoms, foot and eye problems 
  • Other medical conditions 
• Medications (if any) 
  • Education (if any) 
  • Psychosocial status: e.g. attitudes about illness, expectations, 
resources – financial, social and emotional 
 Physical examinations • Weight/waist: BMI, waist circumference 
• Cardiovascular system: e.g. blood pressure measurement 
• Eyes: e.g. pupil dilation 
• Feet: e.g. skin condition, sensation 
• Peripheral nerves: e.g. sensation 
• Urinalysis: e.g. albumin 
 
 
 
Laboratory evaluation • Glycaemia: HbA1c, BGL 
• Lipids: LDL-C, HDL-C, total cholesterol, triglycerides 
• Renal function: plasma creatinine (eGFR), microalbuminuria 
• Other tests when necessary 
Treatment Plan Individualised 
treatment targets 
• Glycaemic  control: BGL, HbA1c 
• Control of risk factors for complications: lipids, blood pressure, 
BMI, cigarette consumption 
• Urinary albumin excretion 
• Physical activity 
 Development of 
treatment plans 
• Antidiabetic medications 
• Diet 
• Physical activity 
• Prevention/treatment of complications 
Patient education Patient education • Diabetes disease process 
  • Treatment targets 
  • Treatment plan 
- Antidiabetic medicines: dosage instructions, use of insulin 
devices, storage requirements, special precautions, 
common/important adverse effects  
  - Exercise 
  - Diet 
  - Prevention/treatment of complications:  e.g. foot care, 
smoking cessation, medications for high lipid/blood 
pressure levels 
  • Monitoring 
  - SMBG (using glucose meter and interpreting the results) 
  - Need for regular medical monitoring  
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Table 2.3   (continued) 
Abbreviations: HbA1c, glycosylated haemoglobin; BGL, blood glucose level; HDL-C, (high-density lipoprotein) 
cholesterol; LDL-C (low-density lipoprotein) cholesterol; BMI, body mass index; eGFR, estimated glomerular 
filtration rate; SMBG, self-monitoring of blood glucose. 
 
 
Stage Activity Component 
Treatment 
administration 
Medications prepared N/A 
Appropriate labels provided • Labels with directions for use  
• Ancillary labels (if required) 
Monitoring Monitor compliance with 
treatment plans 
• Medications 
• Exercise plan 
  • Diet plan 
• Prevention/treatment plans for chronic complications 
  
• Scheduled medical monitoring 
 Monitor treatment outcomes 
  
• Glycaemic control: HbA1c, BGL, SMBG 
• Control of risk factors for complications: lipids, blood 
pressure, BMI, cigarette consumption 
• Presence of complications: cardiovascular system, 
peripheral nerves, renal, eyes, feet  
 Monitor adverse effects • Presence of drug adverse effects 
Review Review of treatment plan 
based on monitoring results 
• Consider treatment plan adjustment 
• Consider education adjustment 
• Refer 
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2.2  Background on Indonesia 
 
 
2.2.1   Geography, population and governance 
 
The Republic of Indonesia consists of approximately 17,000 islands, which lie 
between Asia and Australia. There are five major islands: Sumatra in the west; Java 
in the south; Kalimantan straddling the equator; Sulawesi; and Papua bordering 
Papua New Guinea on the east. Two remaining groups of islands are Maluku and 
Nusa Tenggara. All other islands are small and mostly uninhabited. More than 80% 
of Indonesia’s territory is covered with water; the land area is about 1.9 million 
square kilometres. The large number of islands and their dispersion over a wide area 
has given rise to a diverse culture, as well as hundreds of ethnic groups and 
languages. A majority speak the national language, Bahasa Indonesia. Indonesia’s 
climate is tropical, with two seasons. The dry season extends from May to October 
and the rainy season extends from November to April.53-55 
 
According to the 2010 Population Census, the population of Indonesia was 237.6 
million. This makes Indonesia the fourth most populous country in the world after 
the People’s Republic of China, India and the United States of America (USA). 
Indonesia is a lower-middle income country with a per capita gross national income 
(GNI) of US$ 1,650 and a national poverty rate of 16.7%.56 A rapidly growing share 
of Indonesians, approximately 118.3 million people (49.8%) in 2010, live in urban 
areas and, of these, the majority reside in Java.57  
 
Indonesia is divided administratively into 33 provinces. Each province is subdivided 
into districts (kabupaten) and municipalities (kota). Altogether, there are 399 districts 
and 98 municipalities in Indonesia. Each district/municipality consists of sub-
districts (kecamatan), and each sub-district consists of villages (desa).53 In 2012, 
there were 6,793 subdistricts and 79,075 villages in Indonesia. Each entire village is 
classified as urban or rural.58 
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In 1999, Republic of Indonesia Law No. 22 regarding Regional Governance 
(Pemerintahan Daerah) was enacted; this was later revised by Law No. 32 of 2004.59 
With the implementation of the aforementioned laws, the government system in 
Indonesia has been changed from Centralisation to Decentralisation, which transfers 
authority from the central government to regional governments (i.e., provinces, 
districts and municipalities). The district/municipality level is given broader 
autonomy to manage regional public sectors, such as health, education and 
infrastructure. On the other hand, the provincial level has limited autonomy (i.e. 
sectors that have not been covered in the district/municipality level or that have an 
inter-district/municipality dimension); instead, it acts as a representative of the 
central government. Meanwhile, the central government has to perform the role of 
formulating policy and standards, and providing guidance to provincial and 
district/municipality levels.59, 60 
 
 
2.2.2   Health priorities and diabetes 
 
 
The elderly population in Indonesia is increasing. Based on the 2010 Population 
Census, there were 18.0 million people above 60 years old (7.6% of the total 
population), suggesting that Indonesia is becoming an ageing population in its 
structure.57 Although communicable diseases remain a large burden in Indonesia, the 
increasing ageing population57 and changes in lifestyle6 have contributed to 
epidemiological transition towards non-communicable diseases (NCDs) – also 
known as chronic diseases.  
 
Based on the Riset Kesehatan Dasar – Riskerdas (National Basic Health Research) 
in   2013,   the   prevalences  of   four   main   types   of    NCDs   in   Indonesia   
were: (i) cardiovascular diseases – CVDs [hypertension (25.8%), coronary heart 
disease (1.5%), heart failure (0.3%) and stroke (13.9%)]; (ii) cancers (1.4%); (iii) 
chronic respiratory diseases [chronic obstructed pulmonary disease (3.7%) and 
asthma (4.5%)]; and (iv) diabetes (2.1%).3 While these figures were based on self-
reported data (diagnosis or symptoms), partial data of blood specimens (N=39, 202 
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persons) showed a higher prevalence of diabetes (6.9%), suggesting that many with 
diabetes were undiagnosed. Using the International Diabetes Federation (IDF) 
Diabetes Atlas update data in 2013,1 approximately 8.5 million people (about 5.6%) 
in Indonesia were living with diabetes, and this was estimated to increase to 14.1 
million by 2035. This makes Indonesia amongst the top 10 countries in number of 
people living with diabetes in the world.  
 
It was estimated that in 2010, NCDs accounted for 63% of all deaths in Indonesia, 
with diabetes and CVDs (some of which might relate to diabetes) accounting for 
approximately 33% (Figure 2.3).61 NCDs also are associated with high levels of 
morbidity, not limited to affluent populations in urban settings alone, but also 
affecting poorer people, reducing their earning capacity and, as such, contributing to 
further impoverishment.54 The DiabCare Asia 2008 study (Indonesia) showed that 
patients diagnosed with diabetes had a range of associated complications, including: 
retinopathy (42%), nephropathy (7.3%), neuropathy (63.5%) and CVDs (22.5%).2 
This was complicated by the fact that many more were undiagnosed3 and, while 
those who are diagnosed receive treatment, only a handful – less than 20%2 –  
achieve treatment targets (HbA1c <6.5%). Thus, diabetes and other NCDs represent 
a real burden to Indonesia from the point of view of health, society and economy.  
 
 
Figure 2.3  Causes of death in Indonesia (percentage of total deaths, all ages)61  
 
s 
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The Government, within Rencana Strategis Kementrian Kesehatan – Renstra 
(Ministry of Health Strategic Plan) for 2010–2014,5 has acknowledged NCDs, 
including diabetes, as a national health priority area. The strategy includes initiatives 
around promotion and prevention (for people without NCDs – high risk versus low 
risk), early detection (of previously undiagnosed NCDs) and management (of 
diagnosed NCDs), as well as disease surveillance. Specific to diabetes, the Ministry 
of Health published Guidelines in Controlling Diabetes Mellitus and Metabolic 
Disorders62 to establish directions for central to regional activities in controlling the 
diabetes epidemic. It is difficult, however, to provide a complete picture of diabetes 
activities in Indonesia. Using data from the Ministry of Health63, 64 and the World 
Diabetes Foundation (an organisation established by Novonordisk, currently 
providing grants for diabetes projects in Indonesia),6, 65-71 in addition to an 
Indonesian literature review,8 the main diabetes activities in Indonesia have been 
summarised in Table 2.4. 
 
While the current diabetes activities appear to be isolated, Indonesia has not yet seen 
a coordinated framework of actions amongst stakeholders as well as an integrated 
approach to the care of type 2 diabetes patients.   
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Table 2.4   Diabetes activities/projects in Indonesia 
Objective Activity/project Partnership 
Increasing public 
awareness 
World Diabetes Day each November since 2008, diabetes camps and education programmes6 MoH RI/WDF in partnership with 
NGOs, such as PERSADIA  
 Pos Pembinaan Terpadu Penyakit Tidak Menular – Posbindu PTM (Integrated Health Post for NCDs) is a community-
based health facility, created to increase awareness among the general population about NCDs, recognising the risk 
factors of these diseases and detecting the conditions in the early stages (7,225 Posbindu PTM by 2013)64 
MoH 
Improving the capacity of 
preventing, detecting and 
treating diabetes  
Training: 
1,237 healthcare workers in eight cities (2006-2008)8, 65  
MoH RI/WDF in partnership with 
professional bodies and 
educational institutions 612 GPs in health centres (by 2013)64 
About 1,200 internal medicine specialists by 20126   
450 nurses trained as diabetes nurses and educators (2011-2014)8, 70 
Improving diabetes care 
and prevention (model) 
Establishing three community-based diabetes management centres at the Ternate Island in the North Maluku, Kutai in 
Kalimantan and in East Jakarta  (one centre in Ternate by 2013)6, 71 
MoH RI/WDF in partnership with 
health facilities and educational 
institutions  Implementing integrated community-based approach in the provinces of West Sumatra, Bengkulu and Banten (2010-
2013)8, 67 
 Raising public awareness and training healthcare workers in two rural areas (Kediri) - diabetes awareness information 
posts have been established in 26 districts (2005-2008)8, 68 
 
Improving care and 
prevention of diabetes 
complications 
Diabetic retinopathy training and treatment: renovation of a screening facility, raising awareness (campaign),  staff 
training, screening and treatment (2009-2012) 8, 66 
MoH RI/WDF in partnership with 
health facilities and educational 
institutions Diabetes foot care: staff training, improving 2 foot clinics and establishing 14 new clinics (2008-2011)8, 69 
Developing guidelines or 
materials in diabetes care 
13 materials by 2013, such as Pharmaceutical Care for Diabetes Mellitus (a pocket book for pharmacists), Technical 
Guidance for Detection and Management of Diabetes Mellitus (for primary care workers)64 
MoH RI in partnership with 
professional bodies and 
educational institutions 
 National diabetes guidelines (medical care), such as  Concensus on Diabetes Management and Prevention of type 2 
diabetes in Indonesia (latest version in 2011)8 
PERKENI 
Improving affordability of 
care 
The Government plans to implement universal health coverage for the entire Indonesian population from January 
201464 (see Section 2.2.3.2 Health Financing) 
Government (MoH RI)  
Abrreviations: MoH RI, Ministry of Health, Republic of Indonesia; WDF, World Diabetes Foundation; PERSADIA, Persatuan Diabetes Indonesia (Indonesian Diabetes Association); NGOs, non-govenrment 
organisations; PERKENI, Perkumpulan Endokrinologi Indonesia (Indonesian Society of Endocrinology); GP, general practitioner. 
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2.2.3   Health system  
 
 
2.2.3.1   Structure and health service delivery 
 
Health services in Indonesia are delivered mainly by the government (the public 
sector) and the private sector. The government health system includes a Pusat 
Kesehatan Masyarakat – Puskesmas (Health Centre) in each sub-district. This is 
usually supported by two or three Puskesmas Pembantu – Pustu (Auxiliary Health 
Centres) to further expand its coverage to villages. Moreover, the health centres can 
assist the establishment of Community-based Health Facilities, e.g. Pondok Bersalin 
Desa – Polindes (Village Midwife Clinics), Pos Pelayanan Terpadu – Posyandu 
(Integrated Health Posts), and Pos Kesehatan Desa – Poskesdes (Village Health 
Posts). The system also includes referral pathways from the health centres to the 
District Hospitals (general/specialist), the Provincial Hospitals (general/specialist) 
and the National Top Referral Hospitals (general/specialist) to provide secondary or 
tertiary care (see Table 2.5).60, 72 The specialist hospital is defined as a hospital 
primarily providing healthcare in relation to specific medical areas, organs or 
illnesses.73 
 
 
Table 2.5    The government health structure in Indonesia 
Government structure Health structure  Healthcare facilities 
Central Ministry of Health National Top Referral Hospital 
Provincial Provincial Health Office  Provincial Hospital 
District/Municipality  District Health Office  District/Municipal Hospital  
 
Sub-district  ---- Health Centre 
Village ---- Auxiliary Health Centre 
Community-based Health Facilities, eg. 
Village Midwife Clinic, Integrated 
Health Post, Village Health Post 
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The Indonesian private health system consists mainly of hospitals (general/specialist) 
and clinics [general practitioner (GP) clinics – run by one or several GPs, or 
specialist clinics – run by one or several specialists]. While the GP clinics provide 
primary care, the specialist clinics or hospitals (general/specialist) provide secondary 
or tertiary care. Figure 2.4 summarises the healthcare referral system in Indonesia.72 
Currently, a referral is mandatory for those under health insurance schemes.74 For 
those without insurance plans, or preferring not to use their plans, the use of 
healthcare can be dependent on their preferences and affordability. It was noted that, 
due to the lack of expertise and equipment at primary care levels, the majority of 
patients diagnosed with diabetes may prefer to use secondary and tertiary care levels 
(e.g. hospital-based facilities) for their care.2, 8 
 
 
Figure 2.4  Healthcare referral system in Indonesia72, 74  
 
 
 
Advanced specialised care, e.g.: 
National top referral hospital 
Provincial hospital 
Private hospital 
Specialised care, e.g.: 
District//municipal hospital 
Private hospital 
Specialist clinic 
First and generalised point-of-care, e.g.: 
Health centre 
GP clinic 
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Medications are distributed through district/municipality pharmacy installations, 
pharmacies and drug stores.63 District/municipality pharmacy installations are 
technical units responsible for supplying medications for public primary care 
facilities (health centres).63 Pharmacies (except those which are units of public 
hospitals) and drug stores focus on providing medications to the private sector. Drug 
stores are not required to have a pharmacist on staff (unlike pharmacies) and are 
licensed to sell only non-prescription medications.75 However, many also sell 
prescription drugs, and both pharmacies and drug stores are known to sell 
prescription drugs without doctors’ prescriptions.56  
 
 
2.2.3.2   Health financing  
 
The overall health financing situation in Indonesia is complex and not completely 
documented. Using the WHO Global Health Expenditure database,76 the Indonesian 
total health expenditure in 2011 was US$ 201,950,721 or 2.7% of its GDP (gross 
domestic product). As shown in Table 2.6, this government spending comprises 35% 
of total health expenditure, while 65% is private. By far the largest private spending 
is out-of-pocket payments (fee for service), accounting for nearly half of the total 
health expenditure. It was reported that it is widely accepted among Indonesian 
consumers to use private sector providers for a range of health services and products, 
contributing to higher out-of-pocket payments.77 
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Table 2.6   Health expenditure by source of financing in Indonesia (2011)76 
 
 Value (US$) % of THE 
Total health expenditure (THE) 201,950,721  
General government expenditure, e.g.: 69,916,289 34.6 
      Ministry of health 13,179,445 6.5 
      Social security funds 14,250,279 7.1 
Private expenditure, e.g.: 132,034,432 
  
65.4 
Private insurance 4,789,739 2.4 
Non-profit institutions serving households  
(e.g. NGOs) 
1,935,342 0.9 
Out-of-pocket expenditure 100,708,284 49.9 
Abbreviations: NGOs, non-government organisations; THE, total health expenditure 
 
 
For years, health financing through insurance schemes (social and private) covered 
only a small proportion of the population (about 20%), but this fraction increased 
with the establishment of Asuransi Kesehatan Masyarakat Miskin – Askeskin (Health 
Insurance for the Poor) in 2004.56 Askeskin was a non-contributory scheme designed 
by the Government to increase affordability, accessibility and quality of health 
services to the poor; this was expanded to Jaminan Kesehatan Masyarakat – 
Jamkesmas in 2008 to include the near poor.56 In 2012, around 151.5 million 
Indonesians were covered by some form of health insurance (about 65% of the total 
population), largely through Jamkesmas (see Table 2.7).10  
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Table 2.7   Health insurance coverage in Indonesia (2012)10 
 
Type of health insurance Number of participants 
Social health insurance  
Askes (Health Insurance for Civil Servants) 17,274,520 
TNI/Polri (military and police) 2,200,000 
Jamkesmas (Ministry of Health  - Health Insurance for the Poor/Near 
Poor) 
76,400,000 
JPK Jamsostek (Wokforce Social Security – for private formal sector 
employees) 
5,600,000 
Jamkesda/PJKMU (Regional Governments’ Health Insurance – for 
poor/near poor households not covered by Jamkesmas) 
31,866,390 
Private voluntary health insurance  
Corporate insurance (self-insured) 15,351,532 
Commercial health insurance  2,856,539 
Total 151,548,981 
 
 
In January 2014, the Government established Jaminan Kesehatan Nasional – JKN 
(National Health Insurance) as a move towards providing affordable healthcare to its 
entire population [universal health coverage – based on Republic of Indonesia Law 
No. 20 of 2004 regarding Sistem Jaminan Sosial Nasional – SJSN (National Social 
Security System)].9 This first phase targets coverage of participants in the current 
social health insurance schemes (i.e. Askes, TNI/Polri, Jamkesmas, 
Jamkesda/PJKMU and JPK Jamsostek). In the second phase, the entire population is 
expected to be covered under the national scheme by January 2019.10 The scheme 
includes the government paying for the poor and near poor households, while the 
other participants are required to pay a fee according to a tariff determined by their 
income ranges.10 In providing universal health coverage, it is expected that there will 
be an increasing demand for healthcare, as well as healthcare spending. Thus, 
strengthening the referral system and optimising the use of primary care will be 
paramount. 
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2.2.3.3   Health resources 
 
Indonesia has made impressive gains in extending the reach of health services, 
especially primary care. It has been estimated that more than 90% of the population 
can have access to primary care facilities. Based on the 2012 Indonesia Health 
Profile,63 the Government has constructed 9,510 health centres (in addition to 
approximately 22,000 auxiliary health centres56), giving a ratio of 3.89 health centres 
per 100,000 population. Secondary and tertiary healthcare in Indonesia, however, has 
grown slowly. The 2012 Indonesia Health Profile reported a total of 2,083 hospitals 
(comprising 1,540 public hospitals and 543 private hospitals) with a ratio of 94.6 
hospital beds per 100,000 population.63 As for health facilities supplying 
medications, there is a total of 497 district/municipality pharmacy installations as 
well as a total of 17,613 pharmacies and 7,040 drug stores.63 In addition, there are 
many unlicensed drug stores (estimated to be around 5,000 in 2005) and other 
informal outlets, including more than 90,000 small stores and street peddlers.77 
 
Reliable data on healthcare workers in Indonesia is lacking and often incomplete. 
Badan Pengembangan dan Pemberdayaan Sumber Daya Manusia – BPSDMK 
(National Board of Human Resources Development and Empowerment) recorded a 
total of 567,422 healthcare workers in 2013 (Table 2.8).63 However, this was mainly 
based on the available data from public health facilities. Using data from Konsil 
Kedokteran Indonesia – KKI (Indonesia Medical Council), 88,309 doctors were 
registered within the council, giving a ratio of 36.1 doctors per 100,000 of 
population.63 For pharmacists in Indonesia, the estimate was 45,000 in total, 20,799 
of whom were registered within Ikatan Apoteker Indonesia – IAI (Indonesian 
Pharmacists Association) in 2014.78 
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Table 2.8   Healthcare workers in public facilities (2013)63 
 
Healthcare workers Number of persons 
Medical staff:  
Specialist 27,333 
GP 37,364 
Dentist 11,826 
Nursing staff:  
Nurse 235,496 
Midwife 126,276 
Pharmacy staff (i.e. pharmacist and non-pharmacist staff) 31,223 
Others  97,904 
Total 567,422 
Abbreviations: GP, general practitioner 
 
Based upon international comparisons, Indonesia’s ratios of health facilities 
(hospitals), as well as healthcare workers, to population, have been low. Using the 
database of World Development Indicators in 2007, the number of hospital beds per 
1,000 population was one of the lowest in the East Asia and Pacific region, even 
lower than those of countries with much lower incomes, such as the Lao People’s 
Democratic Republic and Vietnam.7  Similarly, with respect to the total numbers of 
healthcare workers to population, Indonesia had a much lower ratio than most other 
East Asia and Pacific region countries, as well as other countries of its income level 
globally. With regard to the doctor-to-population ratio, when compared with 
countries that have similar income levels, in 2007, Indonesia had a considerably 
lower ratio: 21 doctors per 100,000 (although this improved to 36 in 2012) compared 
with 58 in the Philippines and 70 in Malaysia; and even when compared with 
countries with lower income per capita than Indonesia.7  
 
In addition to the low doctor-to population ratio, it also was reported that Indonesia 
had the lowest ratio of endocrinologists to people with diabetes in Asia (1:118,000), 
and had only about 3,000 internal medicine specialists in 2013.6 Given the small size 
of the medical workforce, one solution offered was to optimise the use of other 
healthcare workers, thus improving access to care.62 
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2.2.4   Community pharmacy  
 
 
2.2.4.1   Pharmacy profession 
 
Based on the Indonesian Government Regulation No. 51 of 2009 regarding 
Pharmacy Practice,75 pharmacists are professional health personnel authorised to 
conduct pharmacy practice that includes: 
• production and quality control of pharmaceutical products  
• safety assurance, procurement, storage and distribution of medications 
• supply of prescription medications 
• provision of drug information services 
• development of drugs, medical products and traditional medicines.  
The work of pharmacists can be supported by pharmacy technicians – those who 
have completed qualifications such as Bachelor of Pharmacy, undergraduate 
Diploma of Pharmacy, undergraduate Diploma of Pharmaceutical Analysis 
(pharmacy analyst), or senior secondary education in pharmacy (pharmacy 
assistant).75 
 
A qualified pharmacist is required to complete the pharmacy undergraduate course 
(Bachelor of Pharmacy) which is followed by one year pre-registration training. 
Every pre-registration trainee has to spend his or her year attending lectures as well 
as gaining experience in hospitals, community pharmacies, industry and the Ministry 
of Health offices. It has been argued that, while this gives the average Indonesian 
pharmacist a wider knowledge of all areas of pharmacy practice, this arrangement 
may not give them sufficient experience in any branch of practice.55  
 
The Ministry of Education regulates pharmacy education in Indonesia. In 2000, 
Asosiasi Perguruan Tinggi Farmasi Indonesia – APTFI (Indonesian Association of 
Higher Education of Pharmacy) was established to serve as a platform for the 
exchange of ideas and strategies in pharmacy education amongst schools of 
pharmacy in Indonesia. In 2008, the association established a national pharmacy 
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curriculum (Bachelor of Pharmacy79and pre-registration training80) in the hope of 
achieving an equivalent level of competency for pharmacy graduates across all 
schools of pharmacy in Indonesia. The national curricula included pharmacotherapy 
subjects as a basis for providing pharmaceutical care. Practising pharmacists are 
registered within Ikatan Apoteker Indonesia – IAI (Indonesian Pharmacists 
Association). In 2011, this professional assosication renewed the standards of 
competency for pharmacists in Indonesia.81 
 
According to the Indonesian Government Regulation No. 51 of 2009,75 practising 
pharmacists should be nationally registered by Komite Farmasi Nasional – KFN 
(National Pharmacy Committee), which is an independent body under the Ministry 
of Health. Guidance about the registration process is provided within the Ministry of 
Health Regulation No. 889 of 2011.82 Pharmacists are obliged to renew their 
registration every five years and each renewal requires a certificate of competency 
issued by the IAI. Supporting this, the association developed a system for 
competency assessment. Currently, the assessment is conducted through an 
examination following a two-day workshop; later, it is planned to adopt a portfolio 
system where pharmacists are required to complete a certain level of credits related 
to continuing professional development/continuing professional education 
(CPD/CPE) activities.83  
 
 
2.2.4.2   Community pharmacy characteristics 
 
It has been estimated that Indonesia has 45,000 pharmacists, of whom 20,799 have 
been registered within the IAI in 2014.78 Based on the 2012 Indonesia Health Profile, 
there are a total of 17,613 pharmacies,63 mainly community-based. A study in 
Jakarta, Indonesia, reported that about 60% of community pharmacy customers 
privately purchased medications and only about 40% purchased medications with 
prescriptions.26 A majority of pharmacies dispensed less than 350 prescriptions 
(which may contain one or more than one medication items) per week. This is in line 
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with a previous study which found that community pharmacies in Jakarta dispensed 
an average of 50 prescriptions per day.24 
 
Community pharmacies in Indonesia focus on providing pharmaceutical services to 
the private sector.77 The government regulation allows a community pharmacy to be 
owned by a pharmacist and/or a person, being either a body corporate or a natural 
person, who is not a pharmacist.75 Regardless of the ownership, a pharmacy is 
required to have a pharmacist manager  who is legally responsible for the pharmacy 
practice.75 Thus, a community pharmacy can be owned by a pharmacist manager 
(Apoteker Penanggungjawab Apotek – APA), a proprietor – a non-‘pharmacist 
manager’ owner (Pemilik Sarana Apotek – PSA) with an employed pharmacist 
manager, or a partnership between the pharmacist manager and proprietor. It was 
reported that the majority of community pharmacies in Jakarta were owned by 
proprietors (73.5%)24 and were independent pharmacies (87.8%)26. Both studies 
reported that more than 70% of the pharmacist managers were working part-time,24,26 
while most of them did not have other employee pharmacists.24  
 
 
2.2.4.3   Community pharmacy practice 
 
Since the introduction of the concept of Pharmaceutical Care in the eighties, this 
initiative has become a dominant form of community pharmacy practice 
worldwide.11, 12 The principles of pharmaceutical care derive from the concept of 
Good Pharmacy Practice (GPP). It is defined as “the responsible provision of 
pharmacotherapy for the purpose of achieving definite outcomes that improve a 
patient’s quality of life. It is a collaborative process that aims to prevent or identify 
and solve medicinal product and health related problems. This is a continuous quality 
improvement process for the use of medicinal products”.84 In 2006, pharmaceutical 
care was included within Indonesian legislation (Ministry of Health Decree No. 
1027/MENKES/SK/IX/2004: Standards for Pharmaceutical Care in Community 
Pharmacies);23 the legislation is followed with technical guidance introduced in 
2008.85  
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Based on the standards, pharmaceutical care in Indonesian community pharmacies 
should include, but not be limited to, the following services:23, 85 
 
1) Prescription medication service 
 
• Prescription review  
Pharmacists should perform prescription review, including:  
- Administrative review (completeness and legal aspects): doctor 
identity (i.e. name, licence number, address), prescription date, 
patient identity (i.e. name, gender, weight), clear instructions for 
use, and other information.  
- Pharmaceutical review: dosage form, strength, stability and 
compatibility, route of administration. 
- Clinical review: known medication adverse effects including 
allergies, interactions with other medications taken, 
appropriateness (dose, frequency, duration and other specific 
conditions/comorbidities). Pharmacists are advised to contact the 
doctor if there is any problem with the prescription. 
 
• Drug dispensing/supply 
- Dispensing medications: This includes preparing/compounding 
medications, labelling and packaging. Prescription medications 
should be provided with an attached label (white for oral use and 
blue for non-oral use). The label is to include patient name and 
medication directions for use according to the prescription. 
Ancillary labels may also be provided, such as “shake well before 
use”.  
- Delivering medications: Prescription medicines should be 
delivered by the pharmacist.75 Before delivering the medicine, 
pharmacists should conduct a final check to ensure that the 
medicine (and information on the label) is the same as on the 
prescription. 
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• Drug information and counselling 
When delivering prescription medicines to the patient or their carer, 
pharmacists should provide drug information and counselling. The drug 
information is, at least, to include: how to use medications, duration of 
use, storage and, if any, specific activity or food that should be avoided 
during treatment. Patient counselling is to identify and solve problems 
related to the patient’s use of medications (based on information obtained 
from the prescription, patient medication record, or patient 
interview/written report). This should be done continuously for patients 
with chronic diseases, such as diabetes.  
 
• Monitoring 
The pharmacist actively monitors the patient’s use of medications 
(effectiveness, adverse effects, compliance and other problems), 
particularly for patients with chronic diseases, such as diabetes.  
 
2) Promotion and education 
Pharmacists should provide health promotion and patient education to motivate 
self-care (i.e. what people do for themselves to establish and maintain health, 
prevent and deal with illnesses; it is a broad concept encompassing hygiene, 
nutrition, lifestyle, environmental factors, socioeconomic factors and self-
medication86). Pharmacists also can help in distributing health information by 
means of oral (e.g. community education) or written (e.g. leaflets, brochures, 
posters) presentations. 
 
3) Home/residential care  
It is recommended that pharmacists (as care givers) can provide 
home/residential care, particularly for the elderly and patients with chronic 
diseases.  
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Pharmaceutical care is a form of multidisciplinary collaboration, which means that 
the pharmacist and the doctor (and possibly other care providers) jointly arrive at an 
optimal treatment plan for the patient.12 It requires that a professional relationship 
between the pharmacist and the patient is established and maintained, and that 
records of a patient’s medications and other specific information are collected and 
evaluated. In the case of prescription medicines, a therapy plan needs to be 
developed involving the doctor and the patient.84 Within the aforementioned 
Indonesian standards, community pharmacies are required to develop Patient 
Medication Records (PMRs) and to have a private counselling area/room to provide 
care.64, 65  
Several studies have been conducted to evaluate community pharmacy practice in 
Indonesia. Studies by Purwanti et al.24 (N=65) and Herman et al.25 (N=40) compared 
community pharmacy practice in Jakarta/Makassar/Jogjakarta, Indonesia using the 
previous standards (Standards for Pharmacy Services in Community Pharmacies, 
200387). These standards consisted of four areas, including: non-prescription 
services, prescription services, information/education services and handling of 
medications. Both studies showed inadequate compliance with the standards, 
particularly for information/education services (32.4% and 58.6%, respectively). In 
addition, a study by Zurmatias26 (N=98) compared community pharmacy practice in 
Jakarta with the GPP88, 89 which consists of four elements (i.e. health promotion, 
supply and use of medicines, self-care, influencing prescribing). The results showed 
that 69.4% of pharmacies were at the level of ‘less than good’. All of these studies, 
however, are limited by their small sample sizes and none have focused on diabetes 
care. 
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2.2.4.4   Method of payment 
 
Typically, reimbursement to the pharmacy is based on the cost of the drug sold plus a 
small mark-up and a prescription fee (i.e. fee for preparing medications according to 
the prescription). Based on the reimbursement rate of JKN, the mark-up factor has 
been set according to the drug cost (see Table 2.9), while the prescription fee is      
Rp 300 (approximately A$ 0.03), or Rp 500 (approximately A$ 0.05) if 
compounding is required, per prescribed item.90 
 
 
Table 2.9   Mark-up factor for supplying medications 
 
Drug cost (per unit) The maximum mark-up factor 
≤ Rp 50,000 (approximately A$ 5) 20% 
< Rp 50,000  to 250,000 (approximately A$ 5 to 25) 15% 
> Rp 250,000 to 500,000 (approximately A$ 25 to 50) 10% 
> Rp 500,000 to 1,000,000 (approximately A$ 50 to 100) 5% 
> Rp 1,000,000 (approximately A$ 100) 2% 
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2.3   Community pharmacy-based services for type 2 diabetes 
patients 
 
Type 2 diabetes is a complex condition that requires more time and expertise than 
one practitioner can provide to achieve optimal therapeutic outcomes for the 
patient.37, 46 With the development of the concept of Pharmaceutical Care, in which 
pharmacists are expected to perform a wider role in patient care,84 an opportunity 
exists for community pharmacists to become more involved in the care of patients 
with type 2 diabetes. 
  
2.3.1   Intervention studies  
 
Extensive studies, worldwide, have tested the effectiveness of community pharmacy-
based interventions in supporting people with type 2 diabetes. Most of the studies 
have been conducted in developed countries and only a few studies have been 
reported from low and middle-income countries such as India14 and Brazil18. The 
range of interventions evaluated can be seen in Table 2.10. 
 
The interventions were measured for their effectiveness using: 
• clinical outcomes, such as glycaemic control,14-18, 20, 21, 91-95 reduction of risk 
factors,16-21, 95 adherence, 16, 17, 20, 96, 97 compliance to screening for 
complications,95 drug-related problems identified/solved16, 17, 20, 21, 96, 97 
• humanistic/social outcomes, such as quality of life,14-17, 22 satisfaction,17, 22, 98 
belief,98  knowledge,14, 17, 20, 21, 94 lifestyle changes,19 self-care activity22  
• economic outcomes, such as health cost.17, 95 
It was shown that community pharmacy interventions provided some improvements 
in those outcomes, though not all were statistically significant. A review which 
included selected studies between 1990 and 200391-94, 96-98 noted that components of 
community pharmacy-based interventions which appear to contribute to 
effectiveness included: patient education/consultation about their diabetes and its 
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treatment, medications and lifestyle changes, and monitoring/reviewing glycaemic 
control.13 
 
 
Table 2.10   Components of type 2 diabetes interventions in community pharmacies 
 
Stage Intervention Component 
Patient education Patient education/consultation  Disease process14 
  Goal setting91 
  Lifestyle: physical activity, diet14, 22, 91 
  Medications14, 96, 98 
  Psychosocial support: patient health beliefs96, 98 
  SMBG: blood glucose meters91 
  Prevention/treatment of complications: foot care, 
smoking cessation, hypertension, dyslipidaemia22 
  Unspecified91, 92, 94, 97/customised17 content 
  Patient self-management services95 
Monitoring/review Monitoring treatment outcomes Review of blood glucose results16, 91, 93 
  Physical examination (blood pressure, weight, 
feet, skin)91 
  HbA1c measurement92 
 Monitoring compliance Adherence questionnaire97 
  Medication review Medication review14, 93, 96, 98 
 Interventions based on patient outcomes 
(pharmacotherapy follow-up) 15, 16, 18-21 
Other Partnership with other health 
professionals 
Liaison with the prescribing doctor91, 98 
 Referral for patient education91, 92 
  Referral to a specialist nurse92 
  Referral for medical advice16, 92, 98 
Abrreviations: SMBG, self-monitoring of blood glucose; HbA1c, glycosylated haemoglobin 
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2.3.2  Reported practices of community pharmacists in type 2 diabetes 
care 
 
Pharmaceutical care is practised in community pharmacies around the world in 
varying forms and degrees.11, 29 Research on the practice of community pharmacists 
in the specific area of diabetes, however, is limited to a small number of studies30-35, 
99, 100 all of which have been undertaken in developed countries. The scope of 
diabetes services identified in these studies can be seen in Table 2.11. 
 
Although the scope of diabetes services was variable across studies, it was generally 
shown that services commonly provided were centred around patient education and 
monitoring. Components of education and monitoring provided by more than 50% of 
the community pharmacies in these studies included: patient education related to 
medications (particularly directions for use, and potential adverse effects), lifestyle 
education (particularly diet, exercise and smoking cessation), supporting patients in 
performing self-monitoring of blood glucose (SMBG), and monitoring compliance 
with medications (Table 2.11). 
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Table 2.11   The provision of diabetes services in community pharmacies 
 
Stage Service Component Being regularly provided 
(% of community pharmacists) 
Initial assessment History-taking Drug history ±70%30 
  Patient educational needs, assessment and resolution 21%31 
  Individualised coronary risk assessment 7%31 
 Physical examinations Foot checks 2%35 
Prescription review Prescription review (clinical aspects) Checking dose regimens/assessing prescriptions for adverse effects or 
interactions 
79%32 
Patient education Patient education/consultation Diabetes and its implications 20%35; 25%32; 44%31 
  Complications of diabetes, e.g. renal ±25%30 
  Treatment targets 10%35; 12%33 
  Medications:  
  - how to use antidiabetic drug 30%32; >50%34; 59%31; 60%33; >90%30  
  - what to expect from medications 2532 
  - potential adverse effects of antidiabetic drug 46%33; ±50%34; >90%30  
  - use/cautions of non-prescription medications 75%32; >80%30 
  - self-administration of insulin 11%33 
  - insulin storage 3733 
  Lifestyle (in general): 28%32; 57%31  
  - exercise 10%35; 15%33; 21%32; <50%34; ±70%30 
  - diet (basic information) 10%35; 15%33; 44%32; ±50%34; ±70%30  
  - alcohol <50%34; ±50%30  
  - other preventive activities - immunisation ±70% 30 
  SMBG (in general): ±50%32; ±70%30  
  - use of blood glucose meter 13%33; 30%35; 36%31; 95%34; 57%99 
  - interpretation of the results 15%35; 29%31; 54%34; 53%99 
  - control/calibration of the device 51%34; 37%99 
  Signs and symptoms/treatment of hypogylcaemia 20%33; ±50% 30  
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Table 2.11   (continued) 
Stage Service Component Being regularly provided 
(% of community pharmacists) 
Patient education Patient education/consultation  Prevention/treatment of complications:  
(continued) (continued) - controlling blood pressure ±50%30 
  - smoking cessation <50%34; 54%31; ±70%30 
  - weight reduction <50%34 
  - foot care 9%33; 49%31 
  Need for regular medical monitoring:  
  - diabetes check-up/review 47%31 
  - eye examination 6%33; ±10%32 
  - laboratory test – HbA1c, lipid, creatinine, microalbuminuria 14%33 
  Patient advice on achieving glycaemic control targets and blood pressure 
targets  
20% and 19%, respectively31 
  Patient advice on information available from patient organisations 28%31 
  Sick-day plan 14%33; ±20%30  
  Wearing medical alert bracelet 6%33; ±50% 30;  
  When to contact the healthcare provider 22%33; ±50%30 
Monitoring/review Monitoring treatment outcomes Review of the patient’s SMBG ±30%30 
  Blood pressure monitoring service 10%31; ±30%34 
  Blood glucose monitoring service 7%31; ±35%34 
  Cholesterol monitoring ±1%34; 6%31 
 Monitoring compliance Review of the patient’s drug refill history >80%30 
  Concordance problem assessment and resolution 36%31 
  Checking with patients if they have followed advice given <50%32 
 Monitoring adverse effects Identifying frequency of hypoglycaemia ±50% 30 
 Medication review Medication review 24%34; 31%31; 
  Providing drug therapy recommendation to the doctor/assisting with dosage 
adjustments 
5%35; ±25%30 
Abreviations: HbA1c, glycolylated haemoglobin; SMBG, self-monitoring of blood glucose
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2.3.3   Views on community pharmacists’ roles in type 2 diabetes care 
 
Understanding pharmacists’, doctors’ and pharmacy customers’ views about the 
roles of pharmacists in type 2 diabetes care would be useful in supporting practice 
change and designing professional development programmes in the area of diabetes.  
 
 
2.3.3.1   Pharmacists’ views 
 
Studies regarding pharmacists’ perspectives on diabetes care have been limited to 
developed countries. Two studies reported that pharmacists generally had a positive 
attitude towards diabetes, including recognition of the need for special training to 
help people with diabetes, the seriousness of the disease and the value of tight 
glycaemic control, as well as understanding the impact of this disease on individuals 
and their need for autonomy.30, 33 Further, some studies looked at diabetes services 
perceived as priority/future roles by community pharmacists.31, 34, 100, 101 It was 
shown that pharmacists were supportive of diabetes care services, particularly in the 
areas of patient education (such as education related to medications, healthy lifestyle 
and SMBG), and monitoring (such as monitoring compliance with medications, 
blood glucose monitoring service and providing feedback of glycaemic control) (see 
Table 2.12).  
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Table 2.12   Pharmacists’ views on their roles in diabetes care 
 
Stage Activity Component  Level of support* 
Dispensing: Dispensing Repeat medication service Strong31 
Beyond dispensing:    
Initial asessment History- taking Coordinated, targeted screening for high risk of CVDs Strong31 
  Assessment of an individual’s pharmaceutical care needs via patient interview Strong31  
Treatment plan Individualised treatment targets Agreeing treatment goals with patients Ambivalent31 
Development of treatment plan Designing and implementating pharmaceutical care plan Ambivalent31 
Patient education Patient education/consultation  Diabetes and its implications Strong34 
  Medications (in general): Strong34, 101 
  - how to use antidiabetic drugs Strong31, 100 
  - what to expect from medications Strong100 
  - potential adverse effects of antidiabetic drugs Strong100 
  - use/cautions of concurrent medications Strong100 
  Lifestyle:  
  - exercise Minimal100 
  - diet (basic information)  Ambivalent34, 100 
  - alcohol Strong100 
  SMBG Strong34, 100 
  Signs and symptoms/treatment of hypogylcaemia Strong100 
  Prevention/treatment of complications  
  - smoking cessation  Ambivalent 34, 100 
  - weight reduction Ambivalent100 
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Table 2.12   (continued) 
Stage Activity Component  Level of support* 
Monitoring/review Monitoring treatment outcomes Monitoring to support pharmaceutical care provision (in general): Ambivalent31 
  - weight measurement Minimal100 
  - blood pressure monitoring service  Ambivalent34 
  - blood glucose monitoring service Strong34 
  - cholesterol monitoring Minimal34 
  Checking patient’s glucose monitoring Strong101  
  Providing patients with routine feedback of glycaemic control, blood pressure and 
cholesterol-monitoring results31 
Strong31 
  Providing a quality control scheme that tests the reliability of home-testing equipment 
and the competence of patients 
Ambivalent31 
 Monitoring compliance Signaling when patients use their medications incorrectly and discussion of this Strong100 
 Medication review  Pharmaceutical care recommendations made to the multidisciplinary team Ambivalent31    
Abrreviations: CVD, cardiovascular disease; SMBG, self-monitoring of blood glucose 
* Level of support: 
- Strong:  ‘desirable’ (concensus achieved from 1st round of questionnaire); or mean >5 (1=totally disagree, 9=totally agree); or priority services selected by >50% of respondents 
- Ambivalent:  ‘desirable’ (concensus achieved after 2nd round of feedback discussion); or mean 3-5 (1=totally disagree, 9=totally agree); or priority services selected by 30-50% of 
respondents 
- Minimal:  ‘undesirable’; or mean <3 (1=totally disagree, 9 = totally agree); or priority services selected by <30% of respondents) 
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2.3.3.2   Doctors’ views 
 
Although the available data reporting doctors’ views on community pharmacists’ 
roles were not specific to diabetes care, the findings have illustrated a range of 
attitudes towards aspects of community pharmacists’ roles (see Table 2.13). Two of 
these studies were conducted in the developing countries of India102 and Malaysia103. 
 
In general, doctors had positive attitudes towards community pharmacists as major 
drug experts in primary care.102-108 Thus, they strongly supported pharmacists in 
extending their roles in relation to drugs (product-related activities) such as technical 
roles of dispensing,108 maintaining patient medication profiles,105, 108, 109 checking for 
prescription errors (clinical aspects),107, 108 patient education related to medications108 
and monitoring compliance with medications,106, 108, 109 as well as being a source of 
medicine information to doctors (advisory roles).102, 107, 108 However, there was little 
support for the idea of pharmacists undertaking more patient-related activities such 
as health screening,105, 106, 109 monitoring treatment progress,105, 108 and assisting in 
development/adjustment of treatment plans (co-decisive roles).105-108  
 
Some of the studies evaluated doctors’ characteristics that might influence their 
attitudes towards the care-providing function of community pharmacists. It was 
reported that doctors’ views correlated significantly with the relationship between 
doctors and pharmacists.104 However, the Malaysian study showed that the majority 
of doctors (98.9%) never or rarely interacted with community pharmacists in relation 
to patient care matters.103 In addition to the relationship between doctors and 
pharmacists, age or years of experience were reported to influence the doctors’ 
perspectives, however, the results were inconsistent among the studies.102, 103, 105, 107  
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Table 2.13   Doctors’ views on community pharmacists’ roles (general) 
 
Stage Activity Component Level of support* 
Dispensing: Dispensing Mostly involved in dispensing Marginal102, 106, 108 
  Technical prescribing information, eg. availablity of medication Strong108 
  Repeat-medication service Variable, depending to the level of 
dependence (12%-81%)104-106, 108 
Beyond dispensing:    
Initial assessment History-taking Maintaining a complete medication profile Marginal105/Strong108 
  Including non-prescription products in patient medication profile Strong109 
Prescription review Prescription review (clinical aspects) Detecting prescription errors (checking dose, interaction, contraindication) Marginal105/Strong107, 108 
  Contacting doctors on matters related to prescribing and prescription errors Marginal103, 109 
Treatment plan Development of treatment plan  Assisting in design of drug therapy plan Minimal105, 106 
 Advice to prescriber Being a source of clinical medicine information for doctors, such as drug 
adverse effects  
Marginal105/Strong102, 107, 108 
  Being a source of clinical advice to doctors, such as selection of a medicine 
for a particular disease state 
Ambivalent104, 108/Marginal109 
  Advising on the cost-effectiveness of medicines for disease states       Ambivalent102, 105/Marginal106, 108 
Patient education Patient education/counselling General counselling Marginal102 
  Health and medicines Marginal103 
  Medications:  
  - safe and appropriate use of the medicine Marginal105, 107, 109 
  - benefit of the medicine Marginal108 
  - drug adverse effects Strong108 
  - how to manage drug adverse effects Ambivalent109 
  Smoking cessation Minimal103 
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Table 2.13   (continued)  
Stage Activity Component Level of support* 
Monitoring/review Monitoring compliance  Monitoring cmpliance with medications Strong106, 108, 109 
 Monitoring treatment outcomes  Assessing effectiveness of treatment by monitoring the patient’s 
progress/response – and letting doctors know if any DRP occurred  
Minimal105, 108 
  Health screening service (in general)  Minimal105/Ambivalent109 
  - screening for raised blood lipids  Minimal106  
  - screening for raised blood pressure Minimal106 
  - screening for glycosuria Ambivalent106 
 Monitoring adverse effects - Monitoring/reporting adverse effects Strong106, 108 
 Medication review Formally reviewing patient’s medicine (screening DRP) and discussing 
possible alteration to medication therapy with doctors (solving DRP)  
Ambivalent105, 107, 108 
  Making dose adjustments to a patient’s medicine/adjusting drug therapy 
using protocols established with doctors 
Minimal 105, 107-109 
 Referral Writing referral forms for patients seen in the pharmacy, but requiring 
treatment from their doctors 
Ambivalent105, 106/Marginal109 
  Referring customers that exhibit drug-related problems to the doctor  Marginal103 
  Referring customers who are not suitable for self-care to the respective 
medical practitioner 
Marginal103 
Abreviations: DRP, drug-related problem 
* Level of support: 
- Strong: >75% of respondents strongly agree/agree; or mean >6 (1=strongly disagree; 7=strongly agree) 
- Marginal: >50-75% of respondents strongly agree/agree); mean >5-6 (1=strongly disagree; 7=strongly agree) 
- Ambivalent: >30-50% of respondents strongly agree/agree); mean >3-5 (1=strongly disagree; 7=strongly agree) 
- Minimal: <30% of respondents strongly agree/agree); mean 1-3 (1=strongly disagree; 7=strongly agree) 
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2.3.3.3   Patients’ views 
 
Studies worldwide have been conducted to investigate customer utilisation of, or 
attitudes towards, community pharmacies (general aspects of care); some have been 
conducted in developing countries such as Indonesia,28, 110 Malaysia,111 South 
Africa,112 Iraq,113  Nigeria,114 and Boznia and Herzegovina.115 However, only a few 
studies have focused on diabetes patients and services;116-120 all were conducted in 
developed countries. In addition to the diabetes studies, a recent literature review 
reported customer or public views towards community pharmacy activities in 
promoting and maintaining health, which can be seen as an integral part of diabetes 
management.121 
 
It has been shown that community pharmacies are essential points of contact for 
health care, with more than half of the study respondents visiting a pharmacy at least 
monthly,113, 119, 122, 123 particularly for purchasing medications.111, 113, 119, 122, 124 In 
general, patients have positive perceptions of community pharmacists. 
Approximately 50% of the respondents perceived pharmacists to have a balanced 
role between that of a member of a health care team and that of a business person;115, 
122-126 and about half of the respondents would initially talk to pharmacists regarding 
information or advice on their medications.113, 123, 124 However, the qualitative 
findings reported that patients wanted their doctors to initiate and validate 
pharmacist-led interventions.120 It was suggested that the extent to which patients 
would engage with the pharmacist depended on the accessibility and level of care 
from their doctors.120, 127 
 
Patients were generally satisfied regarding pharmacists’ professional 
characteristics,28, 115, 122 such as knowledge (on medications),116, 122, 123 
interests/concerns,114, 116, 122, 123, 126 efficiency,114, 116, 122, 123, 126 availability at 
designated hours,114, 125 trustworthiness of the advice,112, 117 
politeness/friendliness/relationship,28, 112, 114, 116, 122 making customers feel 
comfortable,115, 117, 123, 126 and willingness to help.28, 114, 115 Moreover, patients were 
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highly confident about pharmacists’ technical roles of dispensing/supplying 
medications.114, 116  
 
In most studies, patients mainly used or were offered product-related services, such 
as dispensing and education related to medications.22, 28, 111, 112, 114, 115, 122, 123, 125 Only 
a limited number of studies explored patient expectations regarding aspects of 
community pharmacists’ roles (Table 2.14). It was found that patients were strongly 
supportive of their activities related to medicines, such as obtaining a patient’s 
medication history,124, 126, 128, 129 checking prescriptions,82, 85 patient 
education/counselling on medications, 110, 115, 118, 124, 128, 129 and referral to doctors.123, 
124, 128 There were mixed responses towards pharmacists providing a more patient-
centred service, such as discussing patient treatment plans with doctors,126, 129 
offering monitoring services (using clinical testing devices),117, 121, 123, 124, 128 and 
monitoring patient progress.118, 123, 124, 129 In addition, low expectations regarding 
pharmacists providing health advice were described.78, 89 In support of this, the 
qualitative findings reported that participants identified the primary expertise of the 
community pharmacist as medicines supply, and there were differing views about a 
pharmacist’s role being extended to advising on prescription medicines and 
diseases/health, or providing monitoring/screening services.120, 127 
 
Some of the studies further evaluated patient characteristics that may influence their 
views about pharmacist roles. It was reported that older patients118, 123, 127, 128 and 
patients who had diabetes for longer periods of time118 were less likely to believe that 
pharmacists should conduct pharmaceutical care activities, when compared to 
younger patients and to those who had diabetes for a shorter duration. This finding 
was inconsistent with an Iraqi study113 and a UK study (qualitative)120  which 
reported that older patients and those living with diabetes for a long time, 
respectively, were more likely to acknowledge the contributions of pharmacists. In 
addition to the age and duration of diabetes, patients who had contact/formed  a 
relationship with their pharmacists were more supportive of pharmaceutical care 
activities.120, 123, 126 Some other studies showed more positive attitudes of diabetes 
patients who had experienced pharmaceutical care.17, 22, 95, 130, 131  
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It was found that the majority of patients were not willing to pay for advice112, 114, 123, 
128 or diagnostic testing.128 A study in the USA, however, showed that 68% of 
diabetes patients would be willing to pay for a pharmacist to monitor their diabetes, 
and urged third-party payers to reimburse this service.117 In addition to cost, patients 
had mixed responses towards pharmacists’ availability to answer drug-related 
questions (spending enough time),112, 115, 116, 120, 122, 124, 126 and maintaining 
confidentiality.113, 122-124 While some expressed concerns about 
confidentiality/privacy which may relate to the open nature of pharmacies or 
unavailability of a consultation room,120, 123, 124 some felt uncomfortable with the 
situation and the space available for consultation in the pharmacy (e.g. it was 
‘breaking the rules’, or an opiate-substitution service).120, 127 Patients also expressed 
concerns regarding the incomplete nature of community pharmacy service provision 
(e.g. if the pharmacist detected high blood pressure, he would not prescribe 
medication), and the lack of information transfer between the community pharmacy 
and doctors.127  
 
A qualitative study by Tarn et al.132 (USA) linked patients’, doctors’ and 
pharmacists’ views on community pharmacist roles. They all indicated that 
pharmacists often functioned as an intermediary between patients and doctors: to 
expand upon, reinforce and explain doctor-patient discussions about medications as 
well as to negotiate medication changes or refills. Concerns were identified in 
relation to pharmacist-patient and pharmacist-doctor communication, including: 
incomplete information (e.g. patient medical conditions, indications for prescribed 
medications and doctor treatment plans), problems with contacting doctors, and 
pharmacists’ time constraints to provide patient counselling. Doctors also expressed 
concerns regarding variations in the quality and content of pharmacists’ counselling 
(across pharmacies as well as between pharmacy staff).  
 
While the views of pharmacists, doctors and patients regarding diabetes services in 
developed countries are helpful, it is important to better understand the views of 
Indonesian pharmacists, doctors and patients to underpin the development of local 
pharmacy-based services for type 2 diabetes. 
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Table 2.14   Patients’ views on community pharmacists’ roles (general and diabetes care) 
 
Stage Activity Components Level of support* 
Dispensing: Dispensing Mostly involved in dispensing Minimal125, 126 
  Prescription drugs clearly labelled Strong124 
Beyond dispensing:    
  Provision of a wider range of services Ambivalent116, 124/Strong123 
  Management of chronic condition Marginal122 
Initial assessment History-taking Medication history Marginal124, 128/Strong126, 129 
  Medical history Marginal129 
Prescription review Prescription review (clinical aspects) Checking prescription for accuracy in terms of drug name and dose Strong124, 126 
Treatment plan Development of  treatment  plan Talking with doctors about medication treatment plan Variable (42 to >75%)126, 129 
Patient education Patient education/consultation Disease Ambivalent119/Marginal124 
  Medication: Marginal118, 128/Strong110, 124 
  - directions for use of medication Strong115, 124 
  - medication’s action and indication Variable (24 to >75%)115, 124, 128, 129 
  - drug adverse effects/interaction Marginal119, 128/Strong124, 129 
  - drug dosage Ambivalent128 
  - drug storage Minimal128 
  - how to manage drug adverse effects Ambivalent119 
  - answering drug-related questions Strong124 
  - review and discussion of medications with patient Marginal118 
  SMBG Ambivalent119 
  How to manage blood glucose Minimal119 
  How to pay less for medication Marginal119 
  Health promotion/health issues Minimal/Ambivalent121, 128 
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Table 2.14   (continued) 
 
Stage Activity Components Level of support* 
Monitoring/review Monitoring outcome targets Performing screening/monitoring services Variable (26-87%)121, 123, 124, 128 
  - blood glucose Marginal117 
  - blood pressure Ambivalent128 
  - cholesterol Minimal128 
  Monitoring patient’s progress/response to treatment Variable (23->50%)118, 123, 124, 129 
 Medication review Adjusting either the dose of medication or the medication itself (according to 
agreed protocols with doctors) 
Ambivalent123 
 Referral Talking about patient symptoms and advising when to visit doctors Marginal128/Strong123, 124 
Abbreviations: SMBG, self-monitoring of blood glucose 
* Level of support: 
- Strong : >75% of respondents strongly agree/agree; or mean >4 (1=totally disagree, 5 = totally agree) 
- Marginal : >50-75% of respondents strongly agree/agree; or mean >3-4 (1=totally disagree, 5 = totally agree) 
- Ambivalent: >30-50% of respondents strongly agree/agree; or mean >2-3 (1=totally disagree, 5 = totally agree) 
- Minimal: <30% of respondents strongly agree/agree; or mean ≤2 (1=totally disagree, 5 = totally agree) 
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2.3.4   Factors associated with the development of community pharmacy-
based services 
 
The pharmacy profession’s attempts to change from product to patient orientation 
(pharmaceutical care) has been well documented.12, 133-135 However, the practice 
change appears to have been problematic and  than expected.136 Reviews of studies 
exploring factors (potential and actual) affecting service delivery in community 
pharmacies were reported by Roberts et al. (2006)137 and Thornley (2006).136 The 
latter review included 32 papers covering studies in developed countries (i.e. USA, 
UK, Denmark, Malta, the Netherlands, Australia, New Zealand, and Europe) and the 
majority of the studies used quantitative methods, as opposed to qualitative 
techniques. In addition, several papers were published after these reviews25, 27, 35, 138-
144 but only a few of them discussed factors in developing countries, i.e. Thailand,138 
China,144 and Indonesia25, 27. The summary of these factors can be seen in Table 2.15 
(barriers) and Table 2.16 (facilitators). 
 
Although the results of the studies across the various countries tended to be similar in 
nature, caution is advised on assessing the context/magnitude of each factor. Each 
country has different community pharmacy systems, settings, staffing structures, 
remuneration and funding streams, health systems, levels of support and pharmacist 
roles. Two qualitative studies were conducted in Indonesia (Herman et al., 200825 & 
201227) to analyse community pharmacy practice (compared to the standards23, 75, 87) 
and the related factors. The first study focused on SWOT (Strength Weakness 
Opportunity Threat) analyses of the pharmacies; the latter focused on the 
qualifications of pharmacists in delivering services. Both studies reported that 
community pharmacy practices in Indonesia did not fully conform to the standards. 
Concerns were expressed about pharmacist competencies and availability/presence in 
the pharmacy, thus suggesting the need for collaboration between the IAI, the 
government and schools of pharmacy to develop appropriate curricula and CPD/CPE 
activities, registration/competence assessment systems, remuneration systems, 
supporting systems and standards/legislations/policies. Although these studies 
highlighted some barriers and facilitators, the themes were not clearly evident. 
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Two of the studies reviewed the barriers/facilitators that are specific for diabetes 
services in community pharmacies. The first study, by Plake et. al. (2007),35 included 
791 community pharmacists in Iowa, USA. Of those, 241 pharmacists provided at 
least one diabetes care service; issues pertaining to remuneration, workload and 
available time were perceived as the most limiting barriers to providing the services. 
The second study by Berbatis et. al. (2007)139 was part of a national survey of 
community pharmacies in Australia that investigated the provision of extended 
services. It was reported that 48% of the respondents provided diabetes care services; 
logistic regressions were further used to analyse pharmacist/pharmacy characteristics 
associated with the provision of such services. Pharmacies with higher turnover and 
pharmacists with higher CPE hours were predictors for providing diabetes care; 
significant barriers identified were lack of confidence and the service not being 
regarded as ‘part of the job’. While these studies conducted in developed countries 
are helpful, a better understanding of the barriers and facilitators within an 
Indonesian context is vital in supporting the development of local pharmacy-based 
services for type 2 diabetes. 
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Table 2.15   Summary of the barriers for providing community pharmacy-based services  
Barriers Thornley, 
 2006136 
(Review) 
Ngorsuraches 
et al., 2006138* 
Thailand 
Berbatis 
 et al., 2007139* 
Australia 
Gasteluruttia 
et al., 2007140† 
Spain 
Plake et al., 
200735† 
USA 
Niquille et 
al., 2010143* 
Switzerland 
Yang et al., 
2010144* 
China 
Herman et al., 
200825 & 201227† 
Indonesia 
Pharmacist  ,        
Pharmacist attitude/perception         
- poor attitudes and opinions about extended services ♦   ♦ 
fear of change 
    
- lack of willingness ♦        
- low behavioural intention (perceptions that it would be difficult 
to carry out extended services) 
♦        
- low motivation, e.g. image, satisfaction (sense of enjoyment), 
pharmacist roles (obligation), business (added value) 
♦        
Pharmacist confidence  
- lack of confidence in ability to deliver extended service 
♦      
♦ 
  
Pharmacist competence 
- lack of knowledge and skills (competency) 
 
♦ 
 
♦ 
      
♦ 
Pharmacy         
Leadership          
- lack of leadership – internal pharmacy     ♦     
Pharmacy culture/practice orientation  
- profit-oriented 
 
♦ 
       
Pharmacy characteristics         
- physical environment, e.g. lack of consultation space/privacy ♦   ♦   ♦  
Staff resources         
- lack of pharmacists    ♦ 
shortage 
    ♦ 
 lack of presence 
- lack of support staff (suitably qualified) ♦        
- lack of communication and teamwork ♦        
Operational         
- lack of access to patient information/records ♦        
- lack of equipment and technology ♦        
- lack of use of protocols ♦        
- lack of access to reference literature ♦        
- lack of documentation system ♦        
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Table 2.15   (continued) 
Barriers Thornley, 
 2006136 
(Review) 
Ngorsuraches 
et al., 2006138* 
Thailand 
Berbatis et al., 
2007139* 
Australia 
Gasteluruttia 
et al, 2007140† 
Spain 
Plake et al, 
200735† 
USA 
Niquille et al., 
2010143* 
Switzerland 
Yang et al., 
2010144* 
China 
Herman et al., 
200825 & 201227† 
Indonesia 
Pharmacy (continued)         
Time         
- lack of pharmacist time (workload – administrative work) ♦ ♦  ♦ ♦ ♦ ♦ ♦ 
- lack of patient time ♦        
Customer         
Patient attitudes 
- low expectations 
 
♦ 
      
♦ 
 
Patient demand 
- lack of demand 
 
♦ 
   
♦ 
    
Healthcare professional relationship         
Relationship/collaboration with doctors 
- difficult to contact/poor relationship 
 
♦ 
  
♦ 
 
♦ 
   
♦ 
 
♦ 
External environment         
Leadership          
- lack of leadership – profession-wide (lack of guidance)   ♦  ♦     
Education and training         
- inadequate education (curricula) and training for pharmacists    ♦  ♦   
Remuneration 
- lack of remuneration/funding 
 
♦ 
 
♦ 
 
♦ 
 
♦ 
 
♦ 
  
♦ 
 
Legislation         
- Legal barriers or restrictions ♦   ♦     
- Slow introduction of legislations       ♦  
Poor communication with stakeholders ♦        
Non-conducive health care system/structure ♦        
Lack of evidence of benefits of services ♦ ♦       
*Quantitative studies: barriers perceived by >50% of respondents (strongly agree/agree) 
†Qualitative studies: themes of barriers 
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Table 2.16   Summary of the facilitators for providing community pharmacy-based services  
Facilitators Roberts et al., 
2006137 
(Review) 
Thornley,  
2006136 
(Review) 
Berbatis et al., 
2007139* 
Australia 
Gasteluruttia  
et al., 2009141† 
Spain 
Roberts et al., 
2008142* 
Austalia 
Herman et al., 
200825  & 201227† 
Indonesia 
Pharmacist       
Pharmacist attitudes and characteristics       
- good attitudes and opinions about extended services ♦ ♦  ♦   
- willingness ♦ ♦     
- behavioural intention of providing extended services  ♦     
- motivation, e.g. image, satisfaction (sense of enjoyment), 
pharmacist roles (obligation), business (added value) 
♦ ♦     
- fostering level of autonomy ♦ ♦     
- experience of extended services  ♦     
- pharmacist characteristics (e.g. patient centred, participation in CPE 
and higher degrees, effective soft networkers, staff development) 
 ♦     
Pharmacist confidence in ability to provide extended services ♦ ♦     
Pharmacist competence (knowledge and skills) ♦ ♦     
Pharmacy       
Management support and leadership  ♦ ♦     
Pharmacy culture/practice orientation ♦ ♦     
Pharmacy characteristics       
- physical environment, e.g. counselling area, layout, workflow ♦ ♦ ♦ ♦ ♦  
- rural location ♦ ♦     
- low prescription volumes ♦ ♦     
Staff resources       
- sufficient pharmacists    ♦   
- sufficient and qualified pharmacy staff ♦ ♦     
- use of pharmacy technicians ♦      
- communication and teamwork ♦ ♦   ♦  
- delegation of tasks ♦ ♦     
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Table   2.16   (continued) 
Facilitators Roberts et al., 
2006137 
(Review) 
Thornley, 
2006136 
(Review) 
Berbatis et al., 
2007139* 
Australia 
Gasteluruttia  
et al., 2009141† 
Spain 
Roberts et al., 
2008142* 
Austalia 
Herman et al., 
200825  & 201227† 
Indonesia 
Pharmacy (continued)       
Operational       
- access to patient information/records ♦ ♦ ♦    
- equipment and technology ♦ ♦     
- use of protocols ♦ ♦     
- access to reference literature ♦ ♦     
- documentation system ♦ ♦     
- quality assurance  ♦     
- developing relationship with patients  ♦     
Recruitment       
- high proportion of eligible patients visiting pharmacy ♦ ♦     
- appointment system   ♦    
Time       
- allocation of pharmacist time   ♦  ♦   
Customer       
Customer needs       
- attention for special patient groups ♦ ♦     
- improvement in patients’ drug use and outcomes  ♦     
Patient attitudes 
- improving patient attitudes 
♦ ♦     
Patient demands  
- demand for service 
♦ ♦  ♦   
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Table 2.16   (continued) 
Facilitators Roberts et al., 
2006137 
(Review) 
Thornley, 
2006136 
(Review) 
Berbatis et al., 
2007139* 
Australia 
Gasteluruttia  
et al., 2009141† 
Spain 
Roberts et al., 
2008142* 
Austalia 
Herman et al., 
200825  & 201227† 
Indonesia 
Healthcare professional relationship       
Attitudes of doctors  
- improving doctor attitudes and perceptions 
 
♦ 
 
♦ 
    
Relationships/collaborations with doctors       
- good working relationship/communication ♦ ♦  ♦ ♦  
External environment        
Leadership (profession-wide) – examples from leading practitioners ♦   ♦   
Education and training       
- appropriate education (curricula) and training for pharmacists ♦ ♦  ♦  ♦ 
- appropriate education and training for pharmacy assistants  ♦ ♦    ♦ 
- professional and personal development   ♦ ♦ 
study time, 
accreditation 
  ♦ 
CPD/CPE, 
registration/ 
assessment system 
External support and assistance – mentors or advisors ♦ ♦   ♦  
Interaction with other pharmacists ♦ ♦     
Awareness of service – role definition       
- advertising and marketing ♦ ♦  ♦   
- communication with stakeholders  ♦     
Remuneration/incentives ♦ ♦  ♦ ♦ ♦ 
Legislation       
- legal supports  ♦ ♦  ♦  ♦  
standards of practice, 
law enforcement 
Profile within the local community ♦ ♦     
Pharmacy contracts   ♦     
Evidence of benefits of services    ♦   
Abbreviations: CPD, continuing professional development; CPE, continuing professional education 
*Quantitative studies: facilitators perceived by >50% of respondents (strongly agree/agree) or stated as key elements 
†Qualitative studies: themes of facilitators 
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2.4   Study methods 
 
To evaluate community pharmacy practice in the area of type 2 diabetes, data were 
collected employing a combination of questionnaire surveys and face-to-face 
interviews. The use of different data collection techniques to measure specific 
objectives allows triangulation, thus producing more robust data.145 These data 
collection techniques are briefly discussed below. 
 
 
2.4.1   Questionnaire survey 
 
Survey research is viewed as a quantitative approach, with data collected from a 
sample of sufficient size to enable generalisations to be made to a wider population. 
This approach aims to quantify the population in terms of predetermined 
characteristics, to identify frequencies of events, to establish the proportion of 
respondents who hold particular views and/or to describe associations between 
variables.145 Survey research enables the gathering of information from a large 
sample in a wide geographical distribution in a relatively short period of time.145, 146 
 
The survey instrument refers to the questions or questionnaire used to collect the 
data. It is important to consider the issues of validity and reliability when using a 
questionnaire.145 Validity refers to “the extent to which the questionnaire actually 
measures what it is designed to measure”. There are four main categories of validity: 
face validity – whether the questions collect accurate information; criterion validity – 
if the questions correlate with other measures of the same variable; construct validity 
– whether the questions present the concept precisely; and content validity – if the 
questions cover all the relevant issues (study objectives).145  An important step 
towards ensuring content validity is to conduct fieldwork, which generally implies 
organising interviews with a small number of individuals from the target population. 
This should be supported by literature review in order to identify issues which are 
relevant to the objectives of the study, thus providing content validity.145 
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Reliability relates to “the extent to which the findings are reproducible or internally 
consistent”.145  A procedure commonly adopted to check for consistency of 
interpretation and response is the test-retest procedure in which the instrument is 
administered to a different sample of respondents on two separate occasions, 
generally a few weeks apart.145   
 
Questions in a questionnaire may be closed or open ended. For closed questions, 
there is a limitation on the range of responses that can be given. It has been 
suggested that closed questions are often preferred in self-administered 
questionnaires as they are quicker and easier to answer and their use also results in 
less missing data. Closed questions also are more practical for the researcher in terms 
of coding and data analysis.145, 146 On the other hand, open questions allow 
respondents to express themselves more fully. These questions are more difficult for 
the researcher to code and categorise. It has been suggested that open questions are 
usually left to the end of the questionnaire so that respondents have the opportunity 
to add issues not covered in the questionnaire, hence providing a good check of 
content validity.145 
 
Questionnaires which assess respondent views or attitudes rely on respondents 
expressing their opinions based on statements given. Respondents need to have a 
choice of different strengths that best reflects their opinion on particular statements 
given. For this purpose, scales such as the Likert are used.145 This scale was 
developed in 1932 and still remains one of the most commonly used attitudinal 
measurement scales.145 
 
 
2.4.2   Interview  
The interview is a key method in the qualitative approach, aiming to explore 
viewpoints of individuals on the issue of interest.145 It generally relies on a small 
sample that enables detailed work to be conducted; the sample size considerations  
shift focus onto data saturation (i.e. when no more new themes can be derived from 
the data collected).145, 147 Interviewing is a useful method to capture candid and 
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sensitive information from participants who may not feel comfortable sharing in a 
writing or a focus group setting. It also has the advantage of overcoming the 
difficulties of scheduling multiple professionals from different facilities to participate 
in a common discussion at a single time and location.148 
 
The data collection instrument is commonly referred to as the interview guide. In the 
development of the interview guide for qualitative studies, concerns relate to the 
topic headings and the extent to which the guide is structured. An unstructured guide 
provides a few topic headings which are explored according to the issues raised by 
the participant, while a semi-structured guide possibly represents a half-way house 
between providing participants with the opportunities to express their views and 
obtaining information relating to issues of interest to the researcher. The extent of 
structuring also will be governed by the degree to which the researcher has 
preformed ideas regarding the topics on which they want the respondents’ views.145 
 
As for quantitative approaches, Guba and Lincoln suggest that credibility (in 
reference to validity), dependability (in reference to reliability), and transferability 
(in reference to generalisability) should be considered in the pursuit of trustworthy 
qualitative data.149 Credibility refers to the extent to which the data are an accurate 
reflection of the views of the participants. Some techniques are used to address the 
credibility issue, such as having participants validate findings (member checking), 
thick description of the issue of interest, or examination of previous research to 
frame findings.150 Dependability or reliability is often not a pertinent issue in 
qualitative work, in which the data are expected to be context specific. However, 
attempts should be made to provide an in-depth methodological description of the 
study, thereby enabling a future researcher to repeat the work, if not necessarily to 
gain the same results.150 Transferability evaluates whether research findings are 
transferable to other specific settings. To allow transferability, researchers should 
provide sufficient detail of the context of the study for a reader to be able to decide 
whether the prevailing environment is similar to another situation with which he or 
she is familiar and whether the findings can justifiably be applied to the other 
setting.150 
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Chapter 3 
Pharmacy-based services for type 2 diabetes patients:  
Pharmacist survey 
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3.1   Introduction 
 
A range of community pharmacy-based interventions have shown positive outcomes 
in supporting people with type 2 diabetes (see Table 2.10). However, published work 
regarding practices and views of community pharmacists in the area of diabetes has 
been limited to developed countries (see Tables 2.11 and 2.12). 
 
Several studies have been conducted to evaluate community pharmacy practice in 
Indonesia.24-27 Three of these studies used questionnaires (quantitative approaches) to 
gain information from community pharmacists regarding their practices, which then 
were compared to the Government Standards or Good Pharmacy Practice (GPP).24-26 
Results indicated that Indonesian community pharmacy practices have not fully 
conformed to the standards, particularly in practising pharmaceutical care. While 
these studies were not specific to diabetes care and were limited by their small 
sample size, this present study was conducted to provide the first data from 
Indonesian community pharmacists regarding their practices in the area of type 2 
diabetes.   
 
 
3.2   Objectives  
 
The main objectives of this part of the thesis are: 
1. To collect data on the characteristics of community pharmacies and pharmacists 
in Surabaya, Indonesia 
2. To analyse current community pharmacy-based services for type 2 diabetes 
patients 
3. To assess community pharmacists’ views on their roles in type 2 diabetes care 
4. To identify factors (pharmacist/pharmacy characteristics) associated with the 
current provision of community pharmacy-based services for type 2 diabetes 
patients. 
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3.3   Methods 
 
The data collection instrument and methodology used in this study were approved by 
the Human Research Ethics Committee of Curtin University (Appendix 1) as well as 
Ikatan Apoteker Indonesia – IAI (Indonesian Pharmacists Association) (Appendix 3). 
A questionnaire survey of community pharmacists was conducted to address the 
objectives of the study.  
 
 
3.3.1   Setting and sample size 
 
Surabaya is the capital city of the province of East Java, Indonesia, and the second 
largest city in Indonesia. A list of community pharmacies in Surabaya was obtained 
from a survey conducted in 2011.151 Community pharmacies located in specialist 
clinics other than cardiovascular/endocrinology/internal medicine were excluded due 
to their limited contact with type 2 diabetes patients. This left a total population of 
597 community pharmacies. This study aimed to analyse the views of this population 
from a representative sample of pharmacies. In addition, it aimed to identify 
associations between pharmacist/pharmacy characteristics and the provision of 
current services, using logistic regression analysis.  For this type of analysis, a 
sample size of approximately 120 was considered to be the minimum required to 
identify associations between variables exhibiting a moderate effect size (with 80% 
power, and α=0.05).  Therefore, the study aimed to recruit N=200 pharmacies, which 
would have more power to detect associations. Allowing for a 50% response rate to 
the survey, a sample size of approximately 400 community pharmacies was 
considered adequate. A random sample of this size was obtained using the SPSS 
Statistics version 17.0. One pharmacist at each community pharmacy was invited to 
participate.       
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3.3.2   Data collection 
 
 
3.3.2.1   Questionnaire development 
 
The survey questionnaire consisted of three sections: (A) respondent pharmacist 
characteristics, (B) services for type 2 diabetes patients – current practice and views 
on pharmacists’ roles, and (C) pharmacy characteristics; in addition to the cover page 
containing information about the study and a consent form. Section B of the 
questionnaire contained a list of activities related to type 2 diabetes practice that was 
drafted based on a generic model generated from the literature (see Section 2.1.2.3). 
A 6-point Likert scale was used to enable respondents to choose different levels that 
best reflected their current practice (level of frequency of providing each service: 
1=never, 6=always) and views on their roles (extent of agreement for each service to 
be part of their roles: 1=definitely no, 6=definitely yes). This was followed by open-
ended questions: (i) to list any other services provided/viewed as part of their roles; 
and (ii) to explore priority roles: “In your opinion, what are the five most important 
services that should be provided at pharmacies for type 2 diabetes patients?’. The 
questionnaire was face and content validated by a panel of two project supervisors, 
five academics, two board members of the IAI and two Indonesian community 
pharmacists. All of their views and comments were considered and, where 
appropriate, were incorporated into the final questionnaire.  
 
The questionnaire then followed a translation process: (i) forward translation – the 
questionnaire was translated to Bahasa Indonesia by the principal investigator, whose 
first language is Bahasa Indonesia, and the conceptual equivalence was checked by a 
bilingual panel (consisting of the principal investigator and two academics with 
experience in instrument development and translation) to resolve any conflicting 
concepts of the translation; (ii) back-translation – the questionnaire was back-
translated to English by an independent English-first language translator; and (iii) the 
back-translation was compared to the original version by two project supervisors 
whose first language is English.  
 68 
 
The forward-translation questionnaire (Bahasa Indonesia) was piloted by ten 
community pharmacists in Surabaya. They were administered the questionnaire and 
interviewed on their understanding of the questions. The pre-testing resulted in minor 
changes to the final questionnaire (see Appendix 4). To assess reliability, the 
questionnaire was administered on two occasions with a two-week interval. Test-
retest reliability for diabetes services (Question 7, Section B, Appendix 4) was 
calculated using Kappa statistic tests. Responses to the Likert scales were grouped 
(ratings of 1 to 4, and ratings of 5 to 6) to ensure that Kappa was able to be 
calculated (this ensured some responses in each of the two broad categories, both 
before and after the two-week interval). All items reached Kappa scores greater than 
0.40 (ranging from 0.412 to 1.000), indicating ‘acceptable’ to ‘excellent’ levels of 
test-retest reliability. 152  
 
 
3.3.2.2   Questionnaire administration 
 
First round – A seminar on the new pharmacy regulations, with the Heads of both 
the IAI and the District Health Office of Surabaya as speakers, was conducted on 16th 
July 2011. An invitation letter directed to ‘The Pharmacist’ was sent to the random 
sample of 400 community pharmacies. A reservation to attend the seminar was 
required, and it was limited to one pharmacist per pharmacy. Two weeks before the 
seminar, non-responders were contacted by telephone to ensure that they had 
received the invitation and to offer a reservation. The questionnaire was included in 
the seminar kit distributed before the seminar. At the beginning of the seminar, the 
study was explained and the pharmacists were invited to participate. If the 
pharmacists had any questions regarding the questionnaire, they were able to talk to 
the principal investigator during the seminar. Those who completed the questionnaire 
could submit it to the seminar committee, either during the session breaks or at the 
end of the seminar. Upon submission of the questionnaire, it was checked for 
missing data and, if found, the pharmacist respondent was asked for the relevant 
responses (unless he/she chose not to respond). 
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Second round – the same questionnaire was mailed, in August 2011, to the sample 
community pharmacies whose pharmacists did not attend the seminar. A covering 
letter introducing the study was provided (see Appendix 5). After four weeks, the 
pharmacies were contacted by survey staff (via telephone or personal visits to the 
pharmacies) to ensure that the pharmacists had received the questionnaire and to seek 
a response. Upon collection of the questionnaire, the survey staff would check for 
missing data and ask for the related responses (unless the respondent pharmacist 
chose not to respond).  
 
 
3.3.3   Data analysis 
 
The IBM SPSS Statistics version 19.0 was used for data analysis. Descriptive 
statistics were used to summarise the characteristics of pharmacist respondents 
(Section A, Appendix 4) as well as the pharmacy characteristics (Section C, 
Appendix 4). These included frequencies for categorical variables and means, along 
with their 95% confidence intervals, for continuous variables. Medians, along with 
their ranges, were used for continous variables which were not normally distributed.  
The Kolmogorov-Smirnov test was used to test for Normality.  
 
In relation to services for type 2 diabetes patients (Question 7, Section B, Appendix 
4), frequencies were calculated for responses from Likert scales of current practice 
(level of frequency of providing each service), and views on roles (extent of 
agreement for each service to be part of roles). Moreover, content analysis was used 
for responses from open-ended questions to list any other services, and to select the 
five priority services at pharmacies (Questions 8 and 9, Section B, Appendix 4). 
These responses were coded, and frequencies were calculated. 
 
Logistic regression models were employed to identify factors (pharmacist/pharmacy 
characteristics) associated with current provision of pharmacy-based services for 
type 2 diabetes patients. Responses from each type of current activity were classified 
into binary variables which indicated ‘regular service’ (Likert scale ratings of 5 to 6) 
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versus ‘less frequent service’ (Likert scale ratings of 1 to 4), and were used as the 
dependent variables. Pharmacist characteristics included as independent variables 
were gender, experience and diabetes training. Pharmacy characteristics included 
were setting, ownership, number of total customers, number of customers dispensed 
antidiabetic medications and pharmacist availability. The models also included an 
independent variable indicating the pharmacist’s view about whether the sevice 
should be a part of their roles; the responses were classified into binary variables to 
indicate ‘agreement’ (Likert scale ratings of 5 to 6) versus ‘disagreement’ (Likert 
scale ratings of 1 to 4). A backward elimination strategy was used in the 
development of each regression model, whereby all independent variables were 
included initially, and then the least significant variable was dropped (one at a time) 
until the p-value associated with each of the variables remaining in the model was 
less than 0.05. Following convention, a p-value <0.05 was taken to indicate a 
statistically significant association in all tests. 
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3.4   Results 
 
 
3.4.1   Response rate 
 
Response rate refers to the number of community pharmacies whose pharmacists 
returned their questionnaires as a proportion of the sample community pharmacies. 
Of 400 questionnaires distributed to the sample of community pharmacies, a total of 
240 responses were gathered and useable, giving a total response rate of 60%. This 
included: 143 responses to the 204 questionnaires distributed in the first round 
(response rate of 70.1%); and 97 responses out of 196 questionnaires distributed in 
the second round (response rate of 50.5%). 
 
The characteristics of respondent pharmacists (Section A, Appendix 4) as well as 
their responses to the questions related to the pharmacy services in ‘patient 
education’ and ‘monitoring’ domains (Section B, Appendix 4) between the first and 
second round were not significantly different (p-values ranged from 0.060 to 0.989).  
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3.4.2   Pharmacist and pharmacy characteristics 
 
The characteristics of respondent pharmacists (Section A, Appendix 4) are 
summarised in Table 3.1. The majority of respondents were female with a median 
age of 37 years, and were managers of their pharmacies. The term ‘pharmacist 
manager’ was used for a pharmacist who was legally responsible for the pharmacy 
practice. More than half of respondents had more than five years of experience 
(59.2%), and had received training or continuing education concerning diabetes in 
the last year (57.1%).  
 
 
Table 3.1   Respondent pharmacist characteristics  
 
Pharmacist characteristics Frequency (%) 
      N=240 
Gender  
Male  38 (15.8) 
Female 202 (84.2) 
Age, years – median (range) 37 (23 – 79) 
Year of registration, median (range)  2000 (1962 – 2010) 
Position  
Pharmacist manager as well as owner 63 (26.3) 
Pharmacist manager 161 (67.1) 
Other pharmacist 16 (6.6) 
Years of experience as community pharmacist  
<2  years 31 (12.9) 
2-5 years 67 (27.9) 
6-10 years 64 (26.7) 
>10 years 78 (32.5) 
Diabetes training/continuing education in last year    
None 103 (42.9) 
1-5 hours 90 (37.5) 
6-10 hours 23 (9.6) 
>10 hours 24 (10.0) 
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The characteristics of the pharmacy premises (Section C, Appendix 4) are shown in 
Table 3.2. The majority of the pharmacies were located as stand alone (63.6%) and 
owned by proprietors (69.9%). The term ‘proprietor’ was used for a non-‘pharmacist 
manager’ owner. Pharmacist manager ownership accounted for only 30.1% of the 
pharmacies. 
 
The median operating hours of the pharmacies was 14 hours per day, and the 
majority of pharmacies had only one pharmacist, i.e. pharmacist manager. Only 
26.3% of the pharmacies had more than one pharmacist (up to a maximum of four 
pharmacists). To evaluate the notional pharmacist availability in each pharmacy, a 
ratio of total pharmacist working hours per week to total pharmacy opening hours 
per week was calculated. A ratio of 1 or more would indicate that a pharmacist was 
available during pharmacy opening hours. The results ranged from 0.0 to 2.1, with 
most pharmacies having ratios less than 1 (83.7%). This indicated that, in many 
pharmacies, there was no pharmacist on duty at some time when the pharmacy was 
open. 
 
Approximately 40% of the pharmacies had 1,000 to 2,000 customers per month, and 
51 to 100 patients with diabetes per month. A private area/room dedicated for 
counselling was provided by only a small number of premises (21.8%).  
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Table 3.2   Pharmacy characteristics  
 
Pharmacy characteristics Frequency (%) 
     N=239* 
Setting   
Stand alone 152 (63.6) 
Pharmacy within shopping mall complex 10 (4.2) 
Pharmacy within doctor clinic 77 (32.2) 
Ownership   
Pharmacist manager as owner 45 (18.8) 
Single proprietor†  139 (58.2) 
Group proprietor†  28 (11.7) 
Partnership of proprietor and pharmacist manager 27 (11.3) 
Opening days per week, median (range)  7 (6 – 7) 
Opening hours per day, median (range)   
   Monday – Saturday (N=239 pharmacies) 14 (5-24) 
   Sunday (N=153 pharmacies) 13 (2-24) 
Counselling area/room 52 (21.8) 
Number of pharmacists per pharmacy, median (range) 1 (1 - 4) 
Working hours of pharmacist per month, median (range)  
    Pharmacist manager (N=239 pharmacies) 100 (0 – 400) 
    Other pharmacist (N=63 pharmacies) 180 (36– 350)  
Customers per month   
≤500 34 (14.2) 
501 – 1000 59 (24.6) 
1001 – 2000 97 (40.6) 
2001 – 4000 39 (16.3) 
>4000 10 (4.2) 
Customers dispensed oral antidiabetic medications per month   
≤50 93 (38.9) 
51 – 100 108 (45.2) 
101 – 250 23 (9.6) 
251– 500 10 (4.2) 
>500 5 (2.1) 
Customers dispensed insulin per month   
≤10 217 (90.8) 
11 – 50 19 (7.9) 
>50  3 (1.2) 
* From a total of 240 respondents, there was 1 missing response for each variable, giving a total N=239  
† Proprietor is defined as non-‘pharmacist manager’ owner  
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3.4.3   Current pharmacy-based services for type 2 diabetes patients 
 
The participating pharmacists were given a list of services for type 2 diabetes 
patients and they were asked to rate the frequency of providing each service in their 
pharmacies (Question 7, Section B, Appendix 4). No new services were raised from 
the subsequent open-ended question to list any other services provided/viewed as 
part of their roles (Question 8, Section B, Appendix 4). 
 
 
3.4.3.1   Dispensing 
 
All of the respondent pharmacists reported that they frequently (Likert scale ratings 
of 5 to 6) prepared medications and provided labels with instructions for their use for 
type 2 diabetes patients (see Table 3.3).  
 
 
Table 3.3   Current pharmacy-based services related to ‘treatment administration’ 
 
Treatment administration % Rating level of frequency*  
N= 240 
1 2 3 4 5 6 
Prepare medications 0.0 0.0 0.0 0.0 23.3 76.7 
Provide labels with instructions for use  0.0 0.0 0.0 0.0 19.6 80.4 
*1=never, 6=always 
 
 
3.4.3.2   Services beyond dispensing 
 
Services other than dispensing were performed in a relatively limited fashion. The 
only frequent service reported by more than 50% of the repondent pharmacists was 
‘patient education’ on medications, particulary directions for use. Other services, 
related to ‘initial assessment’, ‘treatment plan’, ‘monitoring’ and ‘review’ domains, 
were reported as less common practice. The responses describing current practice are 
summarised in Tables 3.4 to 3.8. 
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a)   Initial assessment 
 
When type 2 diabetes patients visited pharmacies, less than 50% of the pharmacists 
commonly performed ‘initial assessment’ activities. Among those, the most frequent 
activity was the taking of a patient history, particularly in relation to: age (33.3%), 
duration of diabetes (26.6%), lifestyle (35.9%), family history (33%), diabetes 
treatment (41.7%), and history of other medical conditions (28.3%) (see Table 3.4).   
 
 
Table 3.4   Current pharmacy-based services related to ‘initial assessment’ 
 
Initial assessment % Rating level of frequency*  
N=240 
1 2 3 4 5 6 
Patient history:       
Age 15.8 15.8 24.6 10.8 10.4 22.9 
Duration of diabetes 19.2 19.2 18.3 16.7 10.8 15.8 
Lifestyle 16.3 12.9 18.3 16.7 14.2 21.7 
Family history of diabetes 18.3 16.3 18.8 13.8 11.7 21.3 
Presence of other risk factors for complications 17.1 15.4 20.0 18.3 13.3 15.8 
Knowledge about diabetes 17.9 19.2 22.1 16.3 13.3 11.3 
Diabetes treatment 14.6 10.8 18.8 14.2 14.2 27.5 
History of acute complications 21.3 22.5 17.1 15.8 12.1 11.3 
History of chronic complications 21.2 20.3 18.7 12.9 16.2 10.8 
Psychosocial status 28.7 21.3 17.5 18.8 6.7 7.1 
History of other medical conditions 17.9 18.8 21.3 13.8 15.8 12.5 
Baseline physical examination 
(e.g. measure weight/height, blood pressure) 
55.0 15.0 10.4 5.8 7.5 6.3 
Baseline test  
(e.g. check blood glucose) 
42.5 15.3 12.9 8.3 10.4 10.5 
*1=never, 6=always 
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b)   Treatment Plan 
 
Less than 25% of the pharmacists were frequently involved in the development of a 
treatment plan involving medications, diet, exercise, or prevention/treatment of 
chronic complications (see Table 3.5).  
 
 
Table 3.5 Current pharmacy-based services related to ‘treatment plan’ 
 
Treatment plan % Rating level of frequency*  
N=240 
1 2 3 4 5 6 
Setting of individualised treatment targets  
(with/without involvement of other health care members) 
41.3 17.9 15.0 10.4 6.3 9.2 
Development of treatment plans:  
(with/without involvement of other health care members) 
      
Antidiabetic medications 28.7 15.4 18.8 21.3 10.4 5.4 
Exercise  24.6 15.4 18.3 24.2 12.5 5.0 
Diet 23.8 9.2 18.8 23.8 14.2 10.4 
Prevention/treatment of chronic complications  25.0 18.3 20.0 20.0 12.9 3.8 
*1=never, 6=always 
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c)   Patient education 
 
While developing a treatment plan was less common, the more common practice was 
basically providing patient education. More than 50% of the pharmacists frequently 
provided education related to medications: directions for use (72.6%), storage 
requirements (61.3%), special precautions to follow (56.3%), and common/important 
adverse effects (53.4%). Other education often provided by more than 25% of the 
pharmacists included: exercise (39.6%), diet (46.7%), self-monitoring of blood 
glucose – SMBG (35.0%), prevention/treatment of acute complications (35.0%), and 
smoking cessation (38.9%) (see Table 3.6). 
 
 
Table 3.6   Current pharmacy-based services related to ‘patient education’ 
 
Patient education % Rating level of frequency*  
N=240 
1 2 3 4 5 6 
Disease process 25.4 20.4 22.1 15.0 12.5 4.6 
Treatment targets 20.4 19.2 16.6 18.8 16.2 8.8 
Antidiabetic medications:       
Directions for use 5.4 5.8 6.7 9.6 18.8 53.8 
Use of insulin devices  20.0 12.1 15.4 9.6 16.7 26.3 
Storage requirements 8.8 8.3 8.3 13.3 24.6 36.7 
Special precautions to follow 7.5 7.1 12.9 16.3 22.5 33.8 
Common/important adverse effects  9.2 7.5 14.2 15.8 21.7 31.7 
Exercise 14.2 10.0 20.4 15.8 16.7 22.9 
Diet 11.3 7.9 18.3 15.8 19.2 27.5 
SMBG 20.4 9.2 19.2 16.3 15.0 20.0 
Prevention/treatment of acute complications  18.3 13.8 22.1 17.1 15.4 13.3 
Prevention/treatment of chronic complications  22.5 12.9 24.2 16.3 15.4 8.8 
Need for regular medical monitoring  29.2 17.5 20.0 16.3 12.1 5.0 
Foot self-care 34.2 17.8 17.4 14.5 8.3 7.8 
Smoking cessation 19.6 12.1 18.3 11.3 13.8 25.1 
Abbreviations: SMBG, self-monitoring of blood glucose 
*1=never, 6=always 
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c) Monitoring/review  
 
A small number of the pharmacists provided regular follow-up to their patients. Only 
approximately 25% of the pharmacists frequently monitored patient compliance with 
their medications (28.0%) or diet (25.8%). Monitoring of patient responses to 
treatment, either by performing clinical testings (e.g. blood glucose tests) or by 
checking test results/SMBG records, was routinely performed by less than 25% of 
the pharmacists. These monitoring activities are summarised in Table 3.7. 
 
Table 3.7   Current pharmacy-based services related to ‘monitoring’ 
 
Monitoring  % Rating level of frequency* 
N=240 
1 2 3 4 5 6 
Monitor compliance with:       
Antidiabetic medications 25.0 14.6 19.2 13.3 13.8 14.2 
Exercise plan 31.7 15.8 20.0 12.9 10.8 8.8 
Diet plan 29.6 12.9 19.6 12.1 12.9 12.9 
Plan for prevention/treatment of chronic 
complications 32.9 15.8 21.3 13.8 10.8 5.4 
Scheduled medical monitoring 39.2 15.8 20.4 11.7 9.2 3.8 
Monitor treatment outcomes:       
Check records on SMBG 40.8 15.4 16.3 12.1 6.3 9.2 
Carry out blood glucose tests 38.8 13.8 12.9 12.5 8.8 13.3 
Measure BMI  54.2 17.9 11.3 9.6 3.3 3.8 
Measure blood pressure 41.3 15.0 12.5 11.7 8.3 11.3 
Check results on laboratory tests  44.2 17.5 14.2 8.3 5.8 10.0 
Monitor for adverse effects 33.3 18.3 20.4 10.8 10.0 7.1 
Abbreviations: SMBG, self-monitoring of blood glucose; BMI, body mass index 
*1=never, 6=always 
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‘Review’ can be seen as a continuing process of monitoring. It was reported that the 
pharmacists mostly followed up their monitoring activities with referral to other 
health care professionals when necessary (41.6%) and only a small number of 
pharmacists often adjusted education according to patient’s continuing needs 
(26.7%). Adjusting treatment plans was the least common practice (see Table 3.8). 
 
 
Table 3.8   Current pharmacy-based services related to ‘review’ 
 
Review  % Rating level of frequency*  
N=240 
1 2 3 4 5 6 
Review:       
Adjust treatment plans if necessary  
(with/without involvement of other health care members) 
39.2 16.3 15.4 12.5 9.6 7.1 
Refer patients if necessary 19.2 9.6 15.8 13.8 18.3 23.3 
Adjust diabetes education 24.2 18.8 13.3 17.1 12.1 14.6 
*1=never, 6=always 
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3.4.4   Views on pharmacists’ roles in type 2 diabetes care 
 
Given the same list of services related to type 2 diabetes care, the participating 
pharmacists were asked to rate the extent of agreement for each service to be 
provided at pharmacies (Question 7, Section B, Appendix 4). No new services were 
raised from the subsequent open-ended question to list any other services 
provided/viewed as part of their roles (Question 8, Section B, Appendix 4). 
 
 
3.4.4.1   Dispensing 
 
All pharmacists agreed about their traditional role of dispensing, i.e. preparing 
medications and providing labels with instruction for use. These views are 
summarised in Table 3.9. 
 
 
Table 3.9   Views on pharmacy-based services related to ‘treatment administration’ 
 
Treatment administration % Rating extent of agreement*  
N=240 
1 2 3 4 5 6 
Prepare medications 0.0 0.0 0.0 0.0 17.9 82.1 
Provide labels with instructions for use  0.0 0.0 0.0 0.0 13.8 86.3 
*1=definitely no, 6=definitely yes 
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3.4.4.2   Services beyond dispensing 
 
More than 50% of respondent pharmacists agreed that all activities listed within the 
‘initial assessment’, ‘treatment plan’, ‘patient education’, ‘monitoring’, and ‘review’ 
domains were pharmacists’ roles. These views on pharmacists’ roles can be seen in 
Tables 3.10 to 3.14. 
 
 
a) Initial assessment 
 
Among ‘initial assessment’ activities, the majority of pharmacists favoured taking 
patient history (71.2%) when type 2 diabetes patients initially visited the pharmacy 
(see Table 3.10). 
 
 
Table 3.10   Views on pharmacy-based services related to ‘initial assessment’ 
 
Initial Assessment % Rating extent of agreement*  
N=240 
1 2 3 4 5 6 
Patient history:       
Age 2.5 4.2 8.3 12.1 23.8 49.2 
Duration of diabetes 2.1 4.6 7.9 15.0 20.4 50.0 
Lifestyle 2.5 2.5 7.5 12.9 22.1 52.5 
Family history of diabetes 2.9 3.3 7.9 13.3 19.6 52.9 
Presence of other risk factors for complications  2.5 2.9 8.8 11.7 22.9 51.2 
Knowledge about diabetes 2.1 3.3 7.9 15.4 22.9 48.3 
Diabetes treatment 2.1 2.1 8.3 10.0 20.0 57.5 
History of acute complications 3.3 2.1 7.5 14.6 26.3 46.3 
History of chronic complications 3.3 1.7 8.8 13.8 29.2 43.3 
Psychosocial status 4.6 3.3 13.8 20.4 27.5 30.4 
History of other medical conditions 2.5 3.3 8.8 18.3 25.0 42.1 
Baseline physical examination  
(e.g. measure weight/height, blood pressure)   11.7 9.6 8.3 14.6 19.2 36.7 
Baseline laboratory tests  
(e.g. check blood glucose) 10.0 5.0 12.5 9.6 17.1 45.8 
*1=definitely no, 6=definitely yes  
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b) Treatment plan 
 
A smaller proportion of pharmacists favoured involvement in the ‘treatment plan’. 
All of the activities were supported by less than 70% of the pharmacists (see Table 
3.11). 
 
 
Table 3.11   Views on pharmacy-based services related to ‘treatment plan’ 
 
Treatment plan % Rating extent of agreement*  
N=240 
1 2 3 4 5 6 
Setting of individualised treatment targets  
(with/without involvement of other health care members) 
6.7 5.4 14.2 15.4 20.4 37.9 
Development of treatment plans:  
(with/without involvement of other health care members) 
      
Antidiabetic medications 6.3 3.3 10.0 16.3 18.8 45.4 
Exercise  5.0 4.6 8.8 17.1 20.8 43.8 
Diet 4.2 4.6 9.2 12.3 21.3 48.5 
Prevention/treatment of chronic complications  3.8 6.3 8.3 12.9 23.8 45.0 
*1=definitely no, 6=definitely yes  
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c) Patient education 
 
While involvement in the treatment plan was less favoured, more pharmacists agreed 
to provide ‘patient education’ related to: medications (85.0%), diet (76.7%), physical 
activity (72.9%), SMBG (71.7%), prevention of acute complications (70.4%), and 
smoking cessation (73.7%). Details of their views regarding patient education are 
summarised in Table 3.12. 
 
 
Table 3.12   Views on pharmacy-based services related to ‘patient education’ 
 
Patient education % Rating extent of agreement*  
N=240 
1 2 3 4 5 6 
Disease process 4.2 4.2 13.3 15.8 25.0 37.5 
Treatment targets 1.7 3.3 11.3 16.7 23.8 43.3 
Antidiabetic medications:       
Directions for use 0.0 1.7 3.3 5.4 15.4 74.2 
Use of insulin devices  1.7 2.9 3.8 7.1 18.3 66.3 
Storage requirements 0.8 1.3 5.4 6.7 16.7 69.2 
Special precautions to follow 0.4 2.9 3.3 10.4 17.1 65.8 
Common/important adverse effects  0.8 1.7 6.3 9.2 20.0 62.1 
Exercise 1.7 3.3 9.6 12.5 27.5 45.4 
Diet 2.5 2.5 6.3 12.1 22.5 54.2 
SMBG 3.3 2.1 7.1 15.8 27.9 43.8 
Prevention/treatment of acute complications  1.7 4.2 9.2 14.6 29.6 40.8 
Prevention/treatment of chronic complications  2.5 3.8 11.3 14.6 30.0 37.9 
Need for regular medical monitoring  3.8 5.8 13.3 19.6 22.9 34.6 
Foot self-care 5.4 5.0 14.6 16.3 23.3 35.4 
Smoking cessation 1.7 2.1 9.2 13.3 20.4 53.3 
Abbreviations: SMBG, self-monitoring of blood glucose  
*1=definitely no, 6=definitely yes  
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d) Monitoring/review 
 
Among ‘monitoring’ activities, the majority of pharmacists favoured monitoring 
compliance with medications (71.7%). Monitoring blood glucose (either by carrying 
out blood glucose tests, or checking test results/SMBG records) and monitoring 
adverse effects were favoured by more than 60% of the pharmacists. Details of their 
views regarding monitoring are summarised in Table 3.13. 
 
 
Table 3.13   Views on pharmacy-based services related to ‘monitoring’  
 
Monitoring % Rating extent of agreement* 
N=240 
1 2 3 4 5 6 
Monitor compliance with:       
Antidiabetic medications 1.7 0.8 11.7 14.2 19.2 52.5 
Exercise plan 3.3 4.6 14.6 20.4 21.7 35.4 
Diet plan 2.1 6.3 11.3 17.1 21.7 41.7 
Plan for prevention/treatment of chronic 
complications 
2.9 4.2 14.6 16.7 21.3 40.4 
Scheduled medical monitoring 4.2 5.8 17.5 17.1 20.4 35.0 
Monitor treatment outcomes:       
Check records on SMBG 2.5 5.8 11.7 16.3 20.4  43.3 
Carry out blood glucose tests 5.4 5.0 12.1 7.3 20.0 44.2 
Measure BMI  8.8 6.3 15.4 18.8 21.7 29.2 
Measure blood pressure 5.0 6.7 12.9 14.2 22.9 38.3 
Check results on laboratory tests  5.4 7.5 11.3 15.8 20.4 39.6 
Monitor for adverse effects 4.2 3.3 13.3 12.5 21.3 45.4 
Abbreviations: SMBG, self-monitoring of blood glucose; BMI, body mass index 
*1=definitely no, 6=definitely yes  
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With regard to ‘review’ activities, more pharmacists supported a role in referring 
patients to other health care professionals (73.7%) or adjusting patient education 
(66.3%) rather than adjusting treatment plans (see Table 3.14). 
 
 
Table 3.14   Views on pharmacy-based services related to ‘review’  
 
Review % Rating extent of agreement*  
N=240 
1 2 3 4 5 6 
Review:       
Adjust treatment plans if necessary  
(with/without involvement of other health care members) 
5.4 7.1 13.3 13.3 24.6 36.3 
Refer patients if necessary 2.9 2.9 9.6 10.8 23.3 50.4 
Adjust diabetes education  2.5 4.2 13.3 13.8 22.1 44.2 
*1=definitely no, 6=definitely yes  
 
 
3.4.4.3   Priority services  
 
To further explore the priority roles of pharmacists, an open-ended question was 
given to the pharmacists to list the five most important services that should be 
provided for type 2 diabetes patients at pharmacies (Question 9, Section B, Appendix 
4).  
 
The top five services selected as priorities were from the ‘patient education’ domain: 
education related to medications [directions for use (58.6%), common/important 
adverse effects (25.7%)], education on exercise (36.5%), and education on diet 
(47.7%); and the ‘monitoring’ domain: monitoring compliance with medications 
(27.9%). Presumably, the low priority assigned to dispensing (‘treatment 
administration’) was because it was acknowledged as part of current practice. This 
further exploration of priority services is summarised in Table 3.15. No new services 
were raised from this open-ended question. 
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Table 3.15   Open-ended views on priority services for type 2 diabetes patients 
 
Priority services* Number of responses (%) 
           N=222† 
Treatment administration  
Prepare medications 30 (13.5) 
Provide labels with instructions for use  43 (19.4) 
Initial assessment   
Patient history:  
Diabetes treatment 14 (6.3) 
Patient education  
Disease process (including complications)  20 (9.0) 
Antidiabetic medications:  
Directions for use 130 (58.6) 
Use of insulin devices  20 (9.0) 
Storage requirements 38 (17.1) 
Special precautions to follow 17 (7.7) 
Common/important adverse effects  57 (25.7) 
Exercise 81 (36.5) 
Diet 106 (47.7) 
SMBG 32 (14.4) 
Prevention/treatment of acute complications  21 (9.5) 
Prevention/treatment of chronic complications  20 (9.0) 
Need for regular medical monitoring (e.g. blood glucose levels) 13 (5.9) 
Monitoring  
Monitor compliance with:  
Antidiabetic medications 62 (27.9) 
Monitor treatment outcomes:  
Check records on SMBG 21 (9.5) 
Carry out blood glucose tests 45 (20.3) 
Measure blood pressure 22 (9.9) 
Check results on patient laboratory tests  12 (5.4) 
Monitor for adverse effects 15 (6.8) 
Review  
Refer patients if necessary 11 (5.0) 
Others (not a specific service)  
Develop PMRs (obtain patient history) 17 (7.7) 
Provide diabetes education  32 (14.4) 
Responses to an open-ended question: ‘In your opinion, what are the five most important services that should be 
provided at pharmacies for type 2 diabetes patients?’ 
Abbreviations: SMBG, self-monitoring of blood glucose; PMR, patient medication record 
* Services selected by more than 10 respondents 
† From a total of 240 respondents, there were 5 missing responses and 13 invalid responses, giving a total N=222 
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3.4.5   Associations between current practice and views on roles 
 
Chi-square tests were conducted to test univariate associations between current 
practice (see Section 3.4.3 – responses were categorised into binary variables: Likert 
scale ratings of 5 to 6 indicated ‘regular service’ versus ratings of 1 to 4 indicated 
‘less frequent service’) and views of roles (see Section 3.4.4 – responses were 
categorised into binary variables: Likert scale ratings of 5 to 6 indicated ‘agreement’ 
that a service should be provided versus ratings of 1 to 4 indicated ‘disagreement’). 
Some of the activities were grouped together if they were related to the same theme 
(for example, education related to antidiabetic medications is a composite variable 
based on five questions in that section) for which a mean rating was calculated 
(regular provision of or agreement with this composite variable was assumed if the 
mean rating ≥5). 
 
Dispensing practice (‘treatment administration’) was not tested as it was provided 
and agreed to by all of the pharmacists. The test results are summarised in Table 
3.16. It was shown that pharmacists’ agreement for a service to be part of their roles 
was associated with their pharmacies more frequently offering the service than those 
not sharing the views (all p-values <0.05).  
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Table 3.16   Current practice versus views on roles 
 
Services Being viewed as part of roles*  
 A. Agree B. Disagree  
 n/N (%) 
Being provided 
n/N (%)  
Being provided 
p-value 
Initial assessment    
Patient history† 40/149 (26.9) 2/91 (2.2) <0.0001 
Baseline physical examination 31/134 (23.1) 2/106 (1.9) <0.0001 
Baseline test  47/151 (42.8) 3/89 (3.4) <0.0001 
Treatment plan    
Treatment plan†  24/140 (17.1) 3/100 (3.0) <0.0001 
Patient education    
Disease process 37/150 (24.7) 4/90 (4.4) <0.0001 
Treatment targets 59/161 (36.7) 1/79 (1.3) <0.0001 
Antidiabetic medications† 106/195 (54.4) 5/45 (11.1) <0.0001 
Exercise 92/175 (52.3) 3/65 (4.6) <0.0001 
Diet 110/184 (59.8) 2/56 (3.6) <0.0001 
SMBG 76/172 (44.2) 8/68 (11.8) <0.0001 
Prevention/treatment of acute complications  65/169 (38.5) 4/71 (5.6) <0.0001 
Prevention/treatment of chronic complications  55/163 (33.7) 3/77 (3.9) <0.0001 
Need for regular medical monitoring  39/138 (28.3) 2/102 (2.0) <0.0001 
Foot self-care 37/141 (26.2) 1/99 (1.0) <0.0001 
Smoking cessation 93/177 (52.5) 0/63 (0.0) <0.0001 
Monitoring     
Monitor compliance† 33/130 (25.4) 0/110 (0.0) <0.0001 
Monitor treatment outcomes: 22/130 (16.9) 0/110 (0.0) <0.0001 
Check records on SMBG 117/153 (76.5) 1/87 (1.2) <0.0001 
Carry out blood glucose tests 104/154 (67.5) 3/86 (3.5) <0.0001 
Measure BMI 106/122 (86.9) 1/118 (0.9) <0.0001 
Measure blood pressure 102/147 (69.4) 2/93 (2.2) <0.0001 
Check results on laboratory tests 108/144 (75.0) 2/96 (2.1) <0.0001 
Monitor for adverse effects 39/160 (24.4) 2/80 (2.5) <0.0001 
Review    
 Review† 39/146 (26.7) 1/94 (1.1) <0.0001 
Abbreviations: SMBG, self-monitoring of blood glucose; BMI, body mass index 
*Current practice versus views on roles: (A) pharmacists agreed that the service should be provided (Likert scale 
ratings of 5 to 6) and currently provided the service (Likert scale ratings of 5 to 6); (B) pharmacists disagreed 
with the service (Likert scale ratings of 1 to 4) but currently provided the service (Likert scale ratings of 5 to 6).  
†A composite variable where a mean rating ≥5 was used. 
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3.4.6   Factors associated with current provision of pharmacy-based 
services for type 2 diabetes patients  
 
Logistic regression models were used to identify pharmacist/pharmacy 
characteristics (see Section 3.4.2) and views on roles (see Section 3.4.4) which were 
associated with current practice (see Section 3.4.3). Traditional role of dispensing 
(‘treatment administration’) was not included as this was provided in all pharmacies.  
 
For current practice (dependent variable), responses were categorised into binary 
variables: Likert scale ratings of 5 to 6 indicated ‘regular service’ versus ratings of 1 
to 4 indicated ‘less frequent service’. Some of the activities were grouped together if 
they were related to the same theme (for example, education related to antidiabetic 
medications was a composite variable based on five questions in that section) for 
which a mean rating was calculated (regular provision of this composite variable was 
assumed if the mean rating ≥5). The independent variable of pharmacists’ views on 
their roles was grouped in a similar way, and a mean was calculated for the 
composite variable. The odds ratios, together with 95% confidence intervals of 
significant factors associated with the provision of current services, are summarised 
in Tables 3.17 to 3.21. 
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a) Initial assessment 
 
Among activities related to initial assessment, more pharmacists believed that taking 
patient history was part of their roles (see Section 3.4.4). Respondent pharmacists 
who viewed this as part of their roles and/or completed diabetes training within the 
last year were more likely to take patient histories. In addition, those working at 
pharmacies within doctor clinics were more likely to perform this activity. 
Significant factors associated with the current provision of services related to initial 
assessment are summarised in Table 3.17. When there is a gap in the table, it 
indicates that the factor was not significant and thus was dropped during backward 
elimination used for logistic regression analysis.   
Table 3.17   Odds ratios and 95% confidence intervals of significant factors 
associated with current provision of ‘initial assessment’  
 
 Initial assessment 
 Patient history* Physical 
examination 
Tests 
Diabetes training    
No reference reference  
Yes 4.8 (1.97–11.78) 4.0 (1.49–10.50)  
Setting     
Not within doctor clinic reference   
Within doctor clinic 2.3 (1.04–5.03)   
Counselling area    
No   reference 
Yes   2.3 (1.12–4.92) 
Pharmacist availability†    
Low   NS  
Moderate   reference 
High   2.3 (1.09–5.06) 
Views     
Not part of roles reference reference reference 
Part of roles 6.6 (2.9–14.97) 2.9 (1.7–5.04) 3.0 (1.96–4.51) 
*A composite variable – taking patient history: age, duration of diabetes, lifestyle, family history of diabetes, 
presence of other cardiovascular risk factors, knowledge about diabetes, diabetes treatment, history of acute and 
chronic complications, psychosocial status, history of other medical conditions; a mean rating ≥5 was used 
† Ratio of total pharmacist working hours per total pharmacy opening hours (low <0.17, moderate=0.17–0.75, 
high >0.75) 
NS = not significantly different from the reference 
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b) Treatment plan 
 
Involvement in the ‘treatment plan’ was neither reported as common practice nor 
favoured as a priority role by the majority of the pharmacists (see 3.4.3 and 3.4.4). 
Factors associated with involvement in the treatment plan were pharmacists’ views 
that the service was a part of their roles, and pharmacies having high pharmacist 
availability. The odds ratios for these factors are summarised in Table 3.18.   
Table 3.18   Odds ratios and 95% confidence intervals of significant factors 
associated with involvement in the ‘treatment plan’  
 Treatment Plan* 
Pharmacist availability†   
Low NS 
Moderate reference 
High 4.0 (1.73–9.08) 
Views   
Not part of roles reference 
Part of roles 5.7 (2.57–12.64) 
*A composite variable – involvement in the treatment plan: set of individualised treatment targets; and 
development of treatment plans involving antidiabetic medications, exercise, diet and prevention/treatment of 
chronic complications; a mean rating ≥5 was used 
† Ratio of total pharmacist working hours per total pharmacy opening hours (low <0.17, moderate=0.17–0.75, 
high >0.75) 
NS = not significantly different from the reference 
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c) Patient education  
Providing patient education, particularly regarding medications and lifestyle, was 
selected amongst priority services (see Section 3.4.4). Respondent pharmacists who 
viewed that these activities were a part of their roles were more likely to perform the 
service. Moreover, those working at pharmacies with more than 50 diabetes 
customers per month were more likely to provide education on diet, whereas those 
with lower pharmacist availability were less likely to do so. The odds ratios of 
factors associated with the provision of patient education are summarised in Table 
3.19.  
 
Table 3.19   Odds ratios and 95% confidence intervals of significant factors 
associated with current provision of ‘patient education’ 
 
 Patient Education 
 Medication* Exercise Diet All education† 
Counselling area     
No    reference 
Yes    3.7 (1.63–8.38) 
Diabetes customers      
≤50   reference  
>50   2.6 (1.38–4.73)  
Pharmacist availability‡      
Low   0.3 (0.17–0.70) 0.3 (0.15–0.69) 
Moderate   reference reference 
High   NS NS 
Views      
Not part of roles reference reference reference reference 
Part of roles 3.7 (2.25–6.11) 4.2 (2.71–6.56) 3.5 (2.32–5.24) 4.3 (2.04–9.09)        
*A composite variable – education related to antidiabetic medications: directions for use, use of insulin devices 
(calculated only from those who were currently/previously taking insulin), storage, special precautions and 
common/important adverse effects; a mean rating ≥5 was used 
†A composite variable – all education items: disease process, treatment targets, antidiabetic medications, exercise, 
diet, self-monitoring of blood glucose, prevention/treatment of acute complications, prevention/treatment of 
chronic complications, need for regular monitoring, foot self-care and smoking cessation (calculated only from 
those currently, or had a history of, smoking); a mean rating ≥5 was used  
‡ Ratio of total pharmacist working hours per total pharmacy opening hours (low <0.17, moderate=0.17-0.75, 
high >0.75) 
NS = not significantly different from the reference 
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d) Monitoring/review 
 
Even though ‘monitoring’ was not commonly performed, monitoring compliance 
with medications was selected as a priority service (see Sections 3.4.3 and 3.4.4). 
Factors associated with monitoring compliance included pharmacists’ involvement in 
diabetes training and their views that the service was a part of their roles (acting as 
facilitators), and pharmacies with lower pharmacist availability (acting as a barrier). 
The odds ratios are summarised in Table 3.20. 
 
 
Table 3.20   Odds ratios and 95% confidence intervals of significant factors 
associated with current provision of ‘monitoring’ 
 
 Monitoring 
 
Compliance* 
 
Adverse drug 
reactions  Perform clinical testings‡ 
Check test 
results†  
Diabetes training     
No reference reference  reference 
Yes 4.4 (1.69–11.70) 4.7 (1.45–15.06)  3.7 (1.58–8.76) 
Setting      
Not within doctor clinic  reference reference  
within doctor clinic  5.1 (1.84–13.98)  2.6 (1.02–6.5)  
Diabetes customers     
≤50  reference reference  
>50  3.8 (1.16–12.50) 3.3 (1.08–10.14)  
Pharmacist availability§      
Low 0.2 (0.05–0.73) 0.1 (0.03–0.71) NS NS  
Moderate reference reference reference reference 
High NS NS 3.6 (1.40–9.44) 2.2 (1.03–4.91) 
Views      
Not part of roles reference reference reference reference 
Part of roles 5.4 (2.50–11.51) 5.0 (2.09–12.20) 3.5 (1.70–7.08) 3.6 (1.95–6.80) 
*A composite variable – monitoring compliance with: antidiabetic medications; exercise and diet plan; plan for 
prevention/treatment of complications; and scheduled medical monitoring; a mean rating ≥5 was used 
†A composite variable – checking SMBG and laboratory data; a mean rating ≥5 was used  
‡A composite variable – performing clinical testings (i.e. measuring blood glucose, blood pressure and BMI); a 
mean rating ≥5 was used 
§ Ratio of total pharmacist working hours per total pharmacy opening hours (low <0.17, moderate=0.17–0.75, 
high >0.75) 
NS = not significantly different from the reference 
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As for monitoring, ‘review’ was practised in a limited fashion, with more 
pharmacists believing that their roles involved referring patients or adjusting 
education rather than adjusting treatment plans (see Sections 3.4.3 and 3.4.4). Factors 
associated with performing reviews were pharmacists’ positive attitudes and 
involvement in training, and those working at pharmacies with high pharmacist 
availability or with a counselling area/room (see Table 3.21). 
 
 
Table 3.21   Odds ratios and 95% confidence intervals of significant factors 
associated with current provision of ‘review’ 
 
 Review* 
Diabetes training  
No reference 
Yes 2.6 (1.09–6.37) 
Counselling area  
No reference 
Yes 2.7 (1.19–6.29)  
Pharmacist availability†   
Low NS 
Moderate reference 
High 3.2 (1.39–7.35) 
Views   
Not part of roles reference 
Part of roles 4.0 (1.98–7.88) 
*A composite variable – review comprised of referral, treatment adjustment and education adjustment; a mean 
rating ≥5 was used 
† Ratio of total pharmacist working hours per total pharmacy opening hours (low <0.17, moderate=0.17–0.75, 
high >0.75)  
NS = not significantly different from the reference 
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3.4.7   Remuneration 
 
Given the limited services (beyond dispensing) provided at the time for type 2 
diabetes patients, almost all pharmacists were not remunerated. However, nearly one-
third of the pharmacists would expect remuneration when they provided a 
consultation service for type 2 diabetes patients in the future. These results are 
summarised in Table 3.22. 
 
 
Table 3.22   Pharmacists’ current and proposed remuneration   
Remuneration Frequency (%) 
Current  
N=240 
Proposed  
N=240 
Nothing 237 (98.8) 168 (70.0) 
<Rp 25,000  3 (1.2) 27 (11.3) 
Rp 25,000-50,000  0 (0.0) 38 (15.8) 
>Rp 50,000 0 (0.0) 7 (2.9) 
Abbreviations: Rp, Indonesian rupiah 
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3.5   Discussion 
 
To our knowledge, this is the first study focused on Indonesian community 
pharmacists’ practices and their views regarding type 2 diabetes care.  
  
The questionnaire used in this study was constructed following an expert panel as 
well as a pilot study of the target population (community pharmacists); during the 
actual survey, no new themes were raised from the open-ended questions related to 
pharmacy services, confirming the content-validity of the questionnaire.145 The pilot 
study showed that the Kappa scores for questions related to the pharmacy services 
were greater than 0.40, which were considered to be ‘acceptable’ to ‘excellent’ levels 
of test-retest reliability.152 
 
This study achieved a total response rate of 60% (N=240) which was adequate for 
statistical analyses. A higher response rate was reported for the first round (70.1%) 
compared to the second round (50.5%), however, no differences were found in the 
responses related to diabetes services between these rounds. There is a possibility of 
some non-respondents not sharing the same practice and/or views of respondents, 
hence, some caution should be exercised in generalising the findings. It should be 
emphasised, however, that non-respondent pharmacists in this study were working at 
pharmacies which were not different in terms of the socio-economics of their 
geographical locations153 compared with respondents (p=0.88). In addition, the 
characteristics of the respondent pharmacists in this study compare well with respect 
to gender and age data of community pharmacists registered in Surabaya (2006-
2011)154 and a previous study of community pharmacists in Jakarta, Indonesia.24 
Additionally, the characteristics of pharmacy premises in this study were comparable 
with terms of  ownership24 and number of customers26 (based upon data on the 
number of prescriptions as a fraction of the total customers in the study) to the 
previous studies in Jakarta.  
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3.5.1   Current pharmacy-based services for type 2 diabetes patients 
 
While dispensing was well established as part of community pharmacy practice in 
Surabaya, services beyond dispensing were provided in a limited fashion. The most 
common practice was providing basic medication education on directions for use. 
Other published Indonesian studies, although not specific to diabetes care and limited 
by their small sample sizes, identified a limited role for pharmacists in providing 
pharmaceutical care.24-26   
 
Studies focusing on pharmacy-based services for type 2 diabetes patients in 
developed countries reported variability of the service scope, however these 
generally showed that the services provided were centred around patient education 
and monitoring (see Table 2.11). In line with this present study, some of the studies 
reported that the majority of pharmacists frequently counselled patients on aspects of 
their medications, such as administration30, 31, 33, 34 and adverse effects30. However, it 
also was reported that pharmacists played important roles in providing education on 
lifestyle and smoking cessation,30, 31 supporting patients in self-monitoring of blood 
glucose (SMBG),30, 34, 99 and monitoring compliance with medications.30 Monitoring 
treatment outcomes and involvement in the treatment plan have been reported as less 
common practices in some studies,30, 31, 34, 35 which also is evident in this Indonesian 
study.  
 
 
3.5.2   Views on pharmacists’ roles in type 2 diabetes care 
 
Despite their limited provision of services beyond dispensing, community 
pharmacists in Surabaya reported positive attitudes towards providing care for type 2 
diabetes patients in the future. More than half of the respondent pharmacists agreed 
that pharmacists should be involved in initial assessment, treatment plans, education, 
and monitoring/review. This shows pharmacists’ awareness of their potential 
professional roles even though little had been implemented in their current practice.  
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Services selected as priorities were centred around education related to medications 
and lifestyle, and monitoring compliance with medications. Studies in developed 
countries also shared pharmacists’ preferences around education and monitoring 
services (see Table 2.12). These included, but were not limited to, education about 
medications,31, 34, 100, 101 healthy lifestyle100 and SMBG,34, 100 as well as monitoring 
compliance with medications,100 performing blood glucose tests34 and providing 
feedback on glycaemic control.31, 101 Since diabetes, similar to other chronic diseases, 
requires daily care in the hands of the patient, it is suggested that diabetes health care 
should include patient or carer education to foster self-care.37 These educational 
activities should be followed by monitoring and review of patient outcomes. As 
patients regularly refill their medications in pharmacies and pharmacists are often the 
final health care professionals to have contact with patients before they take 
medications, pharmacists could have potential roles in the areas of education and 
monitoring. Moreover, it was reported that most Indonesian doctors spent little time 
to adequately counsel and educate their patients,155 thus pharmacists could contribute 
to filling this void. These Indonesian pharmacists’ preferences for education and 
monitoring related to medications and lifestyle should be considered when designing 
a model for pharmacist professional development.  
 
 
3.5.3   Factors associated with current provision of pharmacy-based 
services for type 2 diabetes patients 
 
The logistic regression models demonstrated that a pharmacist’s positive attitude 
towards a service was a facilitator for providing the service. This is in line with 
findings from a Norwegian study34 where pharmacists working in pharmacies 
offering diabetes services scored significantly higher agreement for this service 
provision than those working in pharmacies that did not offer them.  
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Pharmacist availability in pharmacies was another factor associated with the 
provision of some services beyond dispensing (either low pharmacist availability 
acting as a barrier or high pharmacist availability acting as a facilitator). Based on the 
Indonesian Government Standards, pharmacy services related to prescribed 
medications should be performed by pharmacists (see Section 2.2.4.3). Hence, this 
regulation requires a pharmacist to be present at all times when the pharmacy is 
open. In this study, less than 20% of the pharmacies in Surabaya had pharmacists 
available throughout their opening hours. Factors contributing to this low level of 
compliance might include weak monitoring systems and law enforcement, making 
the implementation dependent on the pharmacists’ levels of commitment. Since the 
majority of the pharmacies were owned by proprietors (non-‘pharmacist manager’ 
owners), their commitment will also have a major influence on this practice. This 
study found that more pharmacies owned by pharmacist managers had a pharmacist 
available during opening hours compared to those owned by proprietors (30.6% 
versus 10.2%, respectively; p<0.001). This may reflect proprietors being more 
‘business’ oriented; their views may be that without pharmacists being able to 
provide value-added services (and thus increasing income), supplying medication 
can be achieved in less expensive ways without exclusively using pharmacists. In 
this model, pharmacists would only be required for legal purposes (e.g. starting the 
pharmacy, signing copies of prescriptions and controlled drugs reports), leading to 
lower pay for pharmacists. On the other hand, because of poor salaries and shorter 
hours, pharmacists may take on other jobs resulting in them not being available at 
pharmacies. Two studies in Jakarta, Indonesia, reported that about 70% of the 
pharmacists worked in community pharmacies as their secondary jobs.24, 26  
 
This study indicated the problem with underutilisation of community pharmacies that 
may contribute to their lack of affordability to provide resources – including 
maintaining pharmacist availability – for quality services. The majority of 
community pharmacies in this study reported seeing less than 2,000 customers per 
month, with less than 100 of these having type 2 diabetes. This is considerably lower 
than the Australian figure (approximately 1,400 customers per week) despite the 
comparable ratio of population per pharmacy between Surabaya, Indonesia, and 
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Australia (approximately 1:5,000).156 In 2012, about 65% of the Indonesian 
population was covered by some form of insurance plan, largely through Jamkesmas 
(insurance for the poor/near poor),6 through which a limited range of medications can 
be supplied within health centres. Those who can afford care were reported to use 
secondary and tertiary care hospitals,2, 8 thus their medications were mainly supplied 
from hospital-based pharmacies. Many drug stores are also known to sell 
prescription drugs despite being licensed to sell only non-prescription drugs. All of 
these factors may contribute to the lower number of customers in community 
pharmacies. The implementation of Jaminan Kesehatan Nasional – JKN (National 
Health Coverage)9 in 2014 should provide an opportunity to better integrate 
community pharmacies into the health system, enabling their better utilisation. The 
Government and IAI should establish an agreement regarding basic services that 
should be available in the pharmacies. While the current payment under the scheme 
includes a very low prescription fee (see Section 2.2.4.4), it is important to ensure 
adequate remuneration for pharmacists to provide the agreed basic services, thus 
creating a stable environment to sustain and grow their practices.   
 
Compounding the issue of low pharmacist availability was the issue of competency 
to provide pharmaceutical care. This study found that pharmacists’ involvement in 
diabetes training was a facilitator for providing some services beyond dispensing. In 
line with this finding, studies in Australia and Canada have shown that pharmacists 
involved in training provide more activities related to diabetes management when 
compared to other pharmacists.30, 156 In Indonesia, it was not until 2008 that 
pharmacotherapy subjects were incorporated into the national pharmacy curricula, as 
a basis for providing pharmaceutical care. The concept of pharmaceutical care also 
was included within the new standards of community pharmacy practice (see Section 
2.2.4.3). While there are currently a variety of opportunistic CPE courses, some of 
which include general training in diabetes therapeutics, the IAI should consider 
organising formal general diabetes training to deal with the earlier graduates.  
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In addition to the pharmacists’ attitudes, availability and competency, this study 
indicated that pharmacies with counselling areas, or within doctor clinics, or with a 
higher number of diabetes customers per month were more likely to provide some 
services beyond dispensing. Based on the Government Standards, a pharmacy should 
have a private area/room dedicated for counselling (see Section 2.2.4.3). While the 
availability of a counselling area/room allows pharmacists and patients/carers to talk 
privately when providing patient care, this study found that only a small number of 
pharmacies (21.7%) had allocated a counselling area/room. This study also indicates 
that pharmacies within doctor clinics might present opportunities for pharmacists to 
build professional relationships with the doctors, encouraging pharmaceutical care 
practice. It was previously reported that close proximity of practice sites was one of 
the facilitators for developing an effective collaboration.157 Moreover, higher 
customer numbers might be correlated with higher turnover and thus affordability for 
the pharmacy to provide more services (e.g. maintaining pharmacist availability, 
employing adequate staff, diabetes training). An Australian study reported previously 
that higher turnover was one of the predictors for providing diabetes care.156 Reviews 
involving studies in developed countries also confirmed the importance of pharmacy 
layout, cooperation with doctors and financial support for practising pharmaceutical 
care.136, 142  
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3.6   Key findings 
  
• Current pharmacy-based services for type 2 diabetes patients in Surabaya, 
Indonesia: 
- All community pharmacies provided basic services of dispensing.  
- The most common service beyond dispensing was providing education 
related to medications, particularly directions for use (72.6%). 
 
• Views on pharmacists’ roles in type 2 diabetes care:  
- All community pharmacists viewed dispensing as a part of their roles. 
- More than half of the pharmacists believed that they should provide 
services beyond dispensing; services perceived as priorities were centred 
around education related to medications [i.e. directions for use (58.6%), 
common/important adverse effects (25.7%)], lifestyle education [i.e. 
exercise (36.5%), diet (47.7%)], and monitoring compliance with 
medications (27.9%).   
 
• Factors associated with current provision of pharmacy-based services for type 2 
diabetes patients: 
- A pharmacist’s positive view towards a service was associated with the 
current provision of the service.  
- Pharmacist characteristics, i.e. pharmacists’ involvement in diabetes 
training was a facilitator for providing some services beyond dispensing.  
- Pharmacy characteristics that were associated with the provision of some 
services beyond dispensing, i.e.: pharmacies with either low pharmacist 
availability (barrier) or high pharmacist availability (facilitator); 
pharmacies with a higher number of diabetes customers (facilitator), or 
within a doctor clinic (facilitator), or with a counselling area/room 
(facilitator). 
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Chapter 4 
Pharmacy-based services for type 2 diabetes patients: 
Patient survey 
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4.1   Introduction 
 
Type 2 diabetes is a chronic metabolic disorder that requires daily care in the hands 
of patients.37 To develop community pharmacy-based services for type 2 diabetes 
patients, it is important to explore the views of this group of patients. International 
studies have been conducted to investigate patient views regarding aspects of 
community pharmacists’ roles, and some of these studies have included diabetes 
patients (see Table 2.14). However, it should be emphasised that studies involving 
diabetes patients have been limited to developed countries.  
 
In Indonesia, two studies, although not specific to diabetes, have been conducted to 
explore patient views about pharmacy services. The first study assessed patient 
perceptions of the services based on tangible dimensions, reliability and 
responsiveness, assurance and empathy.28 The second study focused on patient 
attitudes/needs in regard to drug information services.110 Both studies reported that 
the majority of patients had positive perceptions of pharmacy services, providing a 
basis for pharmacists to develop their professional roles. This present study is the 
first concerning the views of Indonesian patients with type 2 diabetes, and it will 
inform the development of community pharmacy-based services in this particular 
setting.  
 
 
4.2   Objectives 
 
The main objectives of this part of the thesis are: 
1. To collect data, within Surabaya, Indonesia, on the characteristics of community 
pharmacy clients with type 2 diabetes and their use of pharmacy services.  
2. To assess their views regarding community pharmacists’ roles in type 2 diabetes 
care. 
3. To identify factors (patient characteristics) influencing their views on the roles of 
community pharmacists in type 2 diabetes care. 
 
 106 
 
4.3   Methods 
 
A questionnaire survey of pharmacy clients with type 2 diabetes was conducted to 
address the objectives of this study. All data collection instruments and 
methodologies used in this study were approved by the Human Research Ethics 
Committee of Curtin University (Appendix 1) as well as Ikatan Apoteker Indonesia – 
IAI (Indonesian Pharmacists Association) (Appendix 3).  
 
 
4.3.1   Setting and sample recruitment 
 
This study aimed to analyse the views of pharmacy clients with type 2 diabetes 
concerning pharmacist roles, and to identify factors influencing their views.  A 
minimum sample size of 120 subjects was required in the logistic regression analysis 
to identify associations between the dependent variable (i.e. patient views) and 
independent variables (i.e. patient characteristics),  exhibiting a moderate effect size 
with 80% power and α=0.05.  Hence, this study aimed to recruit approximately 200 
patients to ensure adequate power to detect associations. 
 
Community pharmacies were used as sampling points to provide data on pharmacy 
clients with type 2 diabetes in Surabaya, Indonesia. Ten community pharmacies were 
selected from the 146 community pharmacies in the Pharmacist Survey (Chapter 3) 
that had more than 50 diabetic patients per month, to ensure an adequate number of 
potential respondents. These pharmacies were purposefully selected to include 
different geographical areas and socio-economic levels in Surabaya. Surabaya 
consists of 31 sub-districts which can be categorised into five geographical areas, i.e. 
central, west, east, north and south; and four socio-economic levels, from ‘1: high 
socio-economic level’ to ‘4: low socioeconomic level’.153 Each pharmacy was 
responsible for recruiting approximately 20 patients. Patients eligible for the survey 
were those aged over 18 years, with a diagnosis of type 2 diabetes for which they 
were receiving oral antidiabetic medications. Patients were recruited as they were 
seeking oral antidiabetic medications at these pharmacies. 
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4.3.2   Data Collection 
 
 
4.3.2.1   Questionnaire development 
 
The survey questionnaire consisted of four sections: (A) patient demographics, (B) 
services for type 2 diabetes patients – use of services and views on pharmacists’ 
roles, (C) diabetes profile, and (D) monitoring profile. The questionnaire cover page 
contained information about the study and a consent form. Section B of the 
questionnaire contained a list of services for type 2 diabetes patients that was drafted 
based on a generic model generated from the literature (see Section 2.1.2.3). A 
binary choice question was used to capture patient usage of each service (previous 
use of each service: ‘yes’/’no’), and a 6-point Likert scale was used to reflect patient 
views on pharmacists’ roles (extent of agreement for each service to be part of 
pharmacists’ roles: 1=definitely no, 6=definitely yes). This was followed by an open-
ended question to explore patient priorities in their views of pharmacist roles: ‘In 
your opinion, what are the five most important services that should be provided at 
pharmacies to assist you with your diabetes?’. The questionnaire was face and 
content validated by a panel of two project supervisors, five academics, two board 
members of the IAI, two Indonesian community pharmacists and two diabetes 
patients. All of the panel members’ views and comments were considered and, where 
appropriate, were incorporated into the questionnaire.  
 
The questionnaire then went through the process of translation: (i) forward 
translation – the questionnaire was translated to Bahasa Indonesia by the principal 
investigator, whose first language is Bahasa Indonesia, and the conceptual 
equivalence was checked by a bilingual panel (consisting of the principal 
investigator, and two academics with experience in instrument development and 
translation) to resolve any confusing concepts arising from the translation; (ii) back-
translation – the questionnaire was back-translated to English by an independent 
English-first language translator; and (iii) the back-translation was compared to the 
original version by two project supervisors whose first language was English.  
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The forward-translation questionnaire (Bahasa Indonesia) was piloted by ten type 2 
diabetes patients, and revised wherever appropriate. This resulted in minor changes 
to the final questionnaire (Appendix 6). To assess reliability, the questionnaire was 
distributed on two separate occasions, with a two-week interval. Test-retest 
reliability for diabetes services (Question 10, Section B, Appendix 6) was calculated 
using Kappa statistic tests, where responses were grouped for Likert scale ratings of 
1 to 4, and ratings of 5 to 6 (this ensured some responses in each of the two broad 
categories, both before and after the two-week interval). The resulting Kappa scores 
ranged from 0.412 to 1.000, which were classified as ‘acceptable’ to ‘excellent’ 
levels of test-retest reliability.152 
 
 
4.3.2.2   Questionnaire administration 
 
Owners of the selected community pharmacies were approached by the principal 
investigator, and agreements were sought to use their pharmacies as sampling points. 
In the case of refusal, the related pharmacy was replaced with another pharmacy in 
the same geographical area and socio-economic level, aiming to include ten 
community pharmacies. At each pharmacy, the pharmacist and/or pharmacy staff 
member was briefed about the study and how to complete the questionnaire. Patients 
seeking antidiabetic medications at the pharmacy were introduced to the study and 
were invited to participate. Those who wished to participate were asked to complete 
the consent form, and were informed about how to complete the questionnaire. Once 
completed, the questionnaire was placed in a sealed envelope and submitted to the 
pharmacist/pharmacy staff; the recruitment was continued to include approximately 
20 patients at each pharmacy. The questionnaires were then handed to the principal 
investigator by the agreed deadline. The survey was conducted during the period 
from October 2011 to February 2012. 
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Preliminary data screening was performed to remove patients who had used insulin 
from the beginning of their treatments (Question 13, Section C, Appendix 6) as they 
were assumed to have type 1 diabetes and, therefore, were ineligible for this study. 
 
 
4.3.3    Data Analysis 
 
Descriptive statistics were used to summarise the patient characteristics: 
demographics (Section A, Appendix 6), diabetes profile (Section C, Appendix 6), 
and monitoring profile (Section D, Appendix 6). These included frequencies for 
categorical variables, and means, along with their 95% confidence intervals, for 
continuous variables. Medians, along with their ranges, were used for continous 
variables which were not normally distributed.  The Kolmogorov-Smirnov test was 
used to test for Normality. The IBM SPSS Statistics version 19.0 was used to 
perform the analysis.   
 
In relation to services for type 2 diabetes patients (Question 10, Section B, Appendix 
6), frequencies were calculated for binary responses (‘yes’/’no’) related to the patient 
usage of services and for responses from Likert scales related to the extent of patient 
agreement regarding pharmacists’ roles. Moreover, content analysis was used for 
responses from an open-ended question to explore patient views on the five priority 
services that they considered should be provided at the pharmacies (Question 11, 
Section B, Appendix 6). These responses were coded, and frequencies were 
calculated. 
 
Logistic regression models were employed to identify factors (patient characteristics) 
associated with patients’ views of pharmacists’ roles. Responses regarding patients’ 
views for each type of service were classified into binary variables, to indicate 
‘agreement’ (Likert scale ratings of 5 to 6) versus ‘disagreement’ (Likert scale 
ratings of 1 to 4), and were used as the dependent variables. Patient characteristics 
included as independent variables were gender, age, education, employment, income, 
health insurance cover, diabetes organisation membership, duration of diabetes (time 
since diagnosis), risk factors, complications and diabetes (glycaemic) control (as a 
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composite of hypo/hyperglycaemic symptoms and HbA1c values). The models also 
included an independent variable indicating patients’ previous use of the service 
(binary responses: ‘yes’/’no’). A backward elimination strategy was used in the 
development of each regression model, whereby all independent variables were 
included, initially, and then the least significant variable was dropped (one at a time) 
until the p-value associated with each of the variables remaining in the model was 
less than 0.05. Following convention, a p-value <0.05 was taken to indicate a 
statistically significant association in all tests. 
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4.4   Results 
 
 
4.4.1   Sample recruitment 
 
This study managed to include ten community pharmacies as sampling points after 
approaching eleven community pharmacies in Surabaya, Indonesia. One pharmacy 
refused, as the employee pharmacist was planning to resign and they were in the 
process of recruiting a new one. From the final ten pharmacies, a total of 204 patients 
were recruited; however, eight patients took insulin at the beginning of their 
therapies and were deemed to have type 1 diabetes, leaving a sample size of 196. 
 
 
Table 4.1   Patient recruitment from ten community pharmacies 
 
Pharmacy code Geographical 
area 
Socio-economic 
level 
Number of  
diabetes patients 
per month 
Number of 
diabetes patients 
recruited 
Pharmacy 1 East Surabaya 2 150 21 
Pharmacy 2 Central Surabaya 1 200 18 
Pharmacy 3 East Surabaya 3 70 20 
Pharmacy 4 West Surabaya 4 100 19 
Pharmacy 5 South Surabaya 3 140 20 
Pharmacy 6 Central Surabaya 2 100 20 
Pharmacy 7 South Surabaya 4 100 20 
Pharmacy 8 North Surabaya 1 240 19 
Pharmacy 9 West Surabaya 3 120 20 
Pharmacy 10 North Surabaya 2 100 19 
Total    196 
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4.4.2   Characteristics of pharmacy clients with type 2 diabetes  
 
 
4.4.2.1   Demographic data 
 
The demographic information of participating patients (responses to Section A, 
Appendix 6) is summarised in Table 4.2. Approximately 60% of respondents were 
female and about half of the respondents were aged 60 years or older. Only about 
one-third of the respondents had pursued higher education (i.e. 
diploma/bachelor/postgraduate) (28.1%), and were currently employed (37.2%). 
Approximately half of the respondents did not have health insurance plans. 
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Table 4.2   Demographic data of study respondents 
 
Patient demographics Frequency (%) 
N=196 
Gender   
Male  80 (40.8) 
Female 116 (59.2) 
Age, years – median (range) 60.0 (32–86) 
Ethnicity   
Asian 196 (100.0) 
Others 0 (0.0) 
Highest Education   
No schooling 6 (3.1) 
Primary school  23 (11.7) 
Junior high school  41 (20.9) 
Senior high school  71 (36.2) 
Diploma  18 (9.2) 
Bachelor degree  25 (12.8) 
Postgraduate degree  12 (6.1) 
Employment status  
Working full-time  
(≥40 hours/week) 
53 (27.0) 
Working part-time  
(<40 hours/week) 
20 (10.2) 
Not working  123 (62.8) 
Total household income (from all sources) per month*  
≤Rp 2 million 103 (52.6) 
>Rp 2 million – 5 million  54 (27.6) 
>Rp 5 million – 10 million 25 (12.8) 
>Rp 10 million 12 (6.1) 
Health insurance  
Self-sponsored insurance  31 (15.8) 
Employer-sponsored insurance 56 (28.6) 
Insurance scheme for the poor/near poor  9 (4.6) 
No insurance 100 (51.0) 
Member of a diabetes organisation  
      Yes 74 (37.8) 
      No 122 (62.2) 
Abbreviations: Rp, Indonesian rupiah 
* 2 missing responses 
 114 
 
4.4.2.2   Diabetes profile 
 
The diabetes profiles of participating patients (responses to Section C, Appendix 6) 
are shown in Table 4.3. The median duration of diabetes (time since diagnosis) was   
seven years. More than 80% of the respondents reported that their treatment 
recommendations included oral antidiabetic medications and diet modifications; 
approximately one-fifth of respondents were taking insulin (but this had not 
commenced at the beginning of their therapy). Fewer patients reported 
recommendations regarding exercise (62.8%). It is important to note that this 
variable did not measure whether the doctor gave the medication/diet/exercise 
recommendations, but rather whether the patient remembered and/or reported it. 
 
The questionnaire asked about diabetes-related complications, including 
macrovascular and microvascular diseases with neuropathy, nephropathy and 
retinopathy (Question 17, Section C). Almost 60% of the respondents reported 
having at least one diabetes-related complication. Common complications reported 
were foot discomfort (41.3%) and eye problems (26.5%).  
 
The questionnaire also asked questions relating to other risk factors for complications 
(Question 16, Section C). Most of the patients reported having at least one other risk 
factor, the most common of which was high blood pressure (53.6%), followed by 
high body mass index – BMI (44.9%) and high cholesterol levels (39.5%).  
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Table 4.3   Self-reported diabetes profile of study participants 
 
Patient diabetes profile 
 
Frequency (%) of ‘yes’ 
N=196 
Duration of diabetes, years – median (range)* 7 (1 – 42) 
Current diabetes treatment   
Modifying diet 173 (88.3) 
Exercise programme 123 (62.8) 
Oral Antidiabetic Medication 189 (96.4) 
Insulin  44 (22.4) 
Risk factors‡ 157 (80.1) 
BMI  ≥25 kg/m2† 88 (44.9) 
(History of) smoking  41 (20.9) 
High cholesterol§ 77 (39.5) 
High blood pressure# 104 (53.6) 
Complications‡  115 (58.7) 
Heart disease 34 (17.3) 
Eye problems 52 (26.5) 
Foot discomfort 81 (41.3) 
Foot ulcers 14 (7.1) 
Kidney problems 16 (8.2) 
* Some missing responses 
† BMI, body mass index = weight (kg) divided by height2 (m2); some missing responses 
‡ Respondents responded ‘yes’ for at least one complication/risk factor (Question 17) 
§ Respondents responded ‘yes’, either for “Do you have high cholesterol?” or “Do you take medications to treat 
your high cholesterol?”, or for both (Question 16) 
# Respondents responded ‘yes’, either for “Do you have high blood pressure?” or “Do you take medications to 
treat your high blood pressure?”, or for both (Question 16) 
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4.4.2.3   Monitoring profile 
 
Table 4.4 shows the monitoring profile of participating patients (responses to Section 
D, Appendix 6). Almost half of the respondents reported having had symptoms of 
hypoglycaemia and/or hyperglycaemia during the previous month (44.4%). 
Hyperglycaemia and hypoglycaemia symptoms were reported by 28.7% and 22.1% 
of repondents, respectively. Less than one-third of respondents knew their last 
HbA1c value (27.0%). To provide insight to patients’ diabetes (glycaemic) control, 
these two variables were combined to indicate: fair-good control (i.e. symptoms ‘no’ 
and HbA1c ‘≤8.0%’); poor control (i.e. symptoms ‘yes’ or HbA1c ‘>8.0%’); and 
unknown (i.e. symptoms ‘none/don’t know’ and/or HbA1c values ‘none/don’t 
know’). Using this new variable, most respondents were perceived to have either 
poor diabetes control (45.9%) or unknown diabetes control (42.3%). 
 
In relation to routine tests, one-third of respondents reported self-monitoring of blood 
glucose, with a median of once in the day on one day each week. Quarterly medical 
monitoring was reported by the majority of respondents: blood sugar (86.1%), blood 
pressure (85.1%) and weight (63.9%). Fewer respondents reported compliance to 
annual medical monitoring of: lipid profiles (65.1%), renal function (43.1%), HbA1c 
(33.3%), and feet and eye examinations (23.2% and 21.0%, respectively). 
 
.  
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Table 4.4   Self-reported monitoring profile of study participants 
 
Patient monitoring Frequency (%) of ‘yes’ 
N=195* 
Diabetes (glycaemic) control  
High blood sugar reactions  
(in the last month) 
56 (28.7) 
1−3 times 41  
>3  times 15  
Low blood sugar reactions  
(in the last month) 
43 (22.1) 
1−3 times 37 
>3 times 6 
Severe blood sugar reactions  
(in the last year) 
26 (13.3) 
1−3 times 24  
>3 times 2 
HbA1c  last value  53 (27.0) 
<6.5% 18 
6.5−8% 27 
>8% 8 
Routine tests  
SMBG 
(in the last week) 
74 (37.9) 
Days per week, median (range) 1 (1-7) 
Times per day, median (range) 1 (1-2) 
Medical monitoring 
(in  the last 3 months) 
 
Blood sugar 167 (86.1) 
Blood pressure 166 (85.1) 
Weight 124 (63.9) 
HbA1c measurement 
(in  the last year) 
65 (33.3) 
1 time 29  
2−4 times 33  
>4 times 3 
Medical monitoring 
(in the last year) 
 
Cholesterol 127 (65.1) 
Kidney 84 (43.1) 
Eyes 48 (23.2) 
Feet 41 (21.0) 
Abbreviations: SMBG, self-monitoring of blood glucose; HbA1c, glycosylated haemoglobin 
* 1 missing response 
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4.4.2.4   Use of pharmacy services related to type 2 diabetes care  
The participating patients were given a list of services related to type 2 diabetes care 
and were asked to indicate services that they have received from pharmacies 
(Question 10, Section B, Appendix 6). In addition to the traditional role of 
dispensing (‘treatment administration’), the most frequent services reported were 
‘patient education’ about medications, particularly directions for use (79.6%) and 
special precautions to follow (71.9%). Responses describing patient usage of 
pharmacy services are summarised in Table 4.5.   
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Table 4.5   Patients’ use of pharmacy services related to type 2 diabetes care 
 
Services Frequency (%) of ‘yes’ 
N=196 
Treatment administration  
Prepare medications 196 (100) 
Provide labels with instructions for use  196 (100) 
Patient education  
Disease process 93 (47.4) 
Treatment targets 79 (40.3) 
Antidiabetic medications:  
Directions for use 156 (79.6) 
Use of insulin devices*  27 (61.4) 
Storage requirements 93 (47.4) 
Special precautions to follow 141 (71.9) 
Common/important adverse effects  87 (44.4) 
Exercise 66 (33.7) 
Diet 84 (42.9) 
SMBG 63 (32.1) 
Prevention/treatment of acute complications  67 (34.2) 
Prevention/treatment of chronic complications  45 (23.0) 
Need for regular medical monitoring  48 (24.5) 
Foot self-care 35 (17.9) 
Smoking cessation† 12 (29.3) 
Monitoring  
Monitor compliance with:  
Antidiabetic medications  100 (51.0) 
Exercise plan 62 (31.6) 
Diet plan 78 (39.8) 
Plan for prevention/treatment of chronic complications 44 (22.4) 
Scheduled medical monitoring 38 (19.4) 
Monitor treatment outcomes:  
Check records on SMBG 58 (29.6) 
Carry out blood glucose tests  58 (29.6) 
Measure BMI  40 (20.4) 
Measure blood pressure 55 (28.1) 
Check results on patient laboratory tests  51 (26.0) 
Monitor  for adverse effects 63 (32.1) 
Review  
Refer patients if necessary 69 (35.2) 
Abbreviations: SMBG, self-monitoring of blood glucose; BMI, body mass index 
* The percentage was calculated for patients currently/previously taking insulin (N=44) 
† The percentage was calculated for patients currently (or had a history of) smoking (N=41) 
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4.4.2.5   Satisfaction 
 
In spite of the limited services, 69.4% of respondents expressed high levels of 
general satisfaction (‘very satisfied’ or ‘satisfied’) in regard to services provided by 
pharmacies. 
 
 
Table 4.6   Patient satisfaction 
 
Level of satisfaction Frequency (%) 
N=196 
Very satisfied 37 (18.9) 
Satisfied 99 (50.5) 
Moderately satisfied 47 (24.0) 
Slightly satisfied 10 (5.1) 
Not at all satisfied 3 (1.5) 
 
 
4.4.2.6   Source of diabetes information  
 
Table 4.7 summarises data pertaining to the source of patients’ information about 
diabetes. The majority of patients received the information from their doctor’s office 
or clinic (68.9%). Nearly one-third of patients indicated pharmacies as their source of 
information (28.1%). 
 
 
Table 4.7   Source of information about diabetes 
 
Information source Number of responses
* (%) 
N=196 
Doctor’s office 135 (68.9) 
Others 60 (30.6) 
Pharmacy 55 (28.1) 
Television 45 (23.0) 
Newspaper 39 (19.9) 
Internet 15 (7.7) 
None 11 (5.6) 
* Respondents could name more than one source 
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4.4.3   Views on pharmacists’ roles in type 2 diabetes care 
 
Given the same list of services related to type 2 diabetes care, the participating 
patients were asked to rate the extent of their agreement for each service to be 
provided at pharmacies (Question 10, Section B, Appendix 6). All patients agreed 
with pharmacists’ roles in dispensing (‘treatment administration’). Beyond 
dispensing, more than 70% of respondents expected pharmacists to provide ‘patient 
education’ about medications. Approximately 50% of respondents supported other 
activities related to ‘patient education’ and ‘monitoring’. Patients’ views on 
pharmacists’ roles are shown in Table 4.8. 
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Table 4.8   Patients’ views on pharmacists’ roles in type 2 diabetes care 
 
 
Services 
% Rating extent of agreement*  
N=195* 
 1 2 3 4 5 6 
Treatment administration       
Prepare medications 0.0 0.0 0.0 0.0 21.5 78.5 
Provide labels with instructions for use  0.0   0.0 0.0 0.0 17.4 82.6 
Patient education       
Disease process 13.3 3.1 9.7 12.3 16.9 44.6 
Treatment targets 17.9 3.1 8.7 11.3 19.5 39.5 
Antidiabetic medications:       
Directions for use 3.6 1.5 4.1 8.7 15.9 66.2 
Use of insulin devices† 6.8 6.8 0.0 13.6 15.9 56.8 
Storage requirements 4.1 1.5 10.3 10.3 19.5 54.4 
Special precautions to follow 3.6 1.5 3.6 11.8 17.4 62.1 
Common/important adverse effects  5.6 2.6 7.2 13.3 16.9 54.4 
Exercise 17.9 5.1 10.8 16.9 17.4 31.8 
Diet 16.4 4.1 11.3 16.4 16.9 34.9 
SMBG 14.9 7.7 11.3 11.3 18.5 36.4 
Prevention/treatment of acute complications  10.8 3.1 12.3 9.2 19.0 45.6 
Prevention/treatment of chronic complications  13.3 3.1 12.3 11.8 20.0 39.5 
Need for regular medical monitoring  16.9 6.2 14.4 12.8 14.9 34.9 
Foot self-care 19.0 5.6 14.9 11.8 16.9 31.8 Smoking cessation‡ 9.8 4.9 14.6 12.2 2.6 34.1 
Monitoring       
Monitor compliance with:       
Antidiabetic medications  12.8 5.1 7.7 9.2 13.3 51.8 
Exercise plan 20.0 4.1 8.7 14.9 16.9 35.4 
Diet plan 19.5 3.6 8.2 12.8 19.0 36.9 
Plan for prevention/treatment of chronic 
complications 19.5 4.6 16.4 12.3 14.4 32.8 
Scheduled medical monitoring 20.5 4.1 15.9 10.3 19.0 30.3 
Monitor treatment outcomes:       
Check records on SMBG 25.0 4.1 10.3 8.7 21.0 30.8 
Carry out blood glucose tests  19.9 4.1 10.3 7.7 19.5 38.5 
Measure BMI 24.1 6.7 12.3 11.3 16.9 28.7 
Measure blood pressure 24.6 3.6 11.8 7.2 21.5 31.3 
Check results on patient laboratory tests  24.6 3.6 11.3 10.3 19.0 31.3 
Monitor  for adverse effects 17.4 4.1 11.8 10.3 19.0 37.4 
Review       
Refer patients if necessary 17.4 5.1 12.3 8.7 22.1 34.4 
Abbreviations: SMBG, self-monitoring of blood glucose; BMI, body mass index 
* 1 missing response 
† Percentages were calculated for patients currently/previously taking insulin (N=44) 
‡ Percentages were calculated for patients currently (or had a history of) smoking (N=41) 
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To further explore the priority roles of pharmacists, an open-ended question was 
given to the patients to list the five most important services that should be provided 
in pharmacies to assist them with their diabetes (Question 11, Section B, Appendix 
6).  
 
The top five services perceived as priorities by patients (in addition to pharmacists’ 
traditional roles of dispensing) were from the ‘patient education’ domain – education 
related to medications [i.e. directions for use (64.5%), common/important adverse 
effects (25.5%), storage requirements (26.6%)] and the ‘monitoring’ domain – 
monitoring compliance with medications (37.3%). This further exploration of 
pharmacists’ priority roles is summarised in Table 4.9. No new services were raised 
from this open-ended question. 
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Table 4.9   Patients’ open-ended views on priority roles of pharmacists in type 2 
diabetes care 
 
Priority services* 
 
Number of responses (%) 
N=169† 
Treatment administration  
Prepare medications 35 (20.7) 
Provide labels with instructions for use  66 (39.1) 
 Patient education  
Disease process 27 (16.0) 
Antidiabetic medications:  
Directions for use 109 (64.5) 
Use of insulin devices  15 (8.9) 
Storage requirements 45 (26.6) 
Special precautions to follow 37 (18.9) 
Common/important adverse effects  50 (25.5) 
Exercise 27 (13.8) 
Diet 33 (16.8) 
Prevention/treatment of acute complications  27 (16.0) 
Prevention/treatment of chronic complications  20 (11.8) 
Monitoring  
Monitor compliance with:  
Antidiabetic medications 63 (37.3) 
Monitor treatment outcomes:  
Carry out blood glucose tests 30 (17.8) 
Measure blood pressure 25 (14.8) 
Monitor for adverse effects 23 (13.6) 
Others (not a specific service)  
Provide a complete range of medications 12 (7.1) 
Information about medications 16 (9.5) 
Responses to an open-ended question: “In your opinion, what are the five most important services that should be 
provided at pharmacies to assist you with your diabetes?” 
*Services selected by more than 10 respondents 
†From a total 196 respondents, there were 26 missing responses and 1 invalid response, giving a total N=169 
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4.4.4 Associations between use of pharmacy services and views on 
pharmacists’ roles    
Chi-square tests were conducted to test univariate associations between patients’ use 
of pharmacy services (see Section 4.4.2.4) and their views on the roles of 
pharmacists (see Section 4.4.3 – responses were categorised into binary variables: 
Likert scale ratings of 5 to 6 indicated ‘agreement’ that a service should be provided 
versus ratings of 1 to 4 indicated ‘disagreement’). Dispensing practice (‘treatment 
administration’) was not tested since all respondents used, and agreed on, this 
traditional pharmacist role. The results are summarised in Table 4.10. They indicate 
that patients who had experienced a service generally scored a higher agreement 
level for the service provision than those who had not had such an experience 
(almost all p-values <0.05).  
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Table 4.10   Patients’ use of pharmacy services versus views on pharmacists’ roles 
Services Being used*  
 A. Yes B.  No  
 n/N (%) 
Being viewed as 
pharmacist roles 
n/N (%)  
Being viewed as 
pharmacist roles 
p-value 
Patient education    
Disease process 77/93 (82.8) 43/103 (41.8) <0.0001 
Treatment targets 65/79 (82.3) 50/117 (42.7) <0.0001 
Antidiabetic medications:    
Directions for use 137/157 (82.3) 23/39 (59.0) <0.0001 
Use of insulin devices†  22/27 (81.5) 10/17 (58.8) 0.103 
Storage requirements 74/93 (79.6) 70/103 (68.0) 0.066 
Special precautions to follow 119/141 (84.4) 36/55 (65.5) 0.003 
Common/important adverse effects  77/87 (88.5) 62/109 (56.9) <0.0001 
Exercise 50/66 (75.8) 46/130 (35.4) <0.0001 
Diet 58/84 (69.1) 43/112 (38.4) <0.0001 
SMBG 48/63 (76.2) 59/133 (44.4) <0.0001 
Prevention/treatment of acute complications  53.67 (79.1) 73/129 (56.6) 0.002 
Prevention/treatment of chronic complications  34/45 (75.6) 82/151 (54.3) 0.011 
Need for regular medical monitoring  31/48 (64.6) 66/148 (44.6) 0.016 
Foot self-care 27/35 (77.1) 68/161 (42.2) 0.0002 
Smoking cessation‡ 8/12 (66.7) 11/29 (37.9) 0.093 
Monitoring     
Monitor compliance with:    
Antidiabetic medications  80/100 (80.0) 47/96 (49.0) <0.0001 
Exercise plan 45/62 (72.6) 57/134 (42.5) <0.0001 
Diet plan 56/78 (71.8) 53/118 (44.9) 0.0002 
Plan for prevention/treatment of chronic 
complications 
35/44 (79.6) 57/152 (37.5) <0.0001 
Scheduled medical monitoring 28/38 (73.7) 68/158 (43.0) 0.0007 
Monitor treatment outcomes:    
Carry out blood glucose tests  52/58 (89.7) 61/138 (44.2) <0.0001 
Measure BMI 36/40 (90.0) 53/156 (34.0) <0.0001 
Measure blood pressure 48/55 (87.3) 55/141 (39.0) <0.0001 
Check records on SMBG 50/58 (86.2) 51/138 (37.0) <0.0001 
Check results on patient laboratory tests  40/51 (78.4) 58/145 (40.0) <0.0001 
Monitor  for adverse effects 51/63 (80.9) 59/133 (44.4) <0.0001 
Review    
Refer patients if necessary 55/69 (79.7) 55/127 (43.3) <0.0001 
Abbreviations: SMBG, self-monitoring of blood glucose; BMI, body mass index 
* Patients’ use of the service versus views on pharmacists’ roles: (A) patients viewed the service as part of a 
pharmacist’s role (Likert scale ratings of 5 to 6) among those who had used the service; (B) patients viewed the 
service as part of a pharmacist’s role (Likert scale ratings of 5 to 6) among those who had not used the service. 
† Percentages were calculated for patients currently/previously taking insulin (N=44) 
‡ Percentages were calculated for patients currently (or had a history of) smoking (N=41) 
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4.4.5   Factors associated with views on pharmacists’ roles  in type 2 
diabetes care 
 
Logistic regression models were used to identify patient characteristics (see Sections 
4.4.2.1, 4.4.2.2 and 4.4.2.3) and previous use of services (see Section 4.4.2.4) which 
were associated with patient views on pharmacists’ roles (see 4.4.3). Responses 
regarding the traditional role of dispensing (‘treatment administration’) were not 
tested, as this was a common pharmacy practice.  
 
For patient views (dependent variable), responses were categorised into binary 
variables, with Likert scale ratings of 5 to 6 indicating ‘agreement’ versus ratings of 
1 to 4 indicating ‘disagreement’. Some of the activities were grouped together if they 
were related to the same theme (for example, education related to antidiabetic 
medications was a composite variable based on five questions in that section) for 
which a mean rating was calculated (agreement with this composite variable was 
assumed if the mean rating ≥5.) The responses for the independent variable of 
patient’s previous use of services (binary responses: ‘yes’/’no’) were grouped in a 
similar way and a mean was calculated for this composite variable. In order to 
calculate the mean, a ‘no’ response was classified as ‘0’, and a ‘yes’ was classified as 
‘1’.  The mean was then treated as a continuous variable.  In this case, the odds ratio 
indicates the change in patient views as the mean of the composite variable changes 
from ‘0’ (a ‘no’ response to all the individual questions) to ‘1’ (a ‘yes’ response to all 
questions).  
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Patient education, particularly related to medications, was selected as one of the 
priority roles for pharmacists (see Section 4.4.3). The logistic regression showed that 
patient experience (previous use) with pharmacy-led education was strongly 
associated with their views that these activities should be provided by pharmacists. 
On the other hand, patients with higher incomes were less likely to support 
pharmacists offering education related to medications or healthy living (i.e. diet and 
physical activity), and patients who were working were less supportive of education 
regarding physical activity. The odds ratios of significant factors associated with 
support for education by pharmacists are summarised in Table 4.11. Where there is a 
gap in the table, it indicates that the factor was not significant and thus was dropped 
during backward elimination used for logistic regression analysis. 
 
 
Table 4.11   Odds ratios and 95% confidence intervals of significant factors 
associated with support for ‘patient education’ by pharmacists 
 
 Patient education by pharmacists 
 Medications* Exercise Diet All education† 
Employment     
Not working   reference  reference 
Working  0.3 (0.15-0.83)  0.5 (0.24-0.94) 
Income     
Low reference reference reference reference 
Moderate NS 0.4 (0.17-0.90) NS NS 
High 0.3 (0.10-0.72) 0.3 (0.10-0.80) 0.3 (0.12-0.61) 0.3 (0.10-0.68) 
Previous use of the 
service 
    
No reference reference reference reference 
Yes  4.5 (1.79-11.53) 10.3 (4.6-23.15) 4.4 (2.30-8.30) 4.5 (1.60-12.51) 
* A composite variable – education related to antidiabetic medications: directions for use, use of insulin devices 
(calculated only from those currently/previously taking insulin), storage, special precautions and 
common/important adverse effects; a mean rating ≥5 was used 
† A composite variable – all education: disease process, treatment targets, antidiabetic medications, exercise, diet, 
self-monitoring of blood glucose, prevention/treatment of acute complications, prevention/treatment of chronic 
complications, need for regular monitoring, foot self-care and smoking cessation (calculated only from those 
currently, or had a history of, smoking); a mean rating ≥5 was used 
NS = not significantly different from the reference 
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In addition to education related to medications, patients also selected monitoring 
compliance with medications as a priority role for pharmacists (see Section 4.4.3). 
Having had experience (previous use) with monitoring services was associated with 
support for pharmacists to provide the services. Patients who were working were less 
likely to support pharmacists’ roles in monitoring compliance or treatment outcomes, 
and those with higher incomes were less supportive of pharmacists monitoring 
compliance or adverse drug reactions. On the other hand, patients with 
poor/unknown glycaemic control were more positive regarding pharmacists 
monitoring treatment outcomes or adverse drug reactions, and those who had other 
risk factors were more supportive of pharmacists monitoring adverse drug reactions. 
The odds ratios of significant factors associated with support for monitoring by 
pharmacists are summarised in Table 4.12. 
 
 
Table 4.12   Odds ratios and 95% confidence intervals of significant factors 
associated with support for ‘monitoring’ by pharmacists 
 Monitoring by pharmacists 
Compliance* 
Treatment outcomes 
Adverse drug 
reaction Perform clinical 
testings† 
Check test 
results‡ 
Income     
Low reference   reference 
Moderate NS   NS 
High 0.3 (0.10-0.72)   0.2 (0.09-0.53) 
Employment     
Not working  reference reference reference  
Working 0.43 (0.21-0.88) 0.5 (0.24-0.97) 0.3 (0.15-0.74)  
Risk factors     
No    reference 
Yes    3.4 (1.46-8.03) 
Diabetes (glycaemic) 
control§ 
    
Good/fair   reference reference reference 
Poor   NS 4.9 (1.20-20.55) 3.2 (1.05-9.97) 
Unknown  2.3 (1.22-4.51) 10.2 (2.44-42.95)  4.3 (1.36-13.57) 
Previous use of the 
service 
    
No reference reference reference reference 
Yes  5.2 (1.79-11.52) 13.6 (5.21-35.51) 11.3 (4.51-28.13) 6.3 (2.82-13.90) 
* A composite variable – monitoring compliance with: antidiabetic medications, exercise and diet plan, plan for 
prevention/treatment of complications and scheduled medical monitoring; a mean rating ≥5 was used 
† A composite variable – perform clinical testings (measuring blood glucose, blood pressure and BMI); a mean 
rating ≥5 was used 
‡ A composite variable – check patient self-monitoring records and laboratory data; a mean rating ≥5 was used 
§ Diabetes (glycaemic) control is a composite variable of hyper/hypoglycaemia symptoms and HbA1c values 
NS = not significantly different from the reference 
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Significant factors associated with patient support for pharmacist-initiated referral 
included “working” (less support) or “previous use of the service” (more support). 
The odds ratios of these factors are summarised in Table 4.13. 
 
 
Table 4.13   Odds ratios and 95% confidence intervals of significant factors 
associated with support for ‘referral’ by pharmacists 
 
 Referral by pharmacists 
Employment  
Not working  reference 
Working 0.3 (0.15-0.66) 
Previous use   
No reference 
Yes  6.7 (3.16-14.03) 
 
 
4.4.6   Willingness to pay 
 
The respondents were asked “If pharmacies provide a consultation service to help 
with your diabetes, how much would you be willing to pay for the service (other than 
cost of medications and/or test kits)?” (Question 12, Section B, Appendix 6). A 
majority of respondents were not willing to pay for the services (69.4%).   
 
 
Table 4.14   Patient willingness to pay 
 
Willingness to pay 
 
Frequency (%) 
N=196 
Nothing 142 (72.5) 
<Rp 25,000  30 (15.3) 
Rp 25,000-50,000 21 (10.7) 
>Rp 50,000 3 (1.5) 
Abbreviations: Rp, Indonesian rupiah 
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4.5   Discussion 
 
This is the first study focused on evaluating the characteristics of Indonesian 
community pharmacy clients with type 2 diabetes and their views of community 
pharmacists’ roles in diabetes care. 
 
The questionnaire used in this study was constructed following an expert panel as 
well as a pilot study of the target population (pharmacy clients with type 2 diabetes); 
during the actual survey, no new themes were raised from the open-ended questions 
related to the pharmacy services, confirming the content-validity of the 
questionnaire.145 The pilot study showed that the Kappa scores for all questions 
related to the pharmacy services were greater than 0.40, which were considered as 
‘acceptable’ to ‘excellent’ levels of test-retest reliability.152 
 
The pharmacy clients with type 2 diabetes in Surabaya that were enrolled in this 
study were not from a random sample. Hence, the results may suffer some selection 
bias, and some caution should be exercised in generalising the findings. It should be 
emphasised that there is no access to a sampling frame because full lists of pharmacy 
clients with type 2 diabetes were not accessible due to the lack of patient databases 
within pharmacies, as well as patient confidentiality. This study included ten 
community pharmacies with more than 50 patients with type 2 diabetes; the request 
to sample 20 of their clients was to ensure that a range of clients would be included 
at each pharmacy rather than only sampling those that might support the pharmacy. 
Hence, the use of more pharmacies but less clients per pharmacy could have 
increased selection bias. Moreover, the ten pharmacies included in this study covered 
a range of sampling sites to ensure adequate inclusion of different geographical areas 
and socio-economic levels in Surabaya. It has been argued that, if a number of sites 
are used for sampling, diversity in a wider population may be reflected by 
differences in the sample.145 Supporting this, the characteristics of the respondents in 
this study compared well with respect to age, gender and duration of diabetes to 
those of a population study involving all type 2 diabetic patients visiting 18 medical 
centres across Indonesia between November 2008 and February 2009 (N=1785).2 
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Thus, the findings should provide adequate information on areas where pharmacy 
services can be developed.  
 
 
4.5.1   Characteristics of pharmacy clients with type 2 diabetes 
 
This present study found that the majority of type 2 diabetes patients reported that 
they had complications and/or other risk factors for complications, and/or had 
poor/unknown glycaemic control. In line with this, the population study of type 2 
diabetes patients in Indonesia reported that 81% of type 2 diabetes patients had not 
achieved good glycaemic control (HbA1c <6.5%), and approximately 60% of the 
patients had complications and/or risk factors of complications (i.e. dyslipidaemia 
and/or hypertension).2  
 
Moreover, this present study reported that follow-up care tended to be inadequate, 
with only about one-third of respondents reporting annual HbA1c monitoring and 
eye or foot examinations. Supporting this finding, the Patient and Health Provider 
Survey in Indonesia (2012)6 indicated that the majority of patients had not received 
foot or eye examinations within the past year, only 30% had had their HbA1c 
checked and many had expressed a wish to see health care providers more often. It 
was suggested that this poor quality of care and patient outcomes might relate to the 
lack of awareness, accessibility and affordability of diabetes care.6 It was reported 
that Indonesia has a major deficiency in its health workforce (see Section 2.2.3.3), 
thus contributing to the poor access to diabetes care. Starting in 2014, the 
Government will implement Jaminan Kesehatan Nasional – JKN (National Health 
Coverage) to improve affordability and accessibility of healthcare for the whole 
population. In light of the high rate of diabetes in Indonesia,1 optimising the use of 
health resources – including community pharmacists – would be paramount in 
improving access and quality of diabetes care. 
 
 
 133 
 
This study, however, reported that Indonesian community pharmacists currently had 
little involvement in the care of patients with type 2 diabetes. Respondents mostly 
utilised pharmacists for their traditional roles of dispensing and providing education 
related to medication, particularly directions for use. A previous study conducted in 
Indonesia (i.e. three urban cities: Jakarta, Yogyakarta, Makassar), although not 
focused on diabetes care, confirmed the limited services provided to pharmacy 
clients.28  
 
 
4.5.2   Views on pharmacists’ roles in type 2 diabetes care 
 
Despite limited use of pharmacy based-services in this study, the majority of patients 
reported high satisfaction levels. This might relate to the finding that patients 
provided mixed responses regarding community pharmacists providing services 
beyond dispensing, thus they might not consider this as an important point in judging 
their level of satisfaction. This study reported that patients tended to view the priority 
roles of pharmacists as extensions to their supply roles (i.e. education related to 
medications, and monitoring compliance with medications). This was confirmed by 
findings from international studies, of which some studies involved diabetes patients 
(see Table 2.14). In line with this, two qualitative studies indicated that patients 
identified the primary expertise of the community pharmacist as medicines supply, 
and there were mixed perceptions of community pharmacists’ roles extending to 
advising on prescription medicines, providing disease-related/health advice or 
providing monitoring services (using clinical testing devices).120, 127 
 
As discussed above (Section 4.5.1), there is likely to be a demand for better access to 
quality diabetes care in Indonesia to improve patients’ outcomes. As patients refill 
their medications at pharmacies, this presents an opportunity for pharmacists to assist 
patients in managing their diabetes between doctor visits and, potentially, reduce 
unnecessary visits to their doctors. Positive patient outcomes have been reported 
from pharmacists’ interventions in diabetes care, which were centred on activities 
related to education and monitoring (see Table 2.10). 
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4.5.3   Factors associated with views on pharmacists’ roles in type 2 
diabetes care 
 
While patients had mixed responses for diabetes care to be filled by community 
pharmacists, it is essential to identify factors affecting these expectations in order to 
support pharmacists in taking up a broader role. The logistic regression models found 
that a patient’s support for a service was influenced by his/her experience (previous 
use) with the service. Supporting this finding, studies worldwide have shown that 
type 2 diabetes patients have increased perceptions of pharmacists’ ability to assist 
them after receiving pharmacy-based services.17, 22, 95, 130, 131 It should be emphasised 
that most patients in this study (at the time) received limited services from 
community pharmacies, thus they might not be aware of what pharmacists should 
and could do.  
 
The implementation of JKN in 2014 should provide the opportunity to integrate and 
optimise the use of Indonesian community pharmacies in primary healthcare. It is 
important for the Government and IAI to establish an agreement on the basic services 
that should be available in the pharmacies. While the current payment under the 
scheme includes a very low prescription fee (see Section 2.2.4.4), the IAI should 
negotiate an adequate remuneration for pharmacists to provide the agreed basic 
services, thus enabling community pharmacies to remain viable. This is particularly 
important, as this study showed that most patients were not willing to pay out-of-
pocket expenses for professional services provided by community pharmacists. 
 
In addition to patients’ experiences, patients who were working and had higher 
incomes were generally less supportive of some pharmacy services beyond 
dispensing. This might be because these groups of patients were likely to be younger 
(mean age 63.7 years for non-workers versus 54.0 years for workers, p<0.0001; and 
mean age 60.4 years for income ≤Rp 5 million versus 58.6 years for income >Rp 5 
million, p=0.358). An Iraqi study113 and a UK study120 reported that older patients, or 
those living with diabetes for a long time, were more supportive of pharmacists’ 
contributions than those who were younger or had shorter duration of diabetes. It has 
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been suggested that elderly people are one of the groups whose need for additional 
advice on medications and other related services has been demonstrated.158 
 
Moreover, the logistic regression models showed that patients who had other risk 
factors for complications and had poor/unknown diabetes (glycaemic) control were 
more supportive of pharmacists monitoring treatment outcomes and adverse drug 
reactions. Such patients might reflect those with lower health status, representing a 
target group who might be more motivated and responsive to pharmacists’ 
involvement. It has been suggested that patients who benefit most from pharmacist-
led education/coaching and disease state management services include those with 
poor glycaemic control and multiple comorbidities.159   
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4.6   Key findings 
 
• Characteristics of pharmacy clients with type 2 diabetes in Surabaya Indonesia: 
- The majority of community pharmacy clients with type 2 diabetes 
reported poor follow-up care and health outcomes.  
- All community pharmacies were utilised for dispensing medications, and 
the most common service beyond dispensing was providing education 
related to medications, particularly directions for use (79.6%). 
 
• Views on pharmacists’ roles in type 2 diabetes care: 
- Almost all patients viewed dispensing as part of a community 
pharmacist’s role.  
- There were mixed responses towards pharmacists providing services 
beyond dispensing; services perceived as priorities included: education 
related to medications [i.e. directions for use (64.5%), storage 
requirements (26.6%), common/important adverse effects (25.5%)], and 
monitoring compliance with medications (37.3%).  
 
• Factors associated with views on pharmacists’ roles in type 2 diabetes care: 
- Patients’ previous use of a service was associated with their positive 
attitude towards pharmacists providing the service.  
- Patient characteristics, i.e.: those who had higher incomes or were 
working were less supportive, whereas those with other risk factors for 
complications or poor/unknown glycaemic control were more supportive, 
of pharmacists providing some services beyond dispensing. 
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Chapter 5 
Pharmacy-based services for type 2 diabetes patients: 
 A qualitative study 
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5.1   Introduction 
 
To date, there are no published studies evaluating the viewpoints of Indonesian 
pharmacists and doctors regarding community pharmacy-based services for type 2 
diabetes patients. The development of such services will require improved 
collaboration between pharmacists and doctors who, in the current model of health 
care delivery, are the main diabetes care providers. As highlighted in the literature 
review chapter (see Tables 2.12, 2.13, 2.15 and 2.16), published work regarding 
pharmacists’ and doctors’ views of community pharmacy practice in the area of 
diabetes has been limited to developed countries. 
 
Several studies, although not specific to diabetes care, have been conducted in 
Indonesia to evaluate community pharmacy practice.24-27 Two of these studies used 
qualitative approaches,25, 27  one of which involved interviews of pharmacists and 
doctors.25 Both studies analysed community pharmacy practice (in comparison with 
the Government Standards23, 75, 87) and contributing factors. The results showed that 
community pharmacy practice in Indonesia did not completely conform to the 
standards. While these studies highlighted some issues related to such practice, 
particularly lack of pharmacist competencies and availability/presence in the 
pharmacy; the themes were not clearly evident. Thus, this study aimed to explore the 
views of pharmacists and doctors to provide a better understanding of issues 
associated with type 2 diabetes practice in Indonesian community pharmacies. 
 
 
5.2   Objectives 
 
The objectives of this part of the thesis are: 
1. To explore current type 2 diabetes practice in community pharmacies and doctor 
clinics in Surabaya, Indonesia 
2. To investigate community pharmacists’ and doctors’ views on pharmacists’ roles 
in type 2 diabetes care 
3. To describe factors (potential and actual) associated with the development of 
community pharmacy-based services for type 2 diabetes patients 
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5.3   Methods 
 
The data collection instrument and methodology used in this qualitative study were 
approved by the Human Research Ethics Committee of Curtin University (Appendix 
2) as well as Ikatan Apoteker Indonesia – IAI (Indonesian Pharmacists Association). 
The qualitative research interview was deemed the most appropriate method for 
addressing the objectives because it provided the opportunity to explore in-depth 
views of individuals in order to understand the issues of interest.145  
 
 
5.3.1   Participant selection 
 
The study was carried out in Surabaya, Indonesia, with a purposive sampling of 
doctors and pharmacists in Surabaya, Indonesia. Purposive sampling was chosen to 
maximise the variety within the sample145 because we were interested in obtaining a 
range of doctors’ and pharmacists’ views, rather than to represent them 
proportionately. 
 
Participants for the pharmacist interviews were recruited from pharmacists involved 
in the Pharmacist Survey (Chapter 3) whose pharmacies reported to service more 
than 50 diabetic patients per month (n=146). Initially, ten pharmacists were selected 
by considering a range of characteristics, predominantly the levels of pharmacist 
availability at their pharmacies. Pharmacist availability was a ratio of total 
pharmacist working hours per week to total pharmacy opening hours per week. A 
ratio of one or more would indicate that there was always a pharmacist available 
during pharmacy opening hours. 
 
Participants for the doctor interviews were recruited through contacting doctors that 
were treating at least 50 patients with type 2 diabetes per month. This task was 
difficult as there was no available official data on characteristics of patients visiting 
doctor clinics in Surabaya. Therefore, the community pharmacists involved in the 
interviews were asked to provide information on doctors who frequently prescribed 
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antidiabetic medications. Ten doctors were initially selected to ensure the inclusion 
of a range of characteristics, predominantly their practice levels [i.e. general 
practitioner (GP), internal medicine specialist and consultant/endocrinologist].  
 
Before the completion of the planned 20 interviews (i.e. after the eighth pharmacist 
interview and the eighth doctor interview), no new themes emerged and data 
saturation was considered to have been reached; thus further recruitment beyond ten 
pharmacists and ten doctors was considered unnecessary.  
 
 
5.3.2   Data collection  
 
Each potential community pharmacist and doctor participant was contacted 
personally by the principal investigator to introduce the study (an information sheet 
was provided, see Appendix 7), and to seek their agreement to participate. Once they 
had agreed, the interview was arranged at a convenient location and time for the 
participant. Recruitment was continued until ten community pharmacists and ten 
doctors had agreed to participate. 
 
In-depth face-to-face interviews were conducted between May and December 2012, 
either within the participants’ premises or the principal investigator’s office in the 
Universitas Surabaya. At the beginning of each interview, a brief introduction to the 
project was provided, and a written informed consent was obtained (Appendix 7). All 
interviews were conducted in Bahasa Indonesia by the principal researcher (whose 
first language is Bahasa Indonesia) and a semi-structured interview guide was used 
(see Section 5.3.2.1). At the end of the interview, a separate form was used to gather 
demographic details of participants and their premises (Appendix 8). The interviews 
took from 30 minutes to one hour, and were audio-recorded. All participants were 
reimbursed for their time to participate in the interviews. Reimbursement rates were 
as follows: endocrinologists/consultants Rp 500,000 (approximately A$ 50); GPs and 
internal medicine specialists Rp 200,000 (approximately A$ 20); pharmacists Rp 
150,000 (approximately A$ 15).  
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5.3.2.1   Interview guide 
 
The semi-structured interview guide consisted of a series of open-ended questions 
that were created based on three key topics of interest: (i) current type 2 diabetes 
practice, (ii) views on the roles of community pharmacists in type 2 diabetes care, 
and (iii) factors associated with the development of pharmacist roles. This guide was 
piloted among the principal researcher’s pharmacist colleagues at Universitas 
Surabaya, and was refined as the interviews progressed (Appendix 9). The interview 
guide provided structure and consistency to ensure that the key topics were explored 
in each interview. However, it could be used flexibly with respect to the order in 
which issues were discussed. Time was available to pursue relevant issues raised by 
an interviewee. 
 
 
5.3.3   Data analysis  
 
Data collection and analysis were conducted concurrently throughout the study. The 
audio-recorded data from the interviews (Bahasa Indonesia) was transcribed 
verbatim. Thematic content analysis was used to analyse the interview transcripts.160 
Firsty, this involved familiarisation with the data where each transcript was read and 
re-read several times by the principal investigator; in addition, the recordings were 
listened to, to ensure the accuracy of the transcription. 
 
Secondly, initial coding of the transcript gave each segment/portion a code that 
represented the meaning of what was occurring in the data (free nodes). The code 
words were often the very words or phrase used by the participant. 
Segments/portions within the data were given multiple codes if they were identified 
as describing more than one meaning. Free nodes were organised into broader code 
words of higher conceptual level, i.e. categories. This process included a systematic 
comparison of each segment/portion newly assigned to a category with each of those 
already assigned to that category to ensure they formed a coherent pattern. The 
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categories were examined to identify relationships, and a hierarchical structure 
between categories was developed (tree nodes). The data management was facilitated 
by the use of the NVivo® database (QSR NVivo; version 9.0, QSR International).  
   
The final stage of the report production involved selecting examples of comments to 
illustrate properties of the categories/themes. These comments identified issues 
within the category/theme and presented lucid examples of the points being made. In 
addition, this stage involved translating the comments into English. This approach 
enabled analysis to stay in the source language as far as possible, thus avoiding 
potential limitations when analysing in a language other than the source language.161 
The categories/themes, together with the illustrative comments, were reviewed by the 
surpervisors to ensure the commonsense of their interpretations. The report also was 
sent to the participants for feedback. This was used as a means of ‘member-
checking’ to establish the trustworthiness of the data, which is parallel to validity in 
quantitative research.150  
 143 
 
5.4   Results 
 
 
5.4.1   Participant characteristics 
 
A total of ten community pharmacists and ten doctors were interviewed. The 
characteristics of the participants and their premises are presented in Table 5.1.  
 
Most participating pharmacists were female, more than 40 years old and had 
practised for more than 10 years. Equal numbers of participants were working in 
pharmacies owned by a pharmacy manager or single proprietor or group proprietor; 
and both within or not within doctor clinics. Most of the pharmacies had more than 
1,000 customers per month, with more than 100 customers being dispensed oral 
antidiabetic medications. The number of pharmacists in each pharmacy ranged from 
one to four, with a range of 8-60 working hours per week per pharmacist. The ratios 
of pharmacist availability were calculated by dividing pharmacist working hours per 
week by the pharmacy opening hours per week, resulting in a range from 0.3 to 2.1. 
Thus, a mixture between pharmacies with and without a pharmacist being available 
at all times (ratio ≥1 and ratio <1, respectively) was achieved. 
 
The participating doctors comprised of three GPs, five internal medicine specialists 
and two endocrinologists/consultants. The majority of the doctors were males, more 
than 50 years old and had been practising more than 20 years. Most of them were 
practising in clinics with an on-site pharmacy and half of them were serving 
approximately 100 patients with type 2 diabetes per month (ranging from 50 to 300 
diabetic patients per month).  
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Table 5.1   Characteristics of the participants and their premises 
 
Community pharmacists (N=10)  
Gender, n  
Male  2 
Female 8 
Age, years – median (range) 44 (26–76) 
Position, n  
Pharmacist manager as well as owner 4 
Pharmacist manager 5 
Pharmacist employee 1 
Work experience, years – median (range) 17 (2–37) 
Pharmacy characteristics  
Ownership, n  
Pharmacist manager as owner 4 
Single proprietor 3 
Group proprietor 3 
Setting, n  
Within doctor clinic 5 
Not within doctor clinic 5 
Counselling area/room, n 5 
No. of customers per month, median (range) 1590 (750–5600) 
No. of diabetics per month, median (range) 122 (70–250) 
No. of pharmacists, median (range) 2 (1–4) 
Pharmacists’ working hours per week, median (range)  42 (8-60) 
Opening hours per week, median (range) 100 (76–168) 
Doctors (N=10)  
Gender, n  
Male  9 
Female 1 
Age, years – median (range) 56 (41–82) 
Level, n  
General practitioner (GP) 3 
Internal medicine specialist 5 
Endocrinologist/consultant 2 
Work experience, years– median (range) 25 (4–42) 
Clinic characteristics  
Setting, n  
With on-site pharmacy 8 
Without on-site pharmacy 2 
No. of type 2 diabetics per month, median (range) 100 (50–300) 
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5.4.2   Current type 2 diabetes practice 
 
A model of the current type 2 diabetes practice in doctor clinics and community 
pharmacies, based on themes arising from pharmacist and doctor interviews, 
respectively, is shown in Figure 5.1.  
 
 
Figure 5.1   A model based on themes regarding current type 2 diabetes practice – 
doctor clinics and community pharmacies  
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5.4.2.1   Current type 2 diabetes practice – community pharmacies  
 
Themes related to community pharmacy practice (Figure 5.1) are expanded in Table 
5.2. This table also indicates the number of respondent pharmacists (coded as 
numerals) who provided comments related to the themes. The importance of each 
theme was ranked according to their frequency of appearance in the interviews. A 
theme which appeared in all of the interviews was ranked ‘common service’ and 
assigned *** (highlighted in the table). A theme that appeared in more than half but 
not all of the iverviews was ranked as ‘less common service’ and assigned **; and a 
theme that appeared in equal to or less than half of the interviews was ranked as 
‘least common service’ and assigned *. Further, selected comments were presented 
to provide typical context of the themes. Differing views were illustrated by the 
inclusion of more than one comment for individual themes. 
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Table 5.2   Themes on current type 2 diabetes practice – community pharmacies  
 
Main themes Sub-themes Pharmacist 
codes 
Ranking 
Dispensing: • Preparing medications All *** 
 • Providing labels    
Beyond dispensing:    
a) Initial assessment 
(patient history)  
- first visit* 
• Obtaining information from the doctor 1, 2, 10 * 
• Obtaining information on medications used  1, 2 * 
b) Prescription review • Prescription review – clinical aspects 1, 2, 5, 7 * 
c) Patient education • Medications    
 - Directions for use All *** 
 - Common/important adverse effects  1, 2, 4, 6, 7 * 
 • Diet (general) 6, 7, 8, 10 * 
 • Physical activity (general) 7, 8, 10 * 
 • Psychological support 4, 8 * 
 • Need for regular medical monitoring 8 * 
 • Others according to patients’ inquiries 1, 4, 10 * 
d) Monitoring/review 
- return visit† 
• Monitoring compliance    
- Medications  2, 8, 10 * 
- Diet  8, 10 * 
 - Physical activity 8, 10 * 
 - Scheduled medical monitoring 1 * 
 • Monitoring treatment outcomes    
 - Performing blood glucose tests 1, 2, 3, 6, 8 * 
 - Inquiring about glycaemic control and 
problems 
1, 2, 6, 7, 8, 
10  
** 
* First visit to obtain antidiabetic medications  
† Return visit to refill antidiabetic medications  
 148 
 
5.4.2.1.1   Dispensing (***) 
 
Once doctors have confirmed their diagnoses and prescribed medications, patients 
can have their medications dispensed at pharmacies (Table 5.2). All participating 
pharmacists reported that their pharmacies conducted the traditional tasks of 
dispensing medications, including preparing and labelling medications.  
 
“When we receive a prescription, of course… we will need to dispense the 
medications… put the labels…” (Pharmacist 5) 
 
In terms of labelling, all participants provided labels on directions for use of 
medication (in addition to the typical information of the patient’s name, pharmacy 
details, name of the pharmacist manager, date of dispensing and prescription 
number). However, some of them raised concerns regarding the range of information 
they can include on the label (other than that requested in the prescription). 
 
  “…we are not sure whether pharmacists are allowed to provide additional 
information./…/At the moment, we always inform about timing to take the 
medications. Even though the doctor writes (on the prescription) ‘one tablet 
three times a day, before or after food’, we always put the exact timing (eg. one 
tablet three times a day, 30 minutes after food)… That’s the minimum.” 
(Pharmacist 8) 
 
 
5.4.2.1.2   Services beyond dispensing  
 
Services other than dispensing were variable between pharmacies (Table 5.2). The 
provision of these services generally was opportunistic (i.e. when the pharmacist was 
available and had time to do the service) and inconsistent (not standardised) within 
the pharmacy. These situations are illustrated below. 
 
”Of course, during busy times, we would miss the patients. It depends – 
whenever we are available in the pharmacy and the patients are willing to be 
counselled.” (Pharmacist 2) 
 
 “…they (employee pharmacist) sometimes missed to ask (the prime 
questions).” (Pharmacist 1) 
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The range of services reported includes: 
 
 
a) Initial assessment (patient history) (*)  
 
When a patient had antidiabetic medications dispensed for the first time, a small 
subset of pharmacists conducted a patient interview to collect: 
 
• Information provided by the doctors – this might relate to the disease (e.g. 
diagnosis, complications, outcome targets and/or scheduled medical monitoring) 
or the treatment (eg. medications, lifestyle) 
 
“Usually when we receive a doctor prescription from the patient, we will ask if 
the doctor has provided any information – we even ask if the doctor has 
already informed how to administer the medications, when to do tests, what the 
targets are. Hence, we could reinforce or complement their points.” 
(Pharmacist 1) 
 
• Information regarding all medications taken by the patient, including self-
medications and complementary medicines  
 
 ”When we receive a prescription, we will ask for all medications being taken – 
‘As well as taking these antidiabetic medications, are you taking any other 
medications?’ – If yes, we would check if these medications affect (the diabetes 
treatment)... Hence, this is considered as the most important (information)”. 
(Pharmacist 2)  
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b)   Prescription review – clinical aspects (*) 
 
Based on the prescription (and information gathered during initial assessment), a 
small subset of pharmacists reported that they undertook prescription review for 
clinical issues at the time of dispensing. If any problem with the prescription was 
identified (e.g. inappropriate dose), they would contact the doctor. 
 
”In community pharmacies, we are not able to recommend treatment to 
doctors. This is possibly done in hospitals/… /So, doctors have the authority 
to (decide patient therapy and) prescribe medications. However if we think 
there is inappropriateness – for example, the dosage – we will check with the 
doctor.” (Pharmacist 7) 
 
 
c) Patient education 
 
All pharmacists reported that they had provided verbal education on dosage 
instructions in addition to the pharmacy label, especially for new patients (***). 
 
“Of course it is a bit different. For new patients, we shoud explain about the 
medications – how to administer the medications, also what to do in the case 
of hypoglycaemia. We need to explain all of these.” (Pharmacist 2) 
 
A smaller number of pharmacists provided added information on common/important 
adverse effects (particularly how to recognise and treat hypoglycaemia) (*); and/or a 
general guide on healthy living (*). 
 
 “I always tell them that the most important is a healthy lifestyle... In my 
opinion, physical activity is the most important thing. Antidiabetic medications 
could be considered as supporting only.” (Pharmacist 10) 
 
“The first is education about medications – administration, adverse effects, 
also the importance of compliance. The second is education related to the 
disease – diet or what kind of food that is not allowed, also lifestyle.” 
(Pharmacist 7) 
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Most participating pharmacists did not provide information on the use of insulin as 
this information would have been provided in doctors’ clinics. Other types of 
information were provided according to patient inquiries. 
 
 
d) Monitoring/review 
 
After the medications were issued, some monitoring activities were being 
undertaken, either at the time of a return visit by the patient or via telephone.  
 
 
• Monitoring compliance (*) 
 
Only a small number of pharmacists asked about patients’ compliance to the 
treatment (i.e. medications, physical activity or diet) or the scheduled medical 
monitoring.  
 
 “For routine patients, we usually ask – ‘how did you follow your medication 
instructions and your lifestyle advice?’…” (Pharmacist 8)  
 
“…we use My Diabetes Care Record form (developed by the American 
Diabetes Association). This (form) has listed a set of tests that should be done. 
So, while the patient is here, we can fill the form – ‘Sir, I guess you have not 
done this or this test’ – Then, we will suggest the patient to ask the doctor 
whether the particular test should be done.” (Pharmacist 1) 
 
One of the pharmacies had a procedure to record patients’ medication profiles, and 
called the patients to remind them when they needed to refill their medications.  
 
 “(Tele Farma – name of the procedure) takes records on medication profiles… 
as well as patients’ identity. This programme is about reminding patients via 
phone when their medications are about to finish.” (Pharmacist 6) 
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• Monitoring treatment outcomes 
 
More than half of the pharmacists would inquire of patients regarding their 
glycaemic control and problems (**). 
 
“… When patients refill their medication, we usually just ask if they have any 
problems. Also ‘Have you been checked for your glucose levels by your 
doctor?’ or ‘What has the doctor said about your diabetes?’…” (Pharmacist 8) 
 
In addition, half of the pharmacists reported that they performed blood glucose 
testing if asked by their patients (*). Patients usually learned about the service as they 
were regular customers at the pharmacy or obtained the information from friends or 
relatives. These patients requested the service particularly when they suspected 
episodes of hypoglycaemia or hyperglycaemia. 
 
“… sometimes they just came back from dining out with friends. As they are 
worried that their glucose levels might increase, they came by to the pharmacy 
to have a (blood glucose) test.” (Pharmacist 1) 
 
Only in a few cases did these pharmacists take the initiative to offer monitoring of 
patients’ glucose levels between doctor visits.  
 
  “We take the initiative – ‘After a few days, is it okay for us to call you, Sir?’ or 
‘Maybe if you have some time, would you like to visit our pharmacy? We would 
like to check how the medication is working’.” (Pharmacist 1) 
  
 “… if patients are complaining about symptoms that we think may relate to 
hypoglycaemia or hyperglycaemia, we will suggest to them to have a (blood 
glucose) test.” (Pharmacist 8) 
 
Based on the monitoring results, these pharmacists would refer patients to their 
doctors if any concerns arose. 
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5.4.2.2   Current type 2 diabetes practice – doctor clinics 
 
Themes related to the doctors’ practices (Figure 5.1) are expanded in Table 5.3. This 
table also indicates the number of respondent doctors (coded as numerals) who 
provided comments related to each theme. The importance of each theme was ranked 
according to their frequency of appearance in the interviews. A theme which 
appeared in all of the interviews was ranked as ‘common service’ and assigned *** 
(highlighted in the table). A theme that had appeared in more than half but not all of 
the interviews was ranked ‘less common service’ and assigned **; and a theme that 
had appeared in equal to or less than half of the interviews was ranked as ‘least 
common service’ and assigned *. Further, selected comments were presented to 
provide typical context of the themes. Differing views were illustrated by the 
inclusion of more than one comment for individual themes. 
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Table 5.3   Themes on current type 2 diabetes practice – doctor clinics 
 
Themes Sub-themes Doctor codes Ranking 
a) Initial assessment 
(diagnosis) - first visit 
• Clinical signs and symptoms All *** 
• Physical examination   
• Diagnostic tests   
b) Treatment plan  • Selecting therapy and setting outcome targets All *** 
c) Patient education • Disease process 2, 6 * 
 • Medications   
 - Indications 8 * 
 - Directions for use (especially insulin) 1, 3, 7, 8, 10 * 
 - Common/important adverse effects  1, 2, 6, 7 * 
 • Diet All *** 
 • Physical activity All *** 
 • Prevention of complications (e.g. smoking 
cessation, foot care) 
1, 4, 5, 7, 8, 
9 
** 
 • Other preventive activities (e.g. immunisation)  4, 5 * 
d) Monitoring/review 
–  regular visit 
• Monitoring compliance   
- Medications 2, 3, 4 * 
 - Diet  3, 4 * 
 - Physical activity 3 * 
 • Monitoring treatment outcomes   
 - Physical examinations All *** 
 - Results on requested tests (e.g. glucose levels) All *** 
 - Presenting complaints 1, 2, 3, 4, 5, 
10 
** 
 
 
a) Initial assessment (diagnosis) (***) 
 
All of the participating doctors reported assessing patients to confirm the diagnosis 
of diabetes and the presence of complications. 
 
 “For new patients, we will confirm the diagnosis based on their clinical signs 
and symptoms, laboratory tests, and physical examination… while we will also 
check for complications – and if any, when is the onset?/… / For diagnosis, we 
use the criteria from PERKENI or other professional organisations, such as 
ADA or other Asian organisations.” (Doctor 4) 
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b) Treatment plan; and c) Patient education 
 
Based on the assessment, all of the doctors developed treatment plans that included 
pharmacological and non-pharmacological therapy (***). In regard to non-
pharmacological therapy, all of the doctors reported providing education on diet and 
physical activity (***). 
 
 “After confirming the diagnosis, we will develop treatment plans that may 
include medications and non-pharmacological therapies… In terms of 
medications, these should be selected based on – according to the recent 
recommendation from ADA – patient preference… not only based on 
laboratory tests, but also based on patient’s education level, patient’s life 
expectancy, etc...” (Doctor 4)  
 
 “In terms of non-pharmacological therapy, we would also educate the patients 
on the diet – if necessary, we could refer them to the dietitian – also 
recommend them to keep physically active.” (Doctor 4) 
 
In addition to lifestyle education, some of the doctors reported that they provided 
education related to medications, in particular indications, dosage instructions 
(especially when insulin was prescribed), and common/important adverse effects 
(particularly how to recognise and treat hypoglycaemia) (*); education on preventive 
activities (e.g. smoking cessation, foot care) (**), and education relating to the 
disease itself, including the potential complications (*). The means of education was 
mostly face-to-face during the doctor’s consultation. Moreover, about half of the 
doctors emphasised the limited time available.  
 
 “I guess here (the consultation time) is about two to five minutes… In the 
outpatient clinic, it may be shorter… only three minutes; in the private 
practice, it may be longer… up to five minutes (or) ten minutes… if only they 
ask questions. If they don’t… we sometimes even miss the patient education.” 
(Doctor 2) 
 
In general, the doctors reported that their usual treatment of patients was as 
independent practitioners. Where necessary (and the patients had no financial issues), 
they would refer patients to other health care professionals (eg. neurology specialist, 
dietitian, surgeon); however, follow-up recommendations from these professionals 
were often provided directly to the patients, and not necessarily to them.  
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 ”I sometimes refer the patients to the dietitian. However, the problem is that I 
do not know what the dietitian said/…/My concern is: What if my 
recommendations are not in accordance with theirs? This would be awkward.” 
(Doctor 6) 
 
 
         d)   Monitoring/review 
 
At the beginning of treatment, all doctors would suggest more frequent return visits – 
every one or two weeks – to determine the optimal medication dosage. Then, the 
interval of visits would be gradually lengthened up to every 6 months (but these 
varied between doctors).  
 
”The frequency of visits would be variable. For those taking medications for 
the first time – where the optimal dose needs to be determined – the visits could 
be weekly or fortnightly. After it has been achieved, the visits could be extended 
to every two to four months, even every six months.” (Doctor 8) 
 
One of the doctors, however, mentioned that longer intervals often resulted in poor 
glycaemic control due to the lack of monitoring during this period.  
 
 ”If I tell them to come back after three months… often they are not doing well 
with their glycaemic control. Thus, I ask them to come back every month… so 
that they will be more aware if there is any increase in their levels… that’s the 
most important thing!” (Doctor 2) 
 
Patients with longer intervals between visits (>1 month) would be provided with 
either prescriptions signed ‘repeat’ or prescriptions for the whole period (when they 
could arrange their own times to get the medications refilled).   
 
 “I usually prescribe for a one month supply, and then it could be repeated. 
Most of the times, patients are not willing to get the medications for the whole 
period – ‘I prefer to get it filled every month’ – that’s what the patients said.” 
(Doctor 8) 
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• Monitoring compliance (*) 
 
Unless the patients had poor glycaemic control, only a few doctors would perform 
routine checks on patient compliance with treatment during return visits.  
 
“I usually would check whether the patients have taken their medications on a 
regular basis. Concurrently, I would follow their blood glucose levels... If their 
diet had been handled by a dietitian, I usually would not check this in detail – I 
would only ask in general whether the patients have followed their diet advice. 
That’s it.” (Doctor 4) 
 
 
• Monitoring treatment outcomes 
 
During these return visits, all doctors would perform physical examinations and 
review the test results in order to check the effectiveness of the therapy (***), while 
fewer doctors would routinely ask about presenting problems (**). A letter to request 
laboratory tests was provided to patients at each visit, so that the patients would have 
the tests done and bring the results to the next visit for review.   
  
 ”… we would monitor their glucose levels… in addition to the physical 
examinations on their visits.” (Doctor 7)  
  
 “During return visits, I would check their medical records – what was the 
problem. (Then) I would ask if they are still having the problem...” (Doctor 3) 
 
Additionally, some doctors encouraged patients to perform self-monitoring of blood 
glucose (SMBG) and keep records; but this was rarely done. Two of the doctors 
emphasised the role of SMBG as being particularly important for those on insulin 
therapy.  
 
 “...this (SMBG) is not for all diabetic patients… In particular, diabetic patients 
who are on insulin therapy should be able to perform SMBG. However, those 
who are on oral medications will not need this; it would be adequate for them 
to have the tests at scheduled doctor’s visits, e.g. every three or four months.” 
(Doctor 10) 
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At each visit, all doctors would keep records on patient profiles, such as: medical 
history, family history, presenting problems, medications, and results of physical 
examinations and laboratory tests.  
 
 ”Each patient has a medical status which contains – what we get from the 
initial assessment – family history, history of presenting problems; also data on 
weight, glucose levels and other laboratory tests. The medications being 
prescribed also are recorded.”  (Doctor 5) 
 
Based on the monitoring of results, the doctors would consider any necessary 
adjustments to the treatment plan. 
 
 
5.4.3   Views on pharmacists’ roles in type 2 diabetes care 
 
Themes related to doctors’ and pharmacists’ views on pharmacist roles in diabetes 
care are presented in Table 5.4.  
 
The importance of each theme was ranked according to their frequency of 
appearance in the interviews. A theme which appeared in more than half of the 
interviews with both professional groups (i.e. pharmacists and doctors) was given the 
rank of ‘higher agreement’ and assigned **. A theme that appeared in equal to or less 
than half of the interviews with both professional groups was ranked as ‘lower 
agreement’ and assigned *. Further, selected comments have been used to provide 
typical context related to the themes. Differing views are illustrated by the inclusion 
of more than one comment for individual themes. 
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Table 5.4   Themes on doctors’ and pharmacists’ views on pharmacists’ roles in type 
2 diabetes care 
 
Main themes Sub-themes Pharmacist 
codes 
Doctor 
codes 
Ranking 
Dispensing: • Preparing medications All All ** 
 • Providing labels    
Beyond dispensing:     
a) Initial assessment • Obtaining patient history (PMRs) 1,2,4,5, 6, 
7,8,9,10  
  
b) Prescription review • Prescription review – clinical aspects 1,2,4,5,6,7,8,
10 
2,4,5,8,10 
 
* 
c) Patient education • Medications    
 - Directions for use All 1,2,4,5,7, 
8,9,10 
** 
 - Common/important adverse effects  1,2,4,6,7 2,4,5,8,9  * 
 • Diet (general) 1,2,6,7,8,10 2,8,7 * 
 • Physical activity (general) 1,2,7,8,10 7,8 * 
 • Psychological support 4,8   
 • Regular tests 8   
 • Preventive activities 
(e.g. smoking cessation, foot care) 
 2  
 • Others according to patients’ inquiries 1,4,10   
d)  Monitoring/review • Monitoring compliance     
 - Medications 1,2,6,7,8,10  5,9,10 * 
 - Diet  8,10   
 - Physical activity 8,10   
 - Scheduled medical monitoring 1   
 • Monitoring treatment outcomes    
 - Performing blood glucose tests 1,2,3,6,8    
 - Inquiring about glycaemic control and 
problems 
1,2,4,5,6,7,8, 
10 
2,4,5,7,8 
 
* 
 • Medication review (beyond prescription 
review at the time of dispensing) 
1,2,6,8    
Abbreviations: PMR, patient medication record 
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5.4.3.1   Dispensing (**) 
 
All pharmacists and doctors agreed with the pharmacist’s supply role. In terms of 
labelling, two of the doctors expected pharmacists to provide more complete 
information on the labels.   
 
 “Labels for medications should be prepared as those in the hospitals. In the 
hospitals, labels are printed with clear information on the patient’s name, drug 
name and strength… all is there. This kind of label has not been seen in the 
community pharmacies… they only put on how many times patients should take 
the medications – before or after food – but there is no drug name and strength. 
Hence, it would cause a mess when patients accidentally put the medication in 
the wrong medication bag.”(Doctor 8) 
 
Some pharmacists also recognised the potential role of pharmacists in providing 
additional information on the label to ensure safety and correct use of medications. 
 
 “Up to now, we have never provided additional information on the label. I 
think we should move on to that as patients do not always pay attention to what 
we told them earlier.”  (Pharmacist 8) 
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5.4.3.2   Services beyond dispensing 
 
Participating pharmacists believed that they should extend their roles beyond 
dispensing (see Table 5.4). However, only half or less than half of the doctors were 
supportive of pharmacists performing services other than dispensing and education 
on directions for medication use (see Table 5.4).  
 
 
a) Initial assessment (patient history) 
 
Most of the participating pharmacists considered that they should obtain a Patient 
Medication Record (PMR), which included the patient’s medical and medication 
history, in order to provide patient care. 
 
 ”I guess it would be better if pharmacists could develop a sort of patient record 
the same as those developed by doctors. This could be developed for certain 
patients – not all patients – such as patients with diabetes, etc. We could take 
records – when they first come – on their medical history, medications being 
taken and any problems while taking the medications. All of these are 
important.” (Pharmacist 7) 
 
 
b) Prescription review – clinical aspects (*) 
 
Almost all participating pharmacists, and some doctors, considered that pharmacists 
should check the prescription for clinical issues – such as inappropriate dosage, 
duplication or interactions – and alert the doctor when any problems were identified.  
 
 ”… receiving prescriptions and delivering medications (to the patient) should 
be done by us. That’s what I think.  When a prescription comes into my 
pharmacy, I should be the first to handle… checking for the proper dosage, 
etc.” (Pharmacist 5) 
 
 “Pharmacists sometimes can provide advice, for example in the case of 
duplication – giving a sulphonylurea together with another sulphonylurea – or 
when we find errors in the (dosage) calculations/… /In this case, it will be 
good if they can let us know.” (Doctor 5) 
 
 162 
 
c) Patient education 
 
 
• Education on medications – directions for use (**) 
 
Both health professional groups agreed that pharmacists should contribute to 
educating patients about medications, particularly directions for use (**), and 
common/important adverse effects (especially how to recognise and treat 
hypoglycaemia) (*). 
 
All pharmacists and most doctors emphasised that the most important role for 
pharmacists is to ensure that the medications are taken properly. Pharmacists were 
expected to check with doctors if the dosage instructions on the prescription were 
unclear. 
  
 “Our role is not just supplying the medications, right?... At least we have to 
ensure that we provide the right medications to the right patients… we cannot 
let the patients be messed up with their dosage instructions. This can be fatal.” 
(Pharmacist 5) 
  
 “I expect pharmacists should check whether the patients know how to take 
their medications properly. If they already know – as for regular patients, they 
have used it for years – that should be fine… But if they still do not know – 
even though the doctors have written (appropriate) dosage instructions – the 
pharmacist should explain it again/…/There are various dosage instructions 
for antidiabetic medications… So, we expect pharmacists to check on dosage 
instructions prescribed by doctors… sometimes doctors can miss some 
information, hence pharmacists can add it on or maybe check it with the 
doctors.” (Doctor 10) 
 
Although half of the doctors believed that pharmacists could inform patients about 
common/important drug adverse effects, two of them considered pharmacists should 
limit their information to avoid it hampering patient compliance.  
 
 ”As we have limited time… particularly with regard to education on side 
effects, I expect pharmacists can help. But this is only for the common side 
effects. Indeed, this doesn’t need to be explained in detail.  For example, TZD – 
‘when experiencing oedema of the legs, do not forget to report’; or maybe 
simply telling the patients – ‘do not stop your medications, if any problems are 
raised, you should contact the doctor’/… /If this information (side effects) is 
provided in detail, there are concerns that patients would refuse to take their 
medications.”(Doctor 2) 
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• Education on diet and physical activity (*) 
 
About half of the pharmacists and fewer doctors agreed that pharmacists should 
provide (or reinforce) education (provided by doctors) on lifestyle, i.e. diet and 
physical activity;  
  
 ”I think modification to lifestyle can be our potential role, as doctors usually 
provide the instructions only… Hence, we need to help patients to follow the 
instructions.” (Pharmacist 1) 
 
 ”I expect pharmacists to provide information on dosage instructions… a bit of 
information on diet – ‘Ma’am, do not forget to follow your diet instructions! 
Taking medications only won’t be enough’/…/Also, pharmacists can reinforce 
other information from doctors to make the patients more convinced… since all 
of us say the same things.” (Doctor 7) 
 
 
d) Monitoring 
 
 
• Monitoring compliance with medications (*) 
 
More than half of the pharmacists, but fewer doctors, considered that pharmacists 
should routinely monitor patients with regard to their compliance with medications. 
It was suggested that pharmacists could alert patients when they needed to get their 
medications refilled, in order to ensure medication continuity. 
 
  ”… for regular patients – those who are taking antidiabetic medications or 
other medications that require regular refills – there will be particular 
records/… /The pharmacists will be responsible to alert the patients when 
they need to get their medications filled, and also to perform monitoring… 
follow-up (by phone) – ‘Ma’am how is the progress?’ – It will be like that.” 
(Pharmacist 7) 
 
  ”With regard to medications, please emphasise that patients cannot stop the 
medications/…/When pharmacists find prescriptions signed ‘repeat’, remind 
the patients – ‘Sir, you should not stop taking the medications. You should get 
your medications refilled at least two or three days before they run out’/… 
/When necessary, the pharmacists can make an agreement with the patients – 
‘Sir, do you want us to remind you when you need to get your medications 
refilled?’ – This will be a good approach.” (Doctor 10) 
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• Monitoring treatment outcomes (*) 
 
While doctors performed monitoring during their patients’ return visits, the majority 
of pharmacists considered that they should be responsible for monitoring between the 
visits. The majority of pharmacists and half of the doctors agreed that pharmacists 
could inquire about a patient’s glycaemic control and presentation of problems when 
he/she gets their medications refilled in the pharmacy; and alert their doctor when 
any concerns arise. 
 
“I believe that we should record the patients’ blood glucose levels… follow 
them up on a regular basis...” (Pharmacist 5)  
 
“Monitoring of presenting problems to detect side effects is definitely our 
role.” (Pharmacist 7) 
 
“… If the pharmacist finds that the patient has a high glucose level – ‘No (you 
can’t get the medications) you should go back to your doctor – I don’t think 
that pharmacists should be involved in treatment adjustment though, as this is 
not their role.” (Doctor 5) 
 
Further, a few pharmacists believed that they should conduct a more comprehensive 
medication review (beyond prescription review that occurs at the time of dispensing) 
for at-risk patients. 
 
“During monitoring… we need to assess whether a patient requires a more 
comprehensive review… in which we should consider all of their medications 
as well as other medical conditions.” (Pharmacist 1) 
 165 
 
5.4.4   Factors associated with the development of pharmacy-based 
services for type 2 diabetes patients  
 
The participating doctors and pharmacists identified several factors (potential and 
actual) affecting the delivery of community pharmacy-based services for type 2 
diabetes patients. Themes related to these factors are presented in Table 5.5. Further, 
selected comments have been used to provide typical context related to the themes. 
Differing views are illustrated by the inclusion of more than one comment for 
individual themes. 
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Table 5.5   Factors affecting pharmacy-based service delivery for type 2 diabetes patients, as perceived by pharmacists and doctors  
Main themes 
Sub-themes 
Pharmacist/doctor codes 
 Facilitators Barriers 
Pharmacist Attitude - Positive views towards services beyond 
dispensing  
 See Table 5.4 
 Competence  - Perceived lack of competence P: 3, 5, 6, 9, 10 
Relationships with doctors Doctor’s attitude - Doctors’ previous interactions with 
pharmacists contributed to positive attitudes 
- Lack of support – encroaching on doctors’ 
clinical autonomy, lack of awareness, retailer 
image 
D: 1, 3, 4, 6, 9, 10 
P: 2 ,3, 5, 6, 7, 10 
 Doctor’s accessibility  - Low accessibility – difficult to contact, limited 
time 
P: 2, 10 
D: 1 
Relationships with patients Patient’s attitude  - Lack of demand – lack of awareness, retailer 
image 
P: 3, 5, 6, 8, 9, 10 
 Patient’s accessibility  - Low accessibility – not coming in person, 
having no time, not coming on a regular basis 
P: 1, 2, 3, 4, 5, 6, 9 
Pharmacy environment Practice orientation - Professional orientation  P: 1, 8, 10 
   - Business orientation P: 6 
 Staff resources  - Lack of staff (suitably qualified) P: 5, 3, 10 
  - Task delegation  P: 6, 7 
 Pharmacist availability/time  - Lack of pharmacist availability/time P: 1, 2, 5, 6, 7, 9 
D: 1, 5, 7, 8 
 Operational - Counselling areas/rooms   P: 1, 7 
   - Difficulty to maintain PMRs P: 1, 2, 6, 7, 8 
   - Poor labelling, and lack of other written 
information 
See Sections 5.4.2.1.1 
5.4.2.1.2c, and 5.4.3.1 
  - Protocols/procedures  P: 1, 2, 4, 6 
External environment Organisation of roles - A health system to support delegation of roles 
to pharmacists 
- Lack of a health system to support pharmacist 
roles (doctor dominance) 
D: 1, 2, 4, 6 
P:  3, 5, 6 
 Financing - Remuneration system  P: 6 
 Marketing - Raising public awareness  P: 8 
 Assistance (profession wide) - Training for pharmacists  P: 5, 8, 9, 10 
  - Mentors   P: 3 
Abbreviations: PMR, patient medication record; D, doctor; P, pharmacist 
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5.4.4.1   Pharmacist 
 
Pharmacist characteristics were viewed to be important in the development of 
pharmacy services for type 2 diabetes patients.  
 
 
a) Attitude 
 
The pharmacists believed that they should extend their services beyond dispensing 
(see Table 5.4). This was seen either as an obligation to conform with the 
Government Standards or Ikatan Apoteker Indonesia – IAI (Indonesian Pharmacists 
Association) recommendations, or as a responsibility to their patients. Further, one of 
the pharmacists commented that feeling more involved in delivering a better service 
for patients provided her with professional satisfaction and fulfilment.  
 
“When I did it…. I feel that our profession can contribute to better patient 
outcomes… and it made me feel more confident.” (Pharmacist 1) 
 
In addition, two of the pharmacists believed that practising pharmaceutical care 
might also improve customer satisfaction and, in turn, would benefit their businesses. 
 
“… to make my pharmacy more profitable, I should think how to make the 
customers happy…then they will come back to my pharmacy. Thus, I should 
provide a value-added service.” (Pharmacist 2) 
 
 
b) Competence 
 
While competence was perceived as a basic necessity for practising pharmaceutical 
care, half of the pharmacists expressed concerns regarding pharmacists’ competence. 
 
 “Programmes developed for patient care – disease management – have to be 
supported by competent people… Competency is playing an important role 
here. In my opinion, this is the greatest barrier… pharmacists’ (inadequate) 
competency.” (Pharmacist 6) 
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 “To be honest, I do not have the courage to do it (patient care) on my own… I 
am not that competent. I am afraid to fail it.” (Pharmacist 3) 
  
 “How can we be doctors’ partners? A pharmacist is only studying for five 
years before practising; a doctor is studying longer… then, additional few 
years for specialisation. They have enormous knowledge... experiences as well. 
We might be able to talk about antibiotics… new products… dosage… that’s 
what we know. As for medications for diabetes, pharmacists do not have 
adequate knowledge. I admit it.” (Pharmacist 5) 
 
 
5.4.4.2   Relationships with doctors 
  
Pharmaceutical care was viewed as a form of multidisciplinary care in which the 
pharmacist should have a close relationship with the doctor, who is the main care 
provider. 
 
 
a) Doctor’s attitude 
 
The majority of the doctors expressed concerns about the involvement of 
pharmacists in patient care, since doctors generally considered clinical activity as 
their role.  
 
 “In terms of developing a treatment plan with doctors, it will be too far… As 
we can see… even in the inpatient setting (in a hospital in Surabaya), it is hard 
for the doctors to accept recommendations from the clinical pharmacists... If a 
pharmacy is practising in that way, I guess this will be bad for its business… 
as currently doctors are not used to that kind of practice (thus, suggesting 
patients to get medications from other pharmacies).” (Doctor 1)  
 
 ”In my opinion, pharmacists should not provide anything other than what 
doctors have prescribed. If they find it unclear, they can check with the doctor. 
There is no need for them to inform patients what this medication is used for, 
right? It is not supposed to be a pharmacist’s responsibility, is it? It is the 
doctor’s role to decide what a medication is used for.” (Doctor 6) 
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In line with this, pharmacists were under the impression that doctors were not 
enthusiastic about their involvement in patient care, and any extension of a 
pharmacist’s role could be seen as an encroachment on the doctor’s clinical 
authority.  
 
“Sometimes doctors were irrational. Recently, I found a newborn given 
amoxycillin at the dosage of 200 mg. In my opinion this did not make sense… 
the average weight of newborn babies is about 3 kg or 4 kg maximum, 
amoxycillin dosage is 30 to 40 mg per kg per day, it makes 10 mg each time. If 
you multiply it with the weight, how much do you think is the appropriate 
dosage? It is 40 mg, isn’t it?... sometimes doctors could give more than 100 
mg. When I checked with them, they were so upset with me.” (Pharmacist 5) 
 
“Doctors also have the kind of behaviour… treat patients as ‘my patients’ or 
‘your patients’. So, they are not focusing on the patients, instead they put their 
professional egos on top. This can be a barrier. While we are trying to help 
(with extending our contributions)… they have accused us of encroaching upon 
their authority –‘What has the pharmacist been doing?’…” (Pharmacist 6) 
 
These doctors’ attitudes might be influenced by their lack of awareness of 
pharmacists’ clinical knowledge and continuing professional development roles. 
Thus, they expressed a lack of confidence in involving pharmacists in patient care.   
 
 ”…this should be done carefully and only if the pharmacist is capable of 
providing correct information. So, are pharmacists currently ready to take up 
the service? I guess pharmacy education curriculum should be tailored 
accordingly… As I said pharmacists have a lack of clinical knowledge – they 
are still product-minded – as the result of their education curriculum.” (Doctor 
3) 
  
This lack of awareness may be compounded by doctors’ perceptions around 
pharmacy business roles, in particular when the pharmacy was not owned by the 
pharmacist. 
 
 “The pharmacy business has quite a lot of stakeholders. The pharmacist can be 
just an employee at the pharmacy… Thus, the owner will decide how to run the 
pharmacy… if the owner is more business-oriented, they will just need the 
pharmacist’s name to be put as a manager (and do not care for the 
pharmacists’ professional roles). That’s the barrier.” (Doctor 1) 
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b) Doctor’s accessibility 
 
While providing patient care requires an effective collaboration with the doctor, 
pharmacists expressed concerns about access to doctors. 
 
 ”When we identified problems, contacting doctors was a challenge… 
particularly for those (doctors) with lots of patients.” (Pharmacist 2) 
 
Though doctors generally expected that pharmacists should check with them if their 
prescriptions were unclear, one of the doctors highlighted that doctors’ limited time 
for communication could be a barrier for pharmacists to assume more clinical roles. 
 
 ”…in the primary care setting where the load is high and we should work fast, 
time for communication is limited. Hence, I cannot imagine how pharmacists 
can get involved in developing a treatment plan…. It will be difficult! It may be 
possible in the hospital, but not in the primary care setting.” (Doctor 1) 
 
 
The importance of relationship-building was discussed by some of the pharmacists 
and doctors in terms of improving support from, and access to, doctors. It was 
considered that it could be commenced with an initial communication to make the 
doctors aware of what services pharmacists can provide.   
  
“...if pharmacists can communicate well to the doctors in relation with what 
they are planning to do – particularly if they personally know the doctors – I 
guess it should be okay. However, if pharmacists do not initially contact the 
doctors, they can misunderstand… that pharmacists are encroaching on their 
authority, and causing patients to lessen their doctor visits.” (Doctor 4)   
  
“We have tried to approach some doctors, though not many… As we were 
trying to communicate well regarding patients’ issues, they responded quite 
well… maybe they could see that we had a good intention. However, we are a 
bit worried to contact doctors that we do not personally know.” (Pharmacist 1) 
 
It is essential for pharmacists to demonstrate their competence and value over time to 
gain doctors’ trust. It was shown that two of the doctors had gained trust in 
pharmacists after working together with them over some time.  
 
 ”In my opinon, what the pharmacist ‘X’ has been doing is excellent… As I 
have limited ability, limited time… I guess we should appreciate others who 
are willing to provide more care to the patients.” (Doctor 2) 
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5.4.4.3   Relationships with patients 
 
Pharmaceutical care requires a professional relationship between the pharmacist and 
patients to be established and maintained. 
 
 
a) Patient’s attitude 
 
Pharmacists believed in the importance of patient demand in reinforcing practice 
change.   
  
“(In some cases) they wanted explanations about their medications. So, we 
need to provide the information. Sometimes they were even smarter… they 
were bringing ISO (i.e. a book which contained information on drugs 
distributed within Indonesia) here.” (Pharmacist 4) 
 
”Maybe if there is a demand from the community, we might start to develop our 
roles. Why are we still reticent? In my opinion, this is because the community 
do not put demand on us... I did PMRs before, but not anymore, as there is no 
demand…” (Pharmacist 8) 
 
It was perceived by the pharmacists that the current lack of demand was because 
patients were not aware of what to expect from a pharmacist. In addition, their 
perceptions around pharmacists being retailers as well as healthcare providers might 
create uncertainty in their minds regarding the pharmacists’ roles in patient care.  
 
“Especially for new customers… as they may not be familiar with our 
service… they usually just want to get their medications.” (Pharmacist 1) 
 
”When I told them not to purchase only two or nine tablets (explaining that 
otherwise the problem would recur) … they did not comply… probably they 
thought that I just care to sell my products. This made me feel uneasy… as if I 
was not telling the truth or something like that.” (Pharmacist 3) 
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b) Patient’s accessibility  
 
Pharmacists reported that the provision of patient care was often hampered by 
difficulty in accessing patients, such as them not coming in person, having no time or 
not coming on a regular basis. While patients could choose any pharmacy to dispense 
their prescription and could switch from one to another on successive visits, this 
made patient records and service continuity difficult. 
 
“Patients were mainly ordering (their medications) via phone.” (Pharmacist 1)  
 
”…whenever we are available in the pharmacy and the patients are willing to 
be counselled. Sometimes they just said – ‘Ma’am, I am in a hurry’ – that’s it, 
we’ll miss them.” (Pharmacist 2) 
 
“I wish to have a more thorough patient record… ideally there is data on 
allergies, etc, but we need adequate time to obtain this information from 
patients… as I said… in Indonesia, (most) patients are not covered by 
insurance plans. So that, they could choose whichever pharmacy they like 
(often patients purchased their medications here and switch to another 
pharmacy next month).” (Pharmacist 4) 
 
 
Hence, it is important to develop a professional relationship between the pharmacist 
and the patient to improve support from, and access to, patients. Two of the 
pharmacists reported the use of simple questions about patient medications at the 
first meeting, to help the patients to recognise their needs and to make them aware 
that the pharmacist can help. They suggested that, once the patients valued the 
service, they would be willing to access the service.  
 
“We usually start with asking about their medications… at least to introduce 
them to our role/…/This patient was first counselled about the use of her 
medication a few days ago… now she asks if she can access the service in the 
future.” (Pharmacist 1) 
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5.4.4.4   Pharmacy environment 
 
Pharmacy characteristics were seen as important in supporting the development of 
community pharmacists’ professional roles in type 2 diabetes care. 
 
 
a) Practice orientation 
 
Practice orientation provides clear focus and accountabilities for service delivery by 
pharmacy staff. If management teams are not aware of the professional service, or if 
it is not on their priority list, the service will be very vulnerable to competing 
pressures from the distribution of drugs and business orientation. 
 
“To be honest, in this chain pharmacy ‘X’, issues related to patient-centred 
care have not been paid attention… programmes related to this have not been 
developed so well. What they have developed really well is accounting… 
financial reports, etc.” (Pharmacist 6) 
 
In contrast, professionally active pharmacy owner/managers shared motivation for 
their pharmacies to shift towards a more professional role and did not necessarily 
focus on maximising profit. 
 
“I told the pharmacy staff to refer patients with chronic diseases to the 
pharmacist….so that they can be counselled properly.” (Pharmacist 1) 
 
 
b) Staff resources  
 
It was considered necessary to have adequate pharmacy staff in order to release 
pharmacists’ time for patient care. However, three of the pharmacists reported 
difficulties in recruiting qualified staff. 
 
“… actually I have time… but if I have inadequate human resources, it will take 
my time… as I have to do simple tasks all by myself. If I have enough staff – a lot 
of pharmacist assistants – I will not need to dispense medications – preparing 
labels and such things – that caused me having no time for patient care. So, the 
barrier is lack of time as I have inadequate staff/… /Recruting staff is difficult… 
we can easiliy get a bunch of incompetent ones… but not the competent ones.” 
(Pharmacist 5) 
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Moreover, some pharmacists noted the importance of teamwork and task delegation 
in the pharmacy to support their professional development. Pharmacists could partly 
delegate the control of prescriptions to pharmacist technicians in order to release part 
of their time from the daily dispensing routine to attend to patient care. 
 
 “… from accepting prescriptions to dispensing has been handled by the 
pharmacist assistants where they need to sign for tasks they have performed.  
Then, the pharmacists would provide the education. In other pharmacies, the 
pharmacists might spend most time dispensing… But here, the pharmacists 
should be at the front (counter) directly facing the customers…. When the 
dispensed medication is ready, the pharmacists should hand it to the patients 
(with necessary education).” (Pharmacist 7)   
 
 
c) Pharmacist availability/time 
 
To provide patient care, it was emphasised that a ‘competent’ pharmacist needs at all 
times to be at the pharmacy during opening hours. 
 
 ”In my opinion, prescriptions should be received by me to check for any 
errors… dosage, etc. Even if the errors are made by the doctors, we will still 
take the responsibility for providing wrong medications. So, my senior assistant 
or I should be at the front counter to check for any errors or fraud. If I am not 
available in the pharmacy, I will know nothing… (Hence) It will be only about 
selling medications.” (Pharmacist 5) 
 
 “I have tried to provide this kind of service (patient care), but I could not 
always be available in the pharmacy. This made me feel guilty for those 
patients that already came to the pharmacy… to access the service… but could 
not get it. But… what can I do? I could not wait for this person the whole 
time… as people could come at any time. I also have another job at another 
place.”  (Pharmacist 2) 
 
In line with this, doctors mentioned that involving pharmacists in patient care 
requires them to be available at pharmacies during all opening hours. 
 
 ”… the problem is that pharmacists are not always available at pharmacies… 
hence, education is not provided by pharmacists but is provided by pharmacist 
assistants. This is the common practice.” (Doctor 5) 
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Even during the time when pharmacists were available in the pharmacy, finding 
‘time’ in everyday practice for the development of patient care was an issue. Some 
pharmacists emphasised that patient care required pharmacists not only to spend 
more time with patients (personal approach), which was difficult during busy times 
at the pharmacies, but also to allocate time for other related activities such as 
maintaining PMRs and training/study time.  
 
“The more we are available for counselling, the more time we spend. In general, 
patients expect a personal approach… (when) they can ask about their treatment 
from A to Z… this will take quite a long time. Hence, time is the barrier...” 
(Pharmacist 1) 
 
“…while there are lots of new drugs launched for diabetes, I do not have enough 
time to learn about each of these drugs...” (Pharmacist 5)  
  
”… we got the (monitoring) forms… but we have not recorded on a regular 
basis. This is because the pharmacist – like me – only works for 4 hours, from 5 
to 9 pm. Hence, it is being considered to extend the working hours to 7 hours in 
the future. Especially in the evening – which is the busiest times at the pharmacy 
– we do not have time to make a call (for monitoring purposes).” (Pharmacist 7) 
 
 
d) Operational 
 
In order to perform patient care, half of the pharmacies have developed PMRs. 
However, obtaining complete data and utilising PMRs on a regular basis had proved 
to be a challenge. Several reasons were reported, such as problems with PMR 
retrieval during subsequent visits (hardcopy PMRs), lack of pharmacists’ time and 
lack of patient access. These situations are illustrated below. 
 
“We actually have a monitoring form… it was developed by WHO, but we did 
not consistently record the data in the form/…/It is not like… we can retrieve a 
particular patient’s form whenever we need it… sometimes we need to search for 
it here and there.” (Pharmacist 6) 
 
“It seems that hardcopy PMRs caused them (employee pharmacists) quite a 
load... I often found that lots of temporary notes (i.e. notes written on the back of 
the prescription copy regarding information gathered) had not been transferred 
to the PMRs. Hence, in the future we‘d like to make it easier... maybe we will use 
electronic (PMRs). When facing the patients, pharmacists can directly retrieve 
their data on the computer, and add any new data.“ (Pharmacist 1) 
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”The main problem (with PMRs) is time… obtaining the data requires time. Also, 
the patients should be willing to share their data/…/With regard to time... 
particularly in the evening, we are very busy… thus, we cannot just ‘wait’ for the 
patients (to obtain the data for PMRs) as we have time limits, for example: 
minimum 15 minutes for each dispensing. Then, we also need to do patient care 
…provide information to patients.” (Pharmacist 6) 
 
Two pharmacies, however, had developed databases of medications dispensed for 
individual customers; this enabled the pharmacists to check for any changes in 
medications used during the subsequent dispensings. 
 
“… my pharmacy has developed a database for each patient – name, address, 
medications dispensed. For routine customers, I even have their data on dosage 
instructions… Usually they would ask whether their medications were still the 
same. If yes, that was fine… meaning the same dosage instructions would be 
applied. But if there were changes, I would tell them what medications had been 
changed, and how to take these medications.” (Pharmacist 5) 
 
 
In addition to issues with PMRs, typical pharmacy labels included limited 
information and there was a lack of written information provided by the pharmacists 
(Section 5.4.2.1.1, and 5.4.2.1.2c). Thus, some of the pharmacists and two of the 
doctors suggested improving labelling practice (Section 5.4.3.1). 
 
 
Some pharmacists mentioned that the use of procedures and protocols could be an 
important method to ensure consistency and quality of the service. The need for a 
consultation area/room also was discussed by a few pharmacists, within the context 
of having it available to discuss personal/private issues. 
 
 “Ensuring patients’ quality of life… should be seen as a whole. Starting from 
medications supplied to patients – we already have the protocols, eg. the 
storage…the supplier… distributors, etc – we can guarantee those things/…/In 
the future, we wish to expand to ‘disease management’. However, we can only 
say the word… but we do not know how to do this… we do not have the 
technical procedures.” (Pharmacist 6) 
 
”Usually we will consider the patients’ situation... if there are no other 
customers at the pharmacy or they feel comfortable talking here (shop floor)... 
otherwise we can offer them to talk in the counselling room.”  (Pharmacist 1) 
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5.4.4.5   External enviroment 
 
Structures and support outside pharmacies were perceived to be of key importance 
for community pharmacists’ professional development in type 2 diabetes care. 
 
 
a) Organisation of roles 
 
Indonesian regulations/policies have not, as yet, developed a diverse healthcare 
system to effectively organise roles of healthcare providers to deliver patient-focused 
and integrated care (due to doctor dominance). For example:  
 
• While pharmacists are not allowed by regulations to change brand names without 
doctors’ approvals, some pharmacists expressed their concerns regarding a 
potential unethical alliance between doctors and pharmaceutical companies 
which might influence doctors’ prescribing and professional behaviour.  
 
 “Pharmaceutical companies treat doctors differently… they have even 
sponsored doctors to attend seminars, etc. Doctors cannot be blamed as 
they have the key roles. In developed countries, doctors may only write 
Paracetamol… what brand to be used is up to the pharmacists… However, 
here (Indonesia) is different/… /When we encountered doctors with ‘money 
orientation’, they would refuse to change the brand (according to the 
pharmacy stocks), and asked the patients to get it in other pharmacies.” 
(Pharmacist 5) 
 
This conflict of interest also was acknowledged by one of the doctors, who 
suggested that doctors might not serve the best interests of their patients. This 
may threaten the integration of community pharmacists, since effective 
collaboration will require all providers to agree that the goal is to improve 
patients’ health.   
 
“… though doctors should act in the best interests of their patients… if we 
conduct a survey, we may find this is not the fact… they mostly put patients’ 
interests in the second place, while their personal gain is the first. In this 
situation, collaboration between pharmacists and doctors will be unable to 
achieve… as this can only be achieved when we act in the same interests… 
the patients!”(Doctor 1) 
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• It was noted by some of the doctors that some arrangements within the insurance 
system, e.g. the short interval of doctor visits for patients with stable long-term 
diseases, were inefficient and not cost-effective for the patients.  
 
” Even if we consider that certain patients do not have to come every 
month, the insurance system requires them to come every month or even 
shorter intervals (otherwise the medications will not be covered). The cost 
to fulfil the requirements to make claims (eg. travel, photocopy, etc) is 
sometimes more expensive than the medications.” (Doctor 1) 
 
Such arrangements within the insurance system, or by the doctor, would also 
limit pharmacists’ roles, but pharmacists should assume a responsibility for 
monitoring medications that they supply, as illustrated by one of the pharmacists 
below. 
 
“We often find diabetic patients who have good (glycaemic) control, and 
they just want to get their medications refilled… If we ask them to go back 
to the doctor – ‘arrgh I will get the same there’/ …/This is like holding back 
our roles… we can take the responsibility to monitor safety, etc, as we 
provide the medication to the patients.” (Pharmacist 6) 
 
 
Thus, it was considered that the regulatory bodies (i.e. government and health 
professional bodies) should develop an agreement to clearly separate roles among 
care providers, including community pharmacists and doctors.  
 
“…the IDI (Ikatan Dokter Indonesia - Indonesian Medical Association) and 
the IAI – with the Government as the facilitator – should have an agreement 
about each other’s roles in order to provide optimal care for diabetics, e.g. 
repeat dispensing.”  (Pharmacist 6) 
 
”I am hoping that health professionals share the same understanding of 
diabetes care. So, patients will get the same information from me or from you. 
Basically, I hope that patients will not be afraid of taking insulin, medications, 
regular control, regular SMBG, when necessary. As for this, I cannot work 
alone…” (Doctor 2) 
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b) Funding 
 
Funding was considered important for the establishment and continuity of pharmacy 
services. While, currently, pharmacies have not charged any fees for services other 
than dispensing, one of the pharmacists believed that it is important for pharmacists 
to be part of the health system and to demonstrate their value, thus they should be 
reimbursed for their services, e.g. through Jaminan Kesehatan Nasional – JKN 
(National Health Coverage) which is starting in 2014. 
 
 ”If only a system can be set up (to oblige pharmacists to deliver professional 
services), I would expect pharmacists to get remuneration. However, 
pharmacists should have adequate skills in advance/…/Especially with the 
National Health Coverage coming up... this will clearly define doctors’ and 
pharmacists’ roles. In this case, how can pharmacists not get remuneration if 
we already provide services?” (Pharmacist 6)  
 
 
 
c) Marketing 
 
For a service to be successful, patients should be aware and even demand the service. 
One of the pharmacists considered the importance of a nationwide promotional 
activity to raise patient awareness, and to help in creating demand. 
 
“…for example, raising community awareness to put demand on pharmacies to 
do this and that. But this should be done at the national level. It can’t be done 
at personal levels, or only at regional or local levels (structural levels of the 
IAI).” (Pharmacist 8) 
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d) Assistance (profession-wide) 
 
Due to the perceived lack of competence, some of the pharmacists emphasised the 
importance of support from the IAI and educational institutions in the development 
of pharmacy-based services for type 2 diabetes patients.  This should not be limited 
to providing continuing education or training, but should also provide 
mentors/advisors to assist during the implementation of the service. 
 
“… there should be training for pharmacists… to update our knowledge… to 
help us providing care for the patients.” (Pharmacist 9) 
 
“…If only I could collaborate with the educational institution ‘X’ (for 
example), I am willing to do it (patient care)… Doing it without help is hard for 
me.” (Pharmacist 3) 
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5.5   Discussion 
 
This study included interviews with the two main groups of diabetes care providers 
in Indonesia, i.e. doctors and pharmacists, to explore a range of issues related to 
community pharmacy practice in type 2 diabetes care. This qualitative data is a 
product of views, experiences and perceptions of respondents, thus subjects to bias if 
respondents are not sharing their true responses.145 However, potential bias in this 
study was reduced owing to the lack of pre-determined pharmacist roles in diabetes 
care and reassurance given to the interviewees regarding confidentiality and the 
independence of the research. Although this study used a small sample size, it 
included a range of pharmacists and doctors, enabling it to achieve a detailed and 
comprehensive data set.145 The characteristics of sample pharmacists were consistent 
to those working in Surabaya, Indonesia (Pharmacy Survey, Chapter 3); however no 
demographic data of doctors was available. Moreover, the interviews took between 
30 minutes and one hour; during which, time was made available to pursue relevant 
issues raised by the interviewees. Ten interviews were conducted for each of the 
groups (pharmacist and doctor), but it was clear that no new themes had emerged 
after the eighth interview for each group (data saturation). This suggests that all 
possible issues have been covered.145, 147  
 
 
5.5.1   Current type 2 diabetes practice  
 
Findings from this study indicated that pharmacists and doctors in Surabaya, 
Indonesia, have practised their roles separately. Doctors generally focused on 
diagnosing and prescribing, and often had short consultation times; community 
pharmacists mainly supplied medicines with limited labelling. Services beyond 
dispensing varied between pharmacies, and the delivery was opportunistic and 
inconsistent within pharmacies. The most common pharmacy service was to provide 
basic information on how to use medications. In light of the increasing burden of 
type 2 diabetes1 and the implementation of JKN in 2014,10 the demand for diabetes 
care is expected to surge. This will place a further burden on the limited health 
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workforce in Indonesia (see Section 2.2.3.3) and, thus, better utilisation of health 
resources – including community pharmacists – will be paramount.  
 
 
5.5.2   Views on pharmacist’s roles in type 2 diabetes care 
 
This study indicated that community pharmacists generally believed that they needed 
to perform services beyond dispensing, while doctors showed less expectation for 
this to occur. There was a clear agreement between doctors and community 
pharmacists about the traditional roles of pharmacists in dispensing and basic 
education related to medications, particularly directions for use. There was some 
level of agreement between doctors and pharmacists that this should be extended to 
education on important/common adverse effects.  
 
Some of the doctors and pharmacists in this study also indicated the importance of 
improving the current standard pharmacy label. The typical pharmacy label was 
reported to be limited to the patient’s name and individual directions for use (in 
addition to the general information, i.e. date of dispensing, prescription number, 
pharmacy details and name of the pharmacist manager). Although such a label is 
considered to meet the Indonesian standards of practice (Section 2.2.4.3), the FIP 
Working Group for Labelling has recommended that the minimum information 
should include the patient’s name, generic name (product name) and strength of the 
medicine, and directions for use.162 Moreover, this study indicated ambiguities in 
providing additional information other than that requested on the prescription. The 
use of formal ancillary labels, or Cautionary and Advisory Labels (CALs), as 
practiced in the UK163 and Australia164, has been reported to offer a convenient and 
effective means of providing instructions regarding safe and correct use of 
medications.164 In addition to appropriate labelling, other written information [such 
as Consumer Medicine Information (CMI)165 or the Self Care Fact Card166 as 
practised in Australia] can be considered to reinforce the current practice of 
communicating verbally with patients. 
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Some level of agreement was evident between pharmacists and doctors about 
prescription review for clinical issues, education on healthy living, monitoring of 
compliance and monitoring of therapeutic outcomes. The agreement in regard to 
monitoring therapeutic outcomes was limited to pharmacists inquiring about 
patients’ glycaemic control and problems, and referring patients to doctors if any 
concerns arose. This is worthy of further development because doctors reported 
inconsistent arrangements for follow-up visits, from monthly to biannually, thus 
pharmacists may have the opportunity to perform monitoring when patients get their 
medications refilled at the pharmacy. 
 
In addition to the services congruent with both pharmacists and doctors’ views, it is 
important for pharmacists to expand their clinical roles in the future, even though this 
was not supported by the doctors currently. An example would be medication review 
(beyond prescription review that occurs at the time of dispensing). Various formats 
of medication review are practised in developed countries, ranging from reviews that 
consist mostly of patient counselling aimed to improve medication use [e.g. 
Medication Use Review (MUR) in the UK167 and Diabetes MedsCheck in 
Australia168] to comprehensive clinical medication reviews [e.g. Medication Therapy 
Management (MTM) in the USA169].  The more comprehensive reviews allow 
pharmacists to take more direct responsibility for patient treatment plans and 
outcomes, thus developing their professional roles as part of the diabetes team. 
 
This study generally showed that Indonesian doctors currently exhibit a limited 
position regarding the scope of future pharmacy practice. This was consistent with 
findings from other international studies, although not specific to diabetes care, in 
which doctors strongly supported pharmacists’ traditional roles of dispensing and 
providing patient education related to medications;108 however, doctors also have 
been reported to acknowledge the pharmacist’s role as a source of medicine 
information to doctors,102, 107, 108  and to recognise their roles in prescription review 
(clinical aspects)105, 106 and monitoring compliance.104, 106, 107 Some support has been 
reported for health screening,105, 106, 109 monitoring treatment progress,105, 108 and 
assisting in the development/adjustment of treatment plans (co-decisive roles)105-108 
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(see Table 2.13). It should be emphasised that these findings were mainly from 
developed countries105-109 with possibly more advanced pharmacy practice, thus the 
relationship between doctors and pharmacists might have been better developed.  
 
 
5.5.3   Factors associated with the development of pharmacy-based 
services for type 2 diabetes patients  
 
This study reported a number of factors (potential and actual) related to the 
pharmacy environment as well as external environment, which have contributed to 
the development of pharmacist roles in type 2 diabetes care in Indonesia. It is a 
government requirement that prescription drugs should be issued by pharmacists (see 
Section 2.2.4.3), thus pharmacists should be available during pharmacy opening 
hours. However, this study indicated an issue with pharmacist availability in the 
pharmacies. This was supported by the results of two studies undertaken in Jakarta, 
Indonesia, which reported that approximately 70% of pharmacists worked in 
community pharmacies as their side jobs.14, 16 Moreover, this study indicated that 
Indonesian regulations/policies have not yet developed such a diverse healthcare 
system to effectively organise care providers to deliver patient-focused care (due to 
doctor dominance), thus futher limiting pharmacist roles.  
 
The implementation of JKN would present an opportunity to improve utilisation of 
community pharmacies (more customers/prescriptions). Under the scheme, the 
Government and IAI should consider establishing a formal agreement regarding basic 
services that should be available in pharmacies; advanced services can be proposed 
once pilot studies can provide evidence of their benefits. While the current payment 
under JKN includes a very low prescription fee (see Section 2.2.4.4), the IAI should 
negotiate with the Government to ensure that pharmacists receive adequate 
remuneration for the provision of agreed basic services, to create a stable 
environment for community pharmacies that enables them to remain viable. In turn, 
JKN can be used to reinforce the requirement for community pharmacies to maintain 
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pharmacist availability to be considered as eligible service providers, thus improving 
the quality of pharmacy services. 
 
This present study also illustrated the importance of adequate staffing and task 
delegation within pharmacies. Hence, individual pharmacies need to assess their 
workload capacity; their priority should be to maintain pharmacist availability and, 
when necessary, pharmacy technicians can be used to assist with dispensing. Other 
necessary pharmacy resources identified in this study were the development of 
professional procedures/protocols for specific services, PMRs, appropriate labelling 
and other written information, and consultation areas/rooms. The use of 
protocols/procedures would be beneficial to ensure both quality and consistency of 
service delivery. The IAI should consider developing specific standards and IT 
systems for dispensing, to assist with labelling practice. The use of IT systems would 
also improve access to PMRs, which is of importance in providing pharmaceutical 
care.  
 
In addition to the environmental factors, this study indicated the importance of the 
development of close relationships between pharmacists, doctors and patients in 
providing pharmaceutical care for type 2 diabetics. While pharmacists in this study 
generally indicated positive attitudes to extending their roles, they perceived 
competence as an important issue. It should be noted that pharmacotherapy subjects 
were not incorporated in the national pharmacy curricula until 2008,79, 80 thus a wide 
variation of pharmacotherapy knowledge is expected, particularly for those who 
graduated before 2013 (based on a 5-year length of study to register as a pharmacist). 
This would explain the expressed concerns of pharmacists regarding competency, as 
the median was 17 years of work experience. The limited pharmacotherapy 
knowledge among Indonesian community pharmacists also was reported in a 
previous study.27 With the changes in pharmacy curricula, it is to be expected that all 
new pharmacists will receive general diabetes training as part of their undergraduate 
programme. However, to deal with earlier graduates, the IAI should consider 
organising formal general diabetes training; when necessary, formal diabetes-specific 
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CPD/CPE programmes and an accreditation system can be developed for those 
seeking specialisation. 
 
In terms of pharmacist-doctor relationships, barriers reported were lack of support 
from the doctors and difficulty to access them. Thus, the IAI should consider liaising 
with doctor organisations to discuss interactions/relationships between doctors and 
community pharmacists in providing pharmaceutical care. While working with 
doctors, pharmacists need to demonstrate their value over time, allowing continued 
development of their professional roles. It was suggested that doctors’ acceptance of 
pharmacists’ clinical services was related to their level of exposure to those 
services,104 which is consistent with statements from doctor interviews in this study.  
 
With regard to patients, pharmacists were of the opinion that patients did not bother 
to access services other than dispensing (lack of demand); and patients were often 
difficult to access (e.g. they did not come to the pharmacy in person). This study 
highlighted the importance of a nationwide promotional exercise to raise patient 
awareness when introducing pharmaceutical care. Within the pharmacies, some 
pharmacists in this study reported to use basic questions regarding patient medication 
in order to make the patient aware of the service they provided and to start 
relationship-building. Once the patients engage with their services, it is important for 
the pharmacists to demonstrate the benefits to the patients. It was suggested that 
patients who had experienced a pharmacy service were more likely to support the 
provision of that service.17, 22, 95, 130, 131  
 
In general, factors identified in this study were similar in nature to those reported in 
the international studies (see Tables 2.15 and 2.16);35, 136-144 however, this study 
provided insights within the context of the Indonesian health system.  
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5.6   Key themes 
• Current type 2 diabetes practice in Surabaya, Indonesia: 
- Doctors generally focused on diagnosing and prescribing, and often had short 
consultation times. 
- Community pharmacists mainly supplied medicines (with limited labelling), 
with some providing services beyond dispensing, particularly providing basic 
information on how to use medications.  
• Views on pharmacists’ roles in type 2 diabetes care: 
- There was a strong agreement between pharmacists and doctors around 
pharmacists’ roles in regard to dispensing (with improved labelling) and 
education related to medications (i.e. directions for use). 
- A lower level of agreement was reported about prescription review (clinical 
aspects); education related to medications (i.e. common/important adverse 
effects), and healthy living (i.e. exercise and diet); monitoring compliance 
with medications and monitoring treatment outcomes (i.e. inquiring about 
patients’ glycaemic control and problems). 
• Factors (actual and potential) associated with the development of pharmacy-
based services for type 2 diabetes patients: 
- Pharmacist, i.e.: positive views (facilitator); perceived lack of competence 
(barrier). 
- Relationships with doctors, i.e. lack of doctor support – doctors’ negative 
views regarding encroachment of doctors’ clinical autonomy, low awareness 
towards pharmacist competency, retailer image of pharmacists (barriers); 
difficulty in accessing doctors (barrier); previous interactions (facilitator). 
- Relationships with patients, i.e.: lack of patient demand (barrier); difficulty in 
accessing patients (barrier). 
- Pharmacy environment, i.e.: business orientation (barrier); lack of staff 
(barrier); poor pharmacist availability (barrier); supporting resources, such as 
counselling areas/rooms, professional procedures/protocols, and IT systems 
for labelling and PMRs (facilitators).  
- External environment, i.e.: a health system to support pharmacist roles, 
remuneration, marketing and professional assistance (facilitators). 
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Chapter 6 
General discussion and  
Conclusions
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6.1   Introduction to the chapter 
 
This chapter draws together the key findings/themes from the pharmacist survey 
(Chapter 3), the patient survey (Chapter 4), and the qualitative study of pharmacists 
and doctors (Chapter 5) in relation to the main objectives of this thesis: current 
diabetes practice, views on community pharmacist roles, and factors 
(potential/actual) associated with the development of a diabetes service. It then 
provides general discussion of the findings in addressing the main objectives, and 
proposes a model of Indonesian community pharmacy-based services for type 2 
diabetes patients. The chapter ends with the conclusions from this body of research. 
 
 
6.2   Summary of key findings/themes 
 
A summary of key findings/themes from the pharmacist survey (Chapter 3), the 
patient survey (Chapter 4), and interviews with pharmacists and doctors (Chapter 5) 
in relation to current diabetes practice, potential developments and the contributing 
factors are provided in Tables 6.1, 6.2 and 6.3. 
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Table 6.1   Current pharmacy-based services for type 2 diabetes patients 
 
Pharmacist  Doctor Patient 
 Quantitative findings* Qualitative findings† Qualitative findings† Quantitative findings‡ 
Dispensing: 
100% of pharmacists reported to prepare 
medications and provide labels 
Minimal contact (prescribing-dispensing interface) 
• Doctor’s main role has been to diagnose and prescribe  
• Pharmacist’s main role has been to supply prescribed medicine (with limited 
labelling) 
Dispensing: 
100% of patients reported to utilise community 
pharmacies for dispensing their medications 
Beyond dispensing: 
>50% of pharmacists reported to provide 
patient education related to medications, 
particularly directions for use (72.6%) 
Beyond dispensing: 
• The common practice has provided patient 
education related to medications, 
particularly directions for use 
• Other services have varied among 
pharmacies; and the service provision has 
been opportunistic/inconsistent within the 
pharmacy 
Other services: 
• Doctors commonly have provided patient 
education on lifestyle; other types of 
education have been inconsistent – limited 
consultation time 
• Doctors have monitored patient outcomes 
during visits – intervals of visits ranged from 
monthly to biannually  
Beyond dispensing: 
>50% of patients reported that community 
pharmacies have provided education related to 
medications, particularly directions for use 
(79.6%) 
*Chapter 3: Pharmacist survey 
†Chapter 5: Qualitative study (interviews with pharmacists and doctors) 
‡Chapter 4: Patient survey 
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Table 6.2   Views on pharmacists’ roles in type 2 diabetes care 
 
Roles Pharmacist Doctor 
(Qualitative findings)† 
Patient 
(Quantitative findings)‡  Quantitative findings* Qualitative findings † 
Dispensing 100% of pharmacists viewed dispensing 
as part of their roles 
Clear agreement regarding pharmacists’ dispensing role (with 
improved labelling) 
Almost 100% of patients viewed dispensing 
as part of pharmacists’ roles 
Beyond dispensing 
 
>50% of pharmacists viewed that they 
should extend their roles related to initial 
assessment, treatment plan, education, 
monitoring and review 
  Approximately 50% of patients viewed that 
pharmacists should extend their roles related 
to education and monitoring 
Priorities: 
• Patient education 
- Education related to medications: 
directions for use (58.6%); 
common/important adverse 
effects (25.7%) 
- Education on lifestyle: exercise 
(36.5%); diet (47.7%)  
• Monitoring 
- Monitoring compliance with 
medication (27.9%) 
Higher agreement: 
• Patient education 
- Education related to medications, i.e. directions for use 
 
Lower agreement: 
• Prescription review (clinical aspects) 
• Patient education  
- Education related to medications, i.e. common/important 
adverse effects 
- Education on lifestyle: exercise, diet 
• Monitoring 
- Monitoring compliance with medications 
- Monitoring outcomes (inquiring about glycaemic control and 
problems) 
Priorities: 
 • Patient education 
- Education related to medications: 
directions for use (64.5%); storage 
requirements (26.6%); common/ 
important adverse effects (25.5%) 
• Monitoring 
- Monitoring compliance with 
medications (37.3%) 
*Chapter 3: Pharmacist survey 
†Chapter 5: Qualitative study (interviews of pharmacists and doctors) 
‡Chapter 4: Patient survey 
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Table 6.3   Factors (potential/actual) associated with the development of pharmacy-based services for type 2 diabetes patients 
 
  Facilitators Barriers 
Pharmacist Attitude - Pharmacists generally reported positive views towards 
services beyond dispensing*†; a positive view of  a service 
was a facilitator for providing the service* 
 
 Competence - Training was a facilitator for providing some services 
beyond dispensing* 
- Perceived lack of competence†  
 
Relationships with doctors Doctor’s attitude - Doctors’ previous interactions with pharmacists contributed 
to positive attitudes† 
- Lack of support –  encroaching on doctors’ clinical 
autonomy, lack of awareness, retailer image† 
 Doctor’s accessibility  - Low accessibility – difficult to contact, limited time† 
Relationships with patients Patient’s attitude - Patients’ previous use of a pharmacy service, or those who 
had other risk factors for complications or poor/unknown 
glycaemic control, were associated with positive attitudes‡ 
- Lack of expectations‡  
- Lack of demand – lack of awareness, retailer image† 
- Patients who had higher income and not working were less 
supportive‡ 
 Patient’s accessibility  - Low accessibility – not coming in person, having no time, 
not coming on a regular basis† 
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Table 6.3   (continued) 
  Facilitators Barriers 
Pharmacy environment Current utilisation - Number of diabetes customers was a facilitator for providing 
some services beyond dispensing* 
- Approximately 80% of pharmacies had ≤2,000 customers 
with ≤100 diabetes customers*   
 Practice orientation - Professional orientation† - Business orientation†  
- Approximately 70% of pharmacies were owned by non-
‘pharmacist manager’ (proprietor)* 
 Staff resources  
- Task delegation† 
- Lack of staff (suitably qualified)† 
 Pharmacist availability/time - High pharmacist availability was a facilitator for providing 
some services beyond dispensing* 
- Lack of pharmacist availability (less than 20% of 
pharmacies had a pharmacist available at all times),†* and 
lack of time†  
- Low pharmacist availability was a barrier to some services 
beyond dispensing* 
 Operational - Counselling areas/rooms;† availability of a counselling 
area/room or setting within a doctor clinic were facilitators for 
providing some services beyond dispensing*  
- Only 21.8% of pharmacies had counselling areas/rooms* 
   - Difficulty to maintain PMRs† 
- Poor labelling, and lack of other written information†  
  - Protocols/procedures†  
External environment Organisation of roles  - A health system to support delegation of roles to pharmacists†  - Lack of a health system to support pharmacist roles (doctor 
dominance)† 
 Financing - Remuneration system†  
 Marketing - Raising public awareness†  
 Assistance (profession-wide) - Training for pharmacists†  
  - Mentors†  
Abbreviations: PMR, patient  medication record 
*Chapter 3: Pharmacist survey 
†Chapter 5: Qualitative study (interviews of pharmacists and doctors) 
‡Chapter 4: Patient survey 
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6.3   General discussion 
 
This study is the first in Indonesia to provide a comprehensive picture of community 
pharmacy-based services for type 2 diabetes patients, incorporating information from 
three main stakeholder groups, i.e. pharmacists (survey and interview), patients 
(survey), and doctors (interview). In health services research, triangulation provides 
different perspectives on issues in relation to a research question, and enhances the 
validity of research findings.145 This study is an important addition to the body of 
knowledge regarding community pharmacy practice in type 2 diabetes care (Table 
2.11), potential development of services (Tables 2.12, 2.13, and 2.14), and factors 
associated with service delivery (Tables 2.15 and 2.16), which previously had been 
derived only from studies in developed country. The findings should assist national 
bodies in designing programmes and support for the development of Indonesian 
community pharmacy practice in the area of type 2 diabetes. 
 
 
6.3.1   Current pharmacy-based services for type 2 diabetes patients 
 
Indonesia is a country with a growing type 2 diabetes epidemic. Using the 
International Diabetes Federation (IDF) Diabetes Atlas update data in 2013,1 it was 
estimated that 8.5 million people in Indonesia were living with diabetes, and this is 
expected to increase to 14.1 million by 2035.1 Thus, the Indonesian Government has 
included diabetes as a national health priority area.5 In line with this, pharmaceutical 
care was included within Indonesian legislation (Ministry of Health Republic of 
Indonesia decree No. 1027/MENKES/SK/IX/2004: Standards for Pharmaceutical 
Care in Community Pharmacies; see Section 2.2.4.3), emphasising the need for 
community pharmacists to be more involved in the care of patients with chronic 
diseases, including diabetes.  
 
This present study, however, found that community pharmacies provided limited 
services for type 2 diabetes patients. Both quantitative and qualitative findings 
indicated that the common practice has been supplying medications (with limited 
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labelling) and providing basic medication education, mainly directions for use (Table 
6.1). Previous Indonesian studies, although not specific to diabetes care, have 
confirmed this limited role of community pharmacists.24-26  
 
 
6.3.2   Views on pharmacists’ roles in type 2 diabetes care 
 
The findings indicated that pharmacists generally had positive views about 
expanding their roles in diabetes care; however doctors and patients generally 
reported a lower level of expectation (Table 6.2). Using pharmacists’, doctors’ and 
patients’ consensus on the roles of community pharmacists, potential areas of 
development of pharmacy services are discussed below. 
  
 
a) Dispensing (labelling) 
 
While dispensing has been commonly practised in Indonesian community 
pharmacies, some pharmacists and doctors in this study considered labelling needed 
to be improved. The typical pharmacy label was reported to include the patient’s 
name and individual directions for use, in addition to the general information, such 
as date of dispensing and pharmacy details. Although such a label is considered 
adequate to meet the Indonesian standards (see Section 2.2.4.3), the FIP Working 
Group for Labelling has recommended that the minimum information should include 
the patient’s name, generic name (product name) and strength of the medicine, and 
directions for use.162 This present study also identified ambiguities in providing 
information other than that requested on the prescription. This may be due to the lack 
of guidance within the standards regarding ancillary labels (see Section 2.2.4.3). 
Formal ancillary labels or Cautionary and Advisory Labels (CALs), as used in the 
UK163 or Australia,164 have been reported to offer a convenient and effective means 
of reinforcing pharmacists’ verbal consultations in providing instructions on the safe 
and correct use of medications.164  Thus, the Government and Ikatan Apoteker 
Indonesia – IAI (Indonesian Pharmacists Association) should consider developing 
specific standards for pharmacy labelling (e.g. content and format of basic labels, the 
range of ancillary labels, and list of drugs requiring labels) to provide a regulatory 
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foundation for practice. The use of IT systems for dispensing also would assist in 
improving labelling practice in Indonesia. 
 
 
b) Prescription review (clinical aspects) 
 
Doctors and pharmacists are health professionals who communicate via a 
prescription (from the prescriber to the dispenser). They should share responsibility 
for the appropriateness of the medications prescribed. For this reason, the Indonesian 
standards require pharmacists to assess prescriptions for their administrative, 
pharmaceutical and clinical appropriateness at the point of dispensing.23  
 
Our findings showed some level of agreement between pharmacists and doctors 
towards pharmacists checking for appropriateness of prescription (clinical aspects), 
such as dosage errors, duplication or interactions. In developed countries, a high 
level of support from doctors and patients has been reported (Tables 2.13 and 2.14). 
While clinical assessment of prescriptions has not consistently been performed in 
Indonesian community pharmacies, this should be considered as a potential area of 
development. Checking prescriptions may require pharmacists to refer back to the 
doctors for clarification. This presents an opportunity for pharmacists to start 
professional interactions with doctors and establish awareness of each other’s roles. 
The use of IT systems for dispensing would provide better access to PMRs, which is 
essential in performing prescription review. 
 
 
c) Patient education (medications and lifestyle) 
 
Diabetes education is a critical element of care and is necessary to improve patient 
outcomes.37, 46  Based on the Indonesian standards (see Section 2.2.4.3), it is the 
pharmacists’ responsibility to provide adequate education about dispensed 
medicines. International studies have reported strong support from pharmacists, 
doctors and patients for community pharmacists to provide education related to 
medications (Tables 2.12, 2.13, and 2.14). While this present study reported that the 
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current practice in Indonesia is generally limited to providing basic information on 
dosage instructions, some of the pharmacists, doctors and patients agreed that this 
should be expanded to include important/common adverse effects (particularly how 
to recognise and treat hypoglycaemia). Moreover, doctors and pharmacists showed 
some agreement that community pharmacists should reinforce education about 
healthy living (particularly exercise and diet) provided by doctors. This is 
particularly important, as the qualitative findings indicated that doctors often have 
limited time for consultation. In addition to the current practice of communicating 
verbally with patients, written information [such as Consumer Medicine Information 
(CMI)165 or the Self Care Fact Card166 practised in Australia] should be considered to 
reinforce the communication. 
 
 
d) Monitoring (compliance and treatment outcomes) 
 
The Government Standards require pharmacists to monitor the use of dispensed 
medications (see Section 2.2.4.3). Although monitoring of type 2 diabetes patients 
has not been a common practice in Indonesian community pharmacies, pharmacists, 
patients and doctors all showed some agreement in regard to pharmacists monitoring 
compliance with medications, as well as monitoring treatment outcomes (i.e. 
inquiring of patients regarding their diabetes control and problems, and referring 
patients to doctors if any concerns arise).  
 
As for diabetic patients with stable long-term treatment, the qualitative findings 
indicated that doctors made variable arrangements for follow-up visits, from monthly 
to biannually. For the longer intervals, community pharmacists would have the 
opportunity to provide targetted monitoring of patients presenting with repeat 
prescriptions. In countries such as Australia170 and the UK171, a formal repeat 
dispensing scheme has been established. The scheme enables community 
pharmacists to dispense medications for such patients at regular intervals for a 
defined period of time (e.g. monthly for a period of six months). At the point of each 
dispensing, the pharmacist should be responsible for checking patient compliance 
(e.g. through a PMR or number of refills of prescription, or via a discussion with the 
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patient) and other clinical factors (i.e. checking if the patient achieved their targets or 
experienced adverse effects); if there were any problems, the pharmacist would refer 
the patient back to the doctor. It was reported that repeat dispensing by pharmacists 
offers advantages for patients, doctors and pharmacists alike.172, 173 Adopting 
formalised repeat dispensing in the Indonesian setting would enable doctors to 
lengthen the interval between visits while using community pharmacists to maintain 
monitoring between visits, thus improving the efficient use of the limited medical 
and pharmaceutical workforce in Indonesia (see Section 2.2.3.3).  
 
 
e) Medication review 
 
Although medication review (beyond prescription review) has not currently been 
seen as a priority in this Indonesian study, particularly by doctors, taking direct 
responsibility for individual patients’ medication-related needs is important for the 
professional development of pharmacists and their better integration into the 
healthcare team. Various formats of medication review have been practised, from 
reviews consisting mostly of patient counselling aimed at improving medicine use 
[e.g. Medication Use Review (MUR) in the UK167 and Diabetes MedsCheck in 
Australia168] to comprehensive clinical medication reviews [e.g. Medication Therapy 
Management (MTM) in the USA169].  
 
In Australia, Diabetes MedsCheck is offered to patients who have been recently 
diagnosed with type 2 diabetes (in the last 12 months) or whose type 2 diabetes is 
less than ideally controlled. It is a structured pharmacy service which takes place in 
the pharmacy, involving face-to-face consultations between the pharmacist and 
patient. The elements include gathering patient medication and medical history, 
reviewing and discussing the use of all medicines and medication/monitoring 
devices, and making recommendations to the patient and his/her doctor, if 
appropriate. It is undertaken by community pharmacists, without the need for 
referrals from doctors.168 MTM involves a more comprehensive procedure in which 
the pharmacist undertakes a review to address issues relating to the patient’s use of 
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medicines within the context of their clinical conditions.169 More complex 
procedures require additional access to patients’ specific information, collaboration 
with doctors, and both training and skill development for the pharmacist. 
Considering the baseline of pharmacy practice in Indonesia, medication use review, 
within the scope of Diabetes MedsCheck, would be the most feasible first step to be 
piloted in an Indonesian setting.  
 
 
6.3.3   Factors associated with the development of pharmacy-based 
services for type 2 diabetes patients 
 
The surveys and interviews have identified a number of factors (actual and potential) 
associated with service delivery for type 2 diabetes patients in Indonesian 
community pharmacies. These include issues related to the pharmacists, their 
relationships with doctors, their relationships with patients, the pharmacy 
environment and the external environment (Table 6.3).  Although the findings 
showed similar types of factors as those from international studies (Tables 2.15 and 
2.16), this study provided an understanding within the context of the Indonesian 
health system. This study has broadened the findings from previous qualitative 
studies in Indonesia which were focused on the competence and availability of 
pharmacists.25, 27 
 
 
a) Pharmacy environment and external environment  
 
The pharmacist survey indicated a low utilisation of community pharmacies in 
Surabaya, Indonesia, where the majority of them had less than 2,000 customers per 
month. In 2012, about 65% of the Indonesian population was covered by some form 
of insurance plan, largely through Jamkesmas (insurance for the poor/near poor),56 
via which a limited range of medications can be supplied in health centres. Those 
who can afford care were reported to prefer using secondary and tertiary care levels 
(e.g. hospital-based facilities),2, 8 thus, their medications were mainly supplied from 
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hospital-based pharmacies. Many drug stores are also known to sell prescription 
drugs despite their licenses being to sell only non-prescription medications.77 All of 
these considerations may contribute to the low number of customers in community 
pharmacies. Compounding this, the qualitative findings indicated a lack of 
organisation of roles between healthcare professionals (doctor dominance) to provide 
patient-focused and integrated care, thus further limiting the role of pharmacists.  
 
On the other hand, Indonesia is facing a major deficiency in its health workforce (see 
Section 2.2.3.3), so one option is to optimise the use of currently underulitised 
community pharmacists. Starting in 2014, the Government will gradually establish 
Jaminan Kesehatan Nasional − JKN (National Health Coverage)10 to provide 
healthcare to the entire population. Since a referral system is used, JKN will place 
most care in primary care levels, expecting an increase in the use of GP clinics as 
well as community pharmacies (as most of their customers are from doctor clinics). 
The scheme also will potentially diminish the illegal supply of prescribed 
medications from drug stores. It is important for the Government and IAI to establish 
a formal agreement regarding basic services that should be available in the 
pharmacies. An initial initiative should be provided to pilot advanced services; once 
evidence of improved outcomes is available, widespread implementation and 
remuneration can be negotiated under JKN or private health insurers. 
 
It is a government requirement that prescribed medication should be issued by 
pharmacists (see Section 2.2.4.3), thus pharmacists should be available during 
pharmacy opening hours. This pharmacist survey, however, reported that less than 
20% of the pharmacies in Surabaya potentially had pharmacists available throughout 
their opening hours. This may relate to the underutilisation of community 
pharmacies (lack of turnover/affordability). Compounding this, most of the 
pharmacies were not owned by the pharmacist manager. While supplying medication 
can be done in less expensive ways without exclusively using pharmacists, the 
proprietor may merely use the pharmacist to meet legal requirements with little/no 
obligation for him/her to be in the pharmacy (ensuring lower salary costs). On the 
other hand, because of their poor income, pharmacists might take on other jobs 
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resulting in them not being available at pharmacies. Two studies in Jakarta, 
Indonesia, have reported that about 70% of pharmacists worked in community 
pharmacies as their side jobs.24, 26 As mentioned above, JKN is expected to improve 
utilisation of community pharmacies (more customers/prescriptions), thus increasing 
their turnover/affordability; in turn, JKN can be used to reinforce the requirement for 
community pharmacies to maintain pharmacists’ presence to be eligible service 
providers. Community pharmacies may consider arranging their opening hours based 
on the availability of their pharmacists, or advertising periods of pharmacist 
availability to provide services (e.g. encompassing at least 80% of the opening 
hours). While the current payment under the JKN includes a very low prescription 
fee (see Section 2.2.4.4), the IAI should negotiate an adequate remuneration for 
pharmacists to provide agreed basic services, so that a stable environment is created 
for community pharmacies, enabling them to remain viable.  
 
In addition to pharmacists being available, this present study indicated the 
importance of adequate staff and task delegation within the pharmacy. Hence, 
individual pharmacies need to assess their workload capacity; their priority should be 
to maintain pharmacist availability and, when necessary, pharmacy technicians can 
be used to assist with general dispensing duties. Other pharmacy resources discussed 
in this study were including professional procedures/protocols for specific services, 
PMRs, written information and appropriate labelling, and a consultation area/room. 
The use of protocols/procedures would be beneficial to ensure quality and 
consistency of service delivery, and the development of IT systems through IAI 
would markedly improve labelling quality and access to PMRs. Based on 
Government Standards, a pharmacy should have a private area/room dedicated to 
counselling (see Section 2.2.4.3). While the pharmacist survey reported only a small 
proportion of pharmacies having a consultation area/room, the qualitative findings 
indicated the importance of a consultation area/room to discuss personal/private 
issues.  
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b) Pharmacist 
 
This present study reported that pharmacists generally had a positive attitude to the 
extension of their roles; however, there was an issue of competency to provide 
pharmaceutical care. In Indonesia, it was not until 2008 that pharmacotherapy 
subjects were included in the national pharmacy curricula,79, 80 thus, a wide variation 
of pharmacotherapy knowledge is expected among earlier graduates. Limited 
pharmacotherapy knowledge among community pharmacists also was reported in a 
previous Indonesian study.27 Currently, there are a variety of opportunistic CPE 
courses, some of which include general training in diabetes therapeutics. The 
pharmacist survey found that pharmacists who attended diabetes training appeared to 
want to perform more services for their patients. With the changes in pharmacy 
curricula (inclusion of pharmacotherapy), it would be expected that all new 
pharmacists would receive general diabetes training as part of their undergraduate 
degree programme. However, to deal with earlier graduates, the IAI should consider 
organising formal general diabetes training; when necessary, diabetes-specific 
CPE/CPD activities and an accreditation system can be developed for pharmacists 
seeking to specialise in diabetes care.  
 
 
c) Relationships with doctors 
 
In providing pharmaceutical care, pharmacists will need to develop collaborative 
practice with doctors.12 The qualitative study indicated that the barriers to the 
pharmacist-doctor relationship were lack of support from the doctors and difficulty 
to access them. Thus, to introduce a diabetes service, the IAI should consider 
developing a formal liaison with doctor organisations to enhance understanding of 
pharmacist roles. Pharmacists would also need to explain the service to, and seek 
support from, the local doctors. It was suggested that building a relationship should 
start with professional awareness; during this stage, pharmacists should be the 
primary instigators to build the relationship (unilateral relationship).157 While 
providing the service, pharmacists should demonstrate their values and build 
trustworthy relationships with doctors to achieve an effective collaboration for 
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improving patients’ outcomes (increasing bilateral relationship).157 It was suggested 
that doctors’ attitudes correlated significantly with the relationship between doctors 
and pharmacists,104 which is consistent with the statements from doctor interviews in 
this study. 
 
 
d) Relationships with patients 
 
Pharmacist interviews indicated that the barriers to pharmacist-patient relationships 
were lack of patient demand and difficulty accessing patients (e.g. many patients 
send another person to collect medicines). This might be due to the patients’ lack of 
awareness as to pharmacists’ roles, which was confirmed in the patient survey. Thus, 
to introduce a diabetes service, this study noted the importance of a nationwide 
promotional exercise to raise patients’ awareness. The pharmacist would also need to 
make the patients aware of the service, e.g. asking simple questions about their 
medication at the first meeting. Once the patient has engaged with the service, it is 
important for the pharmacist to demonstrate its benefits to the patient. International 
studies have suggested that patients who had experience with a pharmacy service 
were more likely to support the provision of that service,17, 22, 95, 130, 131 which also is 
evident from the patient survey in this study.  
 
 
The Government and IAI should collaborate to optimise the use of community 
pharmacies by integrating their services into the primary care system and including 
adequate remuneration. Implementation of the services will require pharmacists to be 
available in the pharmacies, together with the availability of adequate pharmacy 
resources and close pharmacist-doctor-patient relationships. 
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6.4   Limitations 
 
This research encountered several limitations, which have been described in detail in 
the preceding chapters. To provide a cohesive summary, the key limitations are 
reiterated here. 
 
There was a possibility of non-response bias in the pharmacist survey (Chapter 3), 
thus, some caution should be exercised in generalising the findings. However, no 
significant differences in the responses between the first and second rounds of the 
survey were found; it has been suggested that late responders (i.e. the responses from 
the second round) may better reflect non-responders.174 Moreover, results from the 
survey compared well with available data for the population,153, 154 as well as with 
prior work in Indonesia.24, 26 
 
Another limitation was selection bias in the patient survey (Chapter 4), as the 
recruited pharmacy clients with type 2 diabetes did not constitute a random sample. 
Thus, some cautions should be used in generalising the findings. It should be 
emphasised, however, that the sampling points covered a range of geographical areas 
and socio-economic levels in Surabaya, and each of them were represented by an 
adequate potential sample. It was argued that, if a number of sites are used for 
sampling, diversity in a wider population may be reflected by differences in the 
sample.145 Supporting this view, the characteristics of the respondents for this study 
were comparable to the available data for the Indonesian population.2 
 
The qualitative data (Chapter 5) might be subject to bias if the respondents were not 
sharing their true responses. However, the potential bias in this study was possibly 
reduced owing to the lack of pre-determined pharmacist roles in diabetes care. 
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6.5   Developing a model of pharmacy-based services for        
type 2 diabetes patients 
 
Based on the findings in this study (Section 6.2) and the previous discussion (Section 
6.3), a two-level development of community pharmacy-based services for type 2 
diabetes patients in Indonesia is discussed below. 
 
 
Figure 6.1   Proposed model of community pharmacy-based services for type 2 
diabetes patients 
 
1st Level: Basic services                   2nd Level: Advanced services 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dispensing  
 
 
Prescription review 
Patient education 
Monitoring  
(repeat dispensing) 
 
Medications issued 
 
Type 2 diabetes patients  
with prescribed medications 
 
Medication use review 
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1st Level: Basic services 
 
The first level should be considered as the basic services in Indonesian community pharmacies that should be offered to all patients with type 2 
diabetes. Monitoring should be considered for any type 2 diabetes patients presenting with a repeat prescription.  
 
Service Components Implementation requirements 
Dispensing  • Select/prepare medications • Personnel:  
- Pharmacist  
• IT requirements:  
- Software for dispensing – to support labelling practices, access to PMRs 
(prescription review), online verification of JKN entitlement and claiming 
• Infrastructure and staffing: 
- Counselling area/room 
- Pharmacy technician may assist in the dispensary (if required) 
• Training 
• Supporting standards, procedures and other materials: 
- Standards for labelling, including the use of ancillary labels  
- Protocols/procedures 
- Educational materials 
• Remuneration: 
- under JKN  
 • Label medications 
 • Provide ancillary labels (where appropriate) 
Prescription review  
 
• Review appropriateness of prescription, including identification 
of actual and potential DRPs (clinical aspects) 
Patient education  
 
• Provide education related to medications (particularly directions 
for use and important/common adverse effects) 
• Reinforce general education on healthy living (particularly 
exercise and diet)  
Monitoring - at the point 
of repeat dispensing 
 
• Monitor compliance with medications 
• Monitor treatment outcomes – inquire about patients’ glycaemic 
control and problems 
• Refer to doctors if any concerns 
  
Abbreviations: IT, information technology; PMR, patient medication record; DRP, drug-related problem; JKN, Jaminan Kesehatan Nasional (National Health Coverage) 
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• Personnel 
The pharmacy should maintain a pharmacist in attendance during opening hours, 
or advertise periods when the pharmacist is available to provide the service (e.g. 
encompassing at least 80% of opening hours). Individual pharmacies will need to 
assess their workload capacity according to the volume of prescriptions 
dispensed. Based on the Standards for Pharmaceutical Care in Community 
Pharmacies (see Section 2.2.4.3), the overall responsibility for supply of 
prescription medications lies with the pharmacist. Pharmacy technicians can be 
used to assist in the dispensary, if required (e.g. in busier community 
pharmacies).  
 
• IT requirements 
The IAI should consider the introduction and use of computerised dispensary 
systems to improve labelling practices. This would also help the pharmacist in 
maintaining PMRs and undertaking prescription reviews (e.g. detect drug to drug 
interactions, overdoses and similar clinical considerations in the dispensing 
process). With the introduction of JKN, the systems could be used as a tool for 
online verification of JKN entitlement and claims. Thus, dispensary computer 
systems should be seen as a fundamental step to improve patient care by 
contributing to the safe and effective dispensing of medicines. 
 
• Supporting standards, procedures and other materials 
In addition to the current generic standard (Standards for Pharmaceutical Care in 
Community Pharmacies; Section 2.2.4.3): 
- The Government and IAI should consider developing specific standards for 
pharmacy labelling that describes the minimum content and format of the 
label. The FIP recommendation for minimum information on the pharmacy 
label includes the patient’s name, product name (generic name) and strength 
of the medicine, and directions for use (see Section 6.3.2a),162 in addition to 
the general information, such as date of dispensing, an identifying code and 
pharmacy details. The standards should also consider including clear 
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guidance on the use of ancillary labels. Appropriate labelling is essential in 
providing instructions on the safe and correct use of medications.  
- The IAI needs to develop service specific protocols/procedures to ensure 
quality and consistency of the service delivery. 
- The IAI, in collaboration with patient organisations [such as Persatuan 
Diabetes Indonesia – PERSADIA (Indonesian Diabetes Association)], should 
consider providing written materials for patient education. In addition to 
appropriate labelling, other written educational materials should be 
considered to support verbal counselling. 
 
• Training 
Pharmacy graduates should be trained to a level where they can confidently 
provide basic services upon registration. Service-specific training may assist the 
service delivery (e.g. how to use the dispensary software, patient recruitment, 
documentation). 
 
• Remuneration   
The Government and IAI should ensure that community pharmacists receive 
adequate remuneration for basic services under JKN. The current method of 
payment under JKN includes the cost of the drug plus a small mark-up and a 
prescription fee (see Section 2.2.4.4). Adequate remuneration should be 
considered to create a stable environment that will enable community pharmacies 
to remain viable. 
 
With the introduction of JKN, the Government and IAI should consider piloting a 
repeat dispensing system for patients with stable long-term treatment (e.g. 6-
month interval of visits). Evidence from the pilot with regard to patient outcomes 
and related health care costs could be used to support a nationwide 
implementation of the system, thus enhancing the pharmacist’s role in patient 
monitoring. 
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2nd Level: Advanced service  
 
This second level for advanced services (e.g. medication use review) should be offered by accredited community pharmacies and pharmacists. 
This service would be offered to at-risk patients, e.g. type 2 diabetes patients who are newly diagnosed or less than ideally controlled.  
 
Service Components Implementation requirements 
Medication use review  
(Based on Diabetes MedsCheck in 
Australia; see Section 6.3.2e)168 
• Gather patient history – medicines and medical conditions 
• Review the use of all medicines and monitoring devices, including:  
- Assess compliance  
- Monitor efficacy (glycaemic control) and adverse effects of 
drugs 
- Monitor disease progress (complications) 
- Assess education needs 
- Provide education and guidance on correct use of medications 
and monitoring devices 
- Discuss management of diabetes and other medical 
conditions, including lifestyle factors and self-management 
• Make recommendations to the patients and doctors, if appropriate 
 
 
• Personnel:  
- Pharmacist  
• IT requirements:  
- Software to perform the service  
• Infrastructure and staffing:  
- Counselling area/room that allows for confidential 
consultation 
- Another pharmacist may be needed to manage professional 
activities within the pharmacy at the time of consultation 
• Training 
• Supporting standards, procedures and other materials 
• Funding: 
- Initial initiative (under agreement between the Government 
and IAI) 
- Potential remuneration from JKN or private health insurers 
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The Government and IAI should consider providing an initial initiative to pilot this 
advanced service. As part of the project, software, training, supporting standards, 
protocols and other materials would need to be developed. The pilot project would be 
beneficial in providing evidence on the clinical, humanistic and economic outcomes 
of the service, which could be used to justify its introduction into the system. This 
implementation would allow potential remuneration under JKN or private insurers. 
Meanwhile, the IAI should develop an accreditation system to determine the 
eligibility of community pharmacies and pharmacists to deliver this advanced 
service; for example, the pharmacy should have a consultation area/room and the 
pharmacist should complete formal diabetes-specific training which also includes 
medication use review. Later the range of advanced services could be expanded, over 
time, to better utilise community pharmacists, with the aim of improving the health 
of type 2 diabetes patients.  
 
 
 211 
 
6.6   Conclusions 
 
The current services provided for type 2 diabetes patients in Indonesian community 
pharmacies have been, mainly, dispensing (with limited labelling) and providing 
education related to medications, particularly directions for use. Better utilisation of 
community pharmacists is paramount in improving diabetes care in Indonesia. 
Pharmacists’, doctors’ and patients’ views in this study have highlighted potential 
service developments. Firstly, the development should be focused on services with 
some level of agreement between the three stakeholder groups: dispensing 
(emphasising improved labelling), prescription review (clinical aspects), education 
(medication and lifestyle education), monitoring (monitoring compliance, and 
monitoring outcomes by inquiring about patients’ glycaemic control and problems). 
Secondly, the development should be focused on pharmacists providing advanced 
diabetes services, such as providing medication use review, thus further expanding 
their professional roles. 
 
A number of factors associated with the development of pharmacy services were 
identified, including factors related to the pharmacists, their relationships with 
doctors and with patients, the pharmacy environment and the external environment. 
The current utilisation of community pharmacies by the Indonesian population in 
Surabaya is remarkably low. Collaboration between the Government and IAI will be 
required to integrate pharmacy services into the primary health system under JKN 
and, thus, to deliver much increased customer traffic to more pharmacies. Otherwise, 
a large number should close down. Pharmacists should be immediately available at 
all opening hours, or for advertised periods (e.g. encompassing at least 80% of the 
opening hours). It is important to establish an appropriate remuneration for pharmacy 
services, so that a stable environment is created for the pharmacy community, 
enabling it to remain viable. The service implementation also will require adequate 
support and resources, including: training, IT systems, infrastructure and staffing, 
supporting standards, procedures and other materials.  
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Further research should be considered to involve the Government and IAI to validate 
the model and to use it as a basis for developing future pharmacy 
services/programmes. It will then be necessary to pilot the services/programmes to 
assess their feasibility and effectiveness. 
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Pharmacist Questionnaire: 
Pharmacy-based Services for Type 2 Diabetes Patients 
 
 
This study is being conducted by Curtin University’s School of Pharmacy with approval from the Indonesian 
Pharmacist Association - Surabaya (No. 001/SK/BPD-IAI/SURABAYA/001). The aim of this study is to explore the 
potential roles of community pharmacists in diabetes care. The results of this study will help shape how future 
pharmacy-based services are designed in order to provide a better care for Type 2 Diabetes patients. This service is 
also of importance for pharmacists to develop as a profession.  
  
As part of this study, we would like to invite community pharmacists in Surabaya to complete a survey. It is your 
decision whether or not to take part in this survey. If you decide to participate, we would ask you to sign a consent 
form (below), and to complete the enclosed questionnaire. The questionnaire should take approximately 15 minutes 
to complete. 
We hope that you will participate, as your answers will make a significant contribution to the development of 
pharmacist professions as well as the improvement of care for Type 2 Diabetes patients. All information provided 
will be treated as strictly confidential. Your information will be combined with that of others, and you will be de-
identified in any publications arising from this study. Should you have any queries, the contact details of the 
investigators are as follows: 
Ms. Yosi Wibowo        Professor Jeff Hughes 
PhD student, School of Pharmacy, Curtin University          Professor Bruce Sunderland 
Pharmacist, Pusat Informasi Obat dan Layanan Kefarmasian    Supervisors, School of Pharmacy, Curtin University 
Universitas Surabaya       Phone : +61 8 9266 7369 
Phone : 031-2981170       Email : J.D.Hughes@curtin.edu.au  
Email : yosi.wibowo@postgrad.curtin.edu.au         B.Sunderland@curtin.edu.au  
         
 
Thank you for participating in this study 
 
 
This study has been approved by the Curtin University Human Research Ethics Committee (Approval No PH-09-11). The Committee is comprised of members of 
the public, academics, lawyers, doctors and pastoral carers.  Its main role is to protect respondents. If needed, verification of approval can be obtained either by 
writing to the Curtin University Human Research Ethics Committee, c/- Office of Research and Development, Curtin University, GPO Box U1987, Perth, 6845 or 
by telephoning +61 8 9266 2784 or by emailing hrec@curtin.edu.au. 
Consent Form 
I consent to the collection and use of the data in the enclosed form based on the understanding of the nature of 
the study as outlined above. I understand that all data provided will be treated with the strictest confidence, and 
respondents will be de-identified in any publications arising from this research. 
 
Signature : _____________________ 
Name  : _____________________  
Pharmacy :_____________________      Date : __/__/2011 
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1. Gender. Please tick (). 
 Male 
 Female 
 
2. Year of birth: 
 
3. In which year did you obtain your registration as a pharmacist? 
 
4. Please tick () your position at the pharmacy you currently work for: 
 Pharmacist manager (‘Apoteker Penanggung Jawab Apotek’) as well as Owner 
 Pharmacist manager (‘Apoteker Penanggung Jawab Apotek’) 
 Employee pharmacist (‘Apoteker Pendamping’) 
 Other (please specify):________________ 
 
5. How long have you been working as a community pharmacist? Please tick (). 
 Less than 2 years 
 2 – 5 years 
 6 – 10 years 
 More than 10 years 
 
6. How much time in total have you spent on training/continuing education on diabetes (eg. seminar, e-learning 
module, self-reading) in the past 12 months? Please tick (). 
 None 
 1 – 5 hours 
 6 – 10 hours 
 More than 10 hours 
1 9   
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7. In relation to services for Type 2 Diabetes patients at PHARMACIES, please indicate your response under Section 
(I) and (II). (Due to the lack of pre-determined pharmacist roles in diabetes care in our country, the provision of services may vary between pharmacies. 
Hence, we are interested to hear your honest response) 
 
(I) 
HOW OFTEN does  
THIS PHARMACY provide  
the following services for  
Type 2 Diabetes patients: 
(Circle one number) 
(II) 
Do you think that  
PHARMACIES SHOULD PROVIDE 
the following services for  
Type 2 Diabetes patients; 
(Circle one number) 
 
Never                            
            
Always 
Definitely 
No 
Definitely 
Yes 
A. INITIAL ASSESSMENT   
Taking patient  history, including:    
• age  1         2         3         4         5        6 1        2        3        4        5        6 
• duration of diabetes  1         2         3         4         5        6 1        2        3        4        5        6 
• lifestyle  
(eg. eating patterns, physical activity habits) 
1         2         3         4         5        6 1        2        3        4        5        6 
• family history of diabetes 1         2         3         4         5        6 1        2        3        4        5        6 
• presence of other risk factors for complications  
(e g. hypertension, dyslipidemia, smoking, family history of 
cardiovascular diseases) 
1         2         3         4         5        6 1        2        3        4        5        6 
• knowledge about diabetes 1         2         3         4         5        6 1        2        3        4        5        6 
• diabetes treatment  1         2         3         4         5        6 1        2        3        4        5        6 
• history of acute complications  
(e.g. hypoglycaemic episodes)  
1         2         3         4         5        6 1        2        3        4        5        6 
• history of chronic complications  
(e.g. retinopathy, nephropathy, neuropathy, diabetic foot, 
cardiovascular diseases)  
1         2         3         4         5        6 1        2        3        4        5        6 
• psychosocial status  
(e.g. attitudes about illness, expectations, resources – 
financial, social and emotional) 
1         2         3         4         5        6 1        2        3        4        5        6 
• history of other medical conditions 1         2         3         4         5        6 1        2        3        4        5        6 
Baseline physical assessment  
(e.g. measure weight/height, blood pressure) 
1         2         3         4         5        6 1        2        3        4        5        6 
Baseline laboratory examinations  
(e.g. check blood glucose) 
1         2         3         4         5        6 1        2        3        4        5        6 
B. TREATMENT PLAN   
Set of individualised treatment targets  
(with/without involvement of other health care members) 
1         2         3         4         5        6 1        2        3        4        5        6 
Develop treatment plans, including: 
(with/without involvement of other health care members)   
• antidiabetic medications 1         2         3         4         5        6 1        2        3        4        5        6 
• exercise  1         2         3         4         5        6 1        2        3        4        5        6 
• diet 1         2         3         4         5        6 1        2        3        4        5        6 
• prevention/treatment of chronic complications  1         2         3         4         5        6 1        2        3        4        5        6 
C. TREATMENT ADMINISTRATION   
Prepare medications 1         2         3         4         5        6 1        2        3        4        5        6 
Provide labels with instructions for use  
(e.g. 1 tablet 3 times daily) 
1         2         3         4         5        6 1        2        3        4        5        6 
DIABETES SERVICES 
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No.7 (continued) (I) 
HOW OFTEN does  
THIS PHARMACY provide the 
following services for  
Type 2 Diabetes patients: 
(Circle one number)  
(II) 
Do you think that  
PHARMACIES SHOULD PROVIDE  
the following services for  
Type 2 Diabetes patients: 
(Circle one number)  
 
Never                            
 
Always 
Definitely 
No 
Definitely 
Yes 
D. PATIENT EDUCATION   
Provide information (written or verbal) about:    
• diabetes disease process 1        2        3        4        5        6 1        2        3        4        5        6 
• treatment targets 1        2        3        4        5        6 1        2        3        4        5        6 
• antidiabetic medications:   
-   directions for use 1        2        3        4        5        6 1        2        3        4        5        6 
-   use of insulin devices  1        2        3        4        5        6 1        2        3        4        5        6 
-   storage requirements 1        2        3        4        5        6 1        2        3        4        5        6 
-   special precautions to follow 1        2        3        4        5        6 1        2        3        4        5        6 
-   common/important adverse effects  1        2        3        4        5        6 1        2        3        4        5        6 
• exercise 1        2        3        4        5        6 1        2        3        4        5        6 
• diet 1        2        3        4        5        6 1        2        3        4        5        6 
• Self-Monitoring of Blood Glucose 
(e g. use of glucose meter and interpretation of the results)  
1        2        3        4        5        6 1        2        3        4        5        6 
• prevention/treatment of acute complications  
(e g. hypoglycaemia) 
1        2        3        4        5        6 1        2        3        4        5        6 
• prevention/treatment of chronic complications  
(e g. cardiovascular diseases) 
1        2        3        4        5        6 1        2        3        4        5        6 
• need for regular medical monitoring 
 (e g. heart, kidney, eye and feet examinations) 1        2        3        4        5        6 1        2        3        4        5        6 
• foot self-care 1        2        3        4        5        6 1        2        3        4        5        6 
• smoking cessation 1        2        3        4        5        6 1        2        3        4        5        6 
E. MONITORING   
Monitor compliance with:   
• antidiabetic medications 1       2       3       4       5       6 1        2        3        4        5        6 
• exercise plan 1       2       3       4       5       6 1        2        3        4        5        6 
• diet plan 1       2       3       4       5       6 1        2        3        4        5        6 
• plan for prevention/treatment of chronic 
complications 
1       2       3       4       5       6 1        2        3        4        5        6 
• scheduled medical monitoring 1       2       3       4       5       6 1        2        3        4        5        6 
Monitor treatment outcomes:   
• check records on patient ‘Self-Monitoring of 
Blood Glucose’ 
1       2       3       4       5       6 1        2        3        4        5        6 
• carry out blood glucose tests 1       2       3       4       5       6 1        2        3        4        5        6 
• measure Body Mass Index (BMI) 1       2       3       4       5       6 1        2        3        4        5        6 
• measure blood pressure 1       2       3       4       5       6 1        2        3        4        5        6 
• check results of laboratory tests 
(e.g. HbA1c, cholesterol, albumin) 
1       2       3       4       5       6 1        2        3        4        5        6 
• check presence of adverse effects 1       2       3       4       5       6 1        2        3        4        5        6 
Adjust treatment plans if necessary  
(with/without involvement of other health care members) 
1       2       3       4       5       6 1        2        3        4        5        6 
Refer patients (e.g. to doctors/specialists) wherever 
appropriate  1       2       3       4       5       6 1        2        3        4        5        6 
Adjust diabetes education based on patients’ 
continuing needs 1       2       3       4       5       6 1        2        3        4        5        6 
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8. If you think there are other Type 2 Diabetes services NOT listed in Question 7, please write them in the Section 
(I); then indicate your response regarding those services under Section (II) and (III).  
 
9. In your opinion, what are the 5 most important services that SHOULD BE PROVIDED at PHARMACIES for Type 2 
Diabetes patients (this may include services listed in Question 7 and 8)? 
(Try to be as specific as possible, eg. providing information about antidiabetic medications)  
 
1  
    
2 
     
3 
     
4 
     
5 
     
 
10. How much does this pharmacy currently charge for providing services for Type 2 Diabetes patients (other than 
cost for medications and/or test kits)? Please tick (). 
 Nothing 
 Any payment less than Rp 25,000 
 Rp 25,000 – 50,000 
 More than Rp 50,000  
 
11. How much do you think this pharmacy should charge for providing a consultation service for Type 2 Diabetes 
patients (other than cost for medications and/or test kits)? Please tick (). 
 Nothing 
 Any payment less than Rp 25,000 
 Rp 25,000 – 50,000 
 More than Rp 50,000  
(I) 
In your opinion, are there other Type 2 Diabetes 
services NOT listed in Question 7? 
(Please fill in the blank) 
(II) 
HOW OFTEN does  
THIS PHARMACY provide the 
following services for  
Type 2 Diabetes patients? 
(Circle one number)  
(III) 
Do you think that  
PHARMACIES SHOULD PROVIDE 
the following services for  
Type 2 Diabetes patients? 
(Circle one number) 
Never 
 
Always 
Definitely 
No 
Definitely 
Yes 
 
 1        2        3        4        5        6 1        2        3        4        5        6 
 
 1        2        3        4        5        6 1        2        3        4        5        6 
 
 1        2        3        4        5        6 1        2        3        4        5        6 
 
 1        2        3        4        5        6 1        2        3        4        5        6 
 
1        2        3        4        5        6 1        2        3        4        5        6 
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12. Which one of the following best describes the setting of this pharmacy? Please tick (). 
 Stand alone  
 Shopping mall complex 
 Pharmacy with doctor clinics 
 Other (please specify):________________ 
 
13. Which one of the following best describes the ownership of this pharmacy? Please tick (). 
 Pharmacist Manager (Apoteker Penanggung Jawab Apotek)  
 Single proprietor (Pemilik Sarana Apotek – perorangan) 
 Group proprietor (Pemilik Sarana Apotek – kelompok/perusahaan) 
 Partnership between proprietor and pharmacist manager 
 Other (please specify):__________________ 
 
14. Is there a private counselling area/room within this pharmacy? Please tick (). 
 Yes 
 No 
 
15. Please record the opening and closing hours in each day for this pharmacy. 
 
16. Please record the total working hours for each pharmacist (including yourself) in this pharmacy. 
 
Pharmacist Total working hours 
Pharmacist Manager ….... hours (per week /per month)* 
Employee pharmacist (A) ….... hours (per week /per month)* 
Employee pharmacist (B) ….... hours (per week /per month)* 
……………. ….... hours (per week /per month)* 
……………. ….... hours (per week /per month)* 
…………….. ….... hours (per week /per month)* 
……………. ….... hours (per week /per month)* 
…………….. ….... hours (per week /per month)* 
* Please cross that are not applied 
Monday Tuesday Wednesday Thursday Friday Saturday Sunday 
Open Close Open Close Open Close Open Close Open Close Open Close Open Close 
              
PHARMACY CHARACTERISTICS 
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17. What is the estimated total number of customers purchasing any items (prescriptions or non-prescriptions) in 
this pharmacy per month? Please tick (). 
 Up to 200 
 201 – 500 
 501 – 1000 
 1001 – 2000 
 2001 – 4000 
 More than 4000 
 
18. What is the estimated number of customers dispensed Oral Antidiabetic Medications in this pharmacy per 
month? Please tick (). 
 Up to 20 
 21 – 50 
 51 – 100 
 101 – 250 
 251 – 500 
 More than 500 
 
19. What is the estimated number of customers dispensed Insulin in this pharmacy per month? Please tick (). 
 Up to 10 
 11 – 25 
 26 – 51 
 51 – 100 
 More than 100 
 
 
THANK YOU FOR YOUR TIME AND PARTICIPATION 
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Survei Apoteker:  
Layanan Diabetes Tipe 2 di Apotek  
 
 
School of Pharmacy, Curtin University dengan persetujuan Ikatan Apoteker Indonesia cabang Surabaya (No. 
001/SK/BPD-IAI/SURABAYA/2010) akan melakukan penelitian untuk menggali peran potensial apoteker di apotek 
dalam layanan Diabetes. Hasil penelitian ini diharapkan menjadi acuan dalam perencanaan layanan di apotek yang 
lebih baik bagi pasien Diabetes Tipe 2. Layanan ini juga penting artinya bagi perkembangan profesi apoteker.  
Sebagai bagian dari penelitian ini, kami mengajak para apoteker di apotek di Surabaya untuk ikut serta dalam survei 
berikut. Bapak/Ibu dapat memutuskan untuk bersedia ataupun tidak bersedia berpartisipasi. Namun, kami percaya 
bahwa Bapak/Ibu akan turut berpartisipasi, karena jawaban Bapak/Ibu akan menjadi sumbangan yang berarti bagi 
perkembangan profesi apoteker, serta bagi peningkatan layanan untuk pasien Diabetes Tipe 2. Untuk itu, kami 
mohon Bapak/Ibu menandatangani lembar persetujuan di bawah ini, serta melengkapi kuesioner terlampir. 
Pengisian kuesioner ini akan memerlukan waktu sekitar 15 menit.  
Semua jawaban akan dirahasiakan. Jawaban Bapak/Ibu akan digabungkan dengan jawaban responden lain, dan 
identitas Bapak/Ibu tidak akan diketahui dalam semua bentuk laporan penelitian ini. Jika Bapak/Ibu mempunyai 
pertanyaan, silakan menghubungi peneliti: 
Ms. Yosi Wibowo        Professor Jeff Hughes 
PhD student, School of Pharmacy, Curtin University          Professor Bruce Sunderland 
Apoteker, Pusat Informasi Obat & Layanan Kefarmasian,    Supervisors, School of Pharmacy, Curtin University 
Universitas Surabaya        Telepon : +61 8 9266 7369 
Telepon : 031-2981170       Email : J.D.Hughes@curtin.edu.au  
Email : yosi.wibowo@postgrad.curtin.edu.au            B.Sunderland@curtin.edu.au 
          
 
Terima Kasih atas Partisipasi Bapak/Ibu 
 
 
 
Penelitian ini telah disetujui oleh Curtin University Human Research Ethics Committee (No. PH-09-011). Komite ini terdiri dari anggota masyarakat, 
akademisi, pengacara, dokter dan pemuka agama. Tugas utamanya adalah memberikan perlindungan bagi responden. Jika diperlukan verifikasi,  Bapak/Ibu 
dapat mengirimkan surat ke Curtin University Human Research Ethics Committee, c/- Office of Research and Development, Curtin University of Technology, 
GPO Box U1987, Perth, 6845, atau menelepon ke +61 8 9266 2784, atau mengirimkan email ke hrec@curtin.edu.au. 
Lembar Persetujuan 
 
Saya menyetujui pengambilan dan penggunaan data pada kuesioner terlampir setelah memahami karakteristik 
penelitian sebagaimana dijelaskan di atas. Saya memahami bahwa seluruh data yang diperoleh akan 
dirahasiakan, dan identitas responden tidak akan diketahui dalam semua bentuk laporan penelitian ini.  
Tanda tangan : ____________________________ 
Nama  : ____________________________   
Nama Apotek : ____________________________     Tanggal : __ - __ - 2011 
 
 
 242 
 
 
 
1. Mohon dicentang (). Jenis kelamin Bapak/Ibu: 
 Pria 
 Wanita 
 
2. Tahun kelahiran Bapak/Ibu:  
 
3. Tahun kelulusan Bapak/Ibu sebagai Apoteker?  
    
4. Mohon dicentang () posisi Bapak/Ibu di apotek tempat Bapak/Ibu bekerja? 
 Apoteker Penanggung-jawab Apotek (APA) sekaligus Pemilik 
 Apoteker Penanggung-jawab Apotek (APA) 
 Apoteker Pendamping  
 Lainnya (mohon disebutkan):________________ 
 
5. Berapa lamakah pengalaman Bapak/Ibu bekerja sebagai Apoteker di apotek? Mohon dicentang (). 
 Kurang dari 2 tahun 
 2 – 5 tahun 
 6 – 10 tahun 
 Lebih dari 10 tahun 
 
6. Berapakah total waktu yang Bapak/Ibu gunakan dalam 12 bulan terakhir untuk mengikuti pelatihan/pendidikan 
berkelanjutan mengenai Diabetes (misalnya: seminar, modul pembelajaran elektronik, belajar mandiri)? 
Mohon dicentang (). 
 Tidak ada 
 1 – 5 jam 
 6 – 10 jam 
 Lebih dari 10 jam 
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7. Terkait dengan layanan untuk pasien Diabetes Tipe 2 di apotek, mohon diberikan jawaban pada Bagian (I) dan 
Bagian (II). (Hingga kini belum diberlakukan standar pelayanan Diabetes di apotek di negara kita. Semuanya tergantung pada kesanggupan masing-
masing apotek. Oleh sebab itu, sangat penting untuk menjawab setiap pertanyaan apa adanya) 
 
(I) 
Seberapa SERING  
 APOTEK Anda memberikan 
layanan di bawah ini untuk pasien 
Diabetes Tipe 2? 
(Lingkari satu angka) 
(II) 
Apakah menurut Anda, 
  suatu APOTEK SEHARUSNYA 
 MENGADAKAN  layanan di bawah 
ini untuk pasien Diabetes Tipe 2? 
 (Lingkari satu angka) 
Tidak 
pernah 
 
Selalu 
Tidak 
diadakan 
Harus  
diadakan 
A. PENILAIAN AWAL   
Menanyakan riwayat pasien meliputi:   
• usia 1         2        3        4        5        6 1        2        3        4       5        6 
• kapan mulai menderita diabetes 1         2        3        4        5        6 1        2        3        4       5        6 
• gaya hidup (misalnya: pola makan, aktivitas fisik) 1         2        3        4        5        6 1        2        3        4       5        6 
• riwayat diabetes dalam keluarga 1         2        3        4        5        6 1        2        3        4       5        6 
• adanya faktor risiko lain untuk terjadinya komplikasi 
(misalnya: hipertensi, dislipidemia, merokok, riwayat penyakit 
kardiovaskuler dalam keluarga) 
1         2        3        4        5        6 1        2        3        4       5        6 
• pengetahuan tentang diabetes 1         2        3        4        5        6 1        2        3        4       5        6 
• pengobatan diabetes yang pernah didapatkan 1         2        3        4        5        6 1        2        3        4       5        6 
• riwayat komplikasi akut  
(misalnya: kejadian hipoglikemia)  
1         2        3        4        5        6 1        2        3        4       5        6 
• riwayat komplikasi kronis (misalnya: retinopati, nefropati, 
neuropati, kaki diabetes, penyakit kardiovaskuler)  1         2        3        4        5        6 1        2        3        4       5        6 
• status psikososial (misalnya: sikap terhadap penyakitnya, 
harapan,  sumber daya – finansial, sosial dan emosional) 1         2        3        4        5        6 1        2        3        4       5        6 
• riwayat penyakit lain 1         2        3        4        5        6 1        2        3        4       5        6 
Melakukan pemeriksaan fisik awal (misalnya: mengukur 
tinggi/berat badan, tekanan darah) 1         2        3        4        5        6 1        2        3        4       5        6 
Melakukan tes laboratorium awal (misalnya: mengukur gula 
darah) 1         2        3        4        5        6 1        2        3        4       5        6 
B. RENCANA PENGOBATAN   
Menetapkan target hasil pengobatan untuk individu 
pasien (dengan/tanpa keterlibatan tenaga kesehatan lain) 1         2        3        4        5        6 1        2        3        4       5        6 
Menyusun rencana pengobatan yang meliputi: 
(dengan/tanpa keterlibatan tenaga kesehatan lain) 
  
• obat antidiabetes 1         2        3        4        5        6 1        2        3        4       5        6 
• olahraga 1         2        3        4        5        6 1        2        3        4       5        6 
• pengaturan makanan 1         2        3        4        5        6 1        2        3        4       5        6 
• pencegahan/pengobatan komplikasi kronis  1         2        3        4        5        6 1        2        3        4       5        6 
C. PEMBERIAN OBAT   
Menyiapkan/meracik obat 1         2        3        4        5        6 1        2        3        4       5        6 
Memberikan label tentang aturan pakai obat  
(misalnya: 1 tablet, 3 kali sehari) 
1         2        3        4        5        6 1        2        3        4       5        6 
LAYANAN DIABETES 
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No. 7 (lanjutan) (I) 
Seberapa SERING 
APOTEK Anda memberikan 
layanan di bawah ini untuk 
pasien Diabetes Tipe 2?  
(Lingkari satu angka) 
(II) 
Apakah menurut Anda, 
  suatu APOTEK SEHARUSNYA 
MENGADAKAN layanan di bawah 
ini untuk pasien Diabetes Tipe 2? 
 (Lingkari satu angka) 
 Tidak 
pernah 
 
Selalu 
Tidak 
diadakan 
Harus  
diadakan 
D. EDUKASI PASIEN   
Memberikan informasi (secara lisan atau tulisan) mengenai:    
• proses penyakit diabetes 1        2       3       4       5       6 1        2        3        4        5       6 
• target hasil pengobatan 1        2       3       4       5       6 1        2        3        4        5       6 
• obat antidiabetes:   
-   aturan pakai obat 1        2       3       4       5       6 1        2        3        4        5       6 
-   cara pakai alat untuk pemberian insulin  1        2       3       4       5       6 1        2        3        4        5       6 
-   cara penyimpanan obat 1        2       3       4       5       6 1        2        3        4        5       6 
-   perhatian khusus terkait penggunaan obat 1        2       3       4       5       6 1        2        3        4        5       6 
-   efek samping obat yang umum/penting  1        2       3       4       5       6 1        2        3        4        5       6 
• olahraga 1        2       3       4       5       6 1        2        3        4        5       6 
• pengaturan makanan 1        2       3       4       5       6 1        2        3        4        5       6 
• Pemantauan Gula Darah Mandiri (misalnya: cara penggunaan 
alat tes gula darah, dan interpretasi hasil tes) 1        2       3       4       5       6 1        2        3        4        5       6 
• pencegahan/pengobatan komplikasi akut  
(misalnya: hipoglikemia)  
1        2       3       4       5       6 1        2        3        4        5       6 
• pencegahan/pengobatan komplikasi kronis  
(misalnya: penyakit kardiovaskuler)  
1        2       3       4       5       6 1        2        3        4        5       6 
• perlunya skrining komplikasi kronis secara rutin (misalnya: 
pemeriksaan jantung, ginjal, mata dan kaki) 1        2       3       4       5       6 1        2        3        4        5       6 
• perawatan-kaki secara mandiri 1        2       3       4       5       6 1        2        3        4        5       6 
• penghentian merokok 1        2       3       4       5       6 1        2        3        4        5       6 
E. PEMANTAUAN   
Memantau kepatuhan terhadap:    
• penggunaan obat antidiabetes 1        2       3       4       5       6 1        2        3        4        5       6 
• program olahraga 1        2       3       4       5       6 1        2        3        4        5       6 
• program pengaturan makanan 1        2       3       4       5       6 1        2        3        4        5       6 
• program pencegahan/pengobatan komplikasi kronis 1        2       3       4       5       6 1        2        3        4        5       6 
• program skrining untuk komplikasi kronis 1        2       3       4       5       6 1        2        3        4        5       6 
Memantau target hasil pengobatan:   
• memeriksa catatan Pemantauan ‘Gula Darah Mandiri’ 
pasien  1        2       3       4       5       6 1        2        3        4        5       6 
• melakukan tes gula darah 1        2       3       4       5       6 1        2        3        4        5       6 
• mengukur Body Mass Index (BMI) 1        2       3       4       5       6 1        2        3        4        5       6 
• mengukur tekanan darah 1        2       3       4       5       6 1        2        3        4        5       6 
• memeriksa hasil tes laboratorium pasien 
 (misalnya: HbA1c, kolesterol, albumin) 1        2       3       4       5       6 1        2        3        4        5       6 
• memeriksa adanya efek samping obat 1        2       3       4       5       6 1        2        3        4        5       6 
Menyesuaikan rencana pengobatan jika diperlukan 
(dengan/tanpa keterlibatan tenaga kesehatan lain)  
1        2       3       4       5       6 1        2        3        4        5       6 
Merujuk pasien jika diperlukan (misalnya: ke dokter/spesialis) 1        2       3       4       5       6 1        2        3        4        5       6 
Menyesuaikan edukasi diabetes dengan mengikuti kebutuhan 
pasien  1        2       3       4       5       6 1        2        3        4        5       6 
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8. Jika menurut Bapak/Ibu masih terdapat layanan untuk pasien Diabetes Tipe 2 yang TIDAK tercantum pada 
pertanyaan No. 7, mohon dituliskan pada Bagian (I); dan mohon memberikan jawaban terkait layanan tersebut 
pada Bagian (II) dan Bagian (III).  
 
9. Mohon disebutkan LIMA layanan utama yang menurut Bapak/Ibu SEHARUSNYA DIADAKAN di suatu APOTEK 
untuk pasien Diabetes Tipe 2 (dapat termasuk layanan yang tercantum pada Pertanyaan No. 7 and 8).  
         (Mohon disebutkan layanannya secara spesifik, misalnya: memberikan informasi mengenai obat antidiabetes) 
 
10. Berapakah biaya yang dipungut oleh apotek Bapak/Ibu saat ini untuk pemberian layanan bagi pasien Diabetes 
Tipe 2 (selain biaya obat dan/atau alat tes)? Mohon dicentang (). 
 Tanpa dipungut biaya  
 Pembayaran kurang dari Rp. 25.000 
 Rp. 25.000 – 50.000 
 Lebih dari Rp. 50.000  
 
11. Menurut Bapak/Ibu, berapakah biaya yang selayaknya dipungut oleh apotek Bapak/Ibu untuk pemberian 
layanan konsultasi bagi pasien Diabetes Tipe 2 (selain biaya obat dan/atau alat tes)? Mohon dicentang (). 
 Tanpa dipungut biaya  
 Pembayaran kurang dari Rp. 25.000 
 Rp. 25.000 – 50.000 
 Lebih dari Rp. 50.000  
(I) 
Menurut Anda,  
apakah ada layanan untuk pasien Diabetes Tipe 2 yang 
TIDAK tercantum pada pertanyaan No. 7?  
(Mohon dituliskan dalam kotak dibawah ini) 
(II) 
Seberapa SERING  
   APOTEK Anda memberikan  
layanan tersebut? 
(Lingkari satu angka) 
(III) 
Apakah menurut Anda, 
  suatu APOTEK SEHARUSNYA 
MENGADAKAN layanan tersebut? 
(Lingkari satu angka) 
Tidak 
pernah 
 
Selalu 
Tidak 
diadakan 
Harus  
diadakan 
 
 1          2        3         4        5         6 1        2        3         4         5        6 
 
1          2        3         4        5         6 1        2        3         4         5        6 
 
 1          2        3         4        5         6 1        2        3         4         5        6 
 
 1          2        3         4        5         6 1        2        3         4         5        6 
 
 1          2        3         4        5         6 1        2        3         4         5        6 
1  
    
2 
     
3 
     
4 
     
5 
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12. Kategori manakah yang paling cocok menggambarkan apotek tempat Bapak/Ibu bekerja? Mohon dicentang (). 
 Satu bangunan apotek yang berdiri sendiri 
 Apotek dalam pusat perbelanjaan 
 Apotek dengan praktek dokter 
Lainnya (mohon disebutkan):________________ 
 
13. Kategori manakah yang paling menggambarkan kepemilikan apotek tempat Bapak/Ibu bekerja? Mohon 
dicentang (). 
 Apoteker Penanggung Jawab Apotek (APA) 
 Pemilik Sarana Apotek (PSA) perorangan  
 Pemilik Sarana Apotek (PSA) kelompok/Badan Usaha  
 Kepemilikan bersama PSA dan APA 
 Lainnya (mohon disebutkan):__________________ 
  
14. Apakah apotek Bapak/Ibu memiliki tempat konseling (dapat berupa: area khusus atau ruang tersendiri yang 
tidak terganggu)? Mohon dicentang (). 
 Ya 
 Tidak 
 
15. Mohon dituliskan jam buka dan jam tutup apotek Bapak/Ibu untuk tiap harinya. 
 
16. Mohon dituliskan total jam kerja masing-masing apoteker (termasuk Bapak/Ibu sendiri) di apotek tempat 
Bapak/Ibu bekerja.  
Apoteker Total jam kerja 
Apoteker Penanggung-jawab Apotek (APA) ….... jam   (per minggu / per bulan)*  
Apoteker pendamping (A) ….... jam   (per minggu / per bulan)* 
Apoteker pendamping (B) ….... jam   (per minggu / per bulan)* 
……………. ….... jam   (per minggu / per bulan)* 
……………. ….... jam   (per minggu / per bulan)* 
…………….. ….... jam   (per minggu / per bulan)* 
……………. ….... jam   (per minggu / per bulan)* 
……………. ….... jam   (per minggu / per bulan)* 
* coret yang tidak perlu 
Senin Selasa Rabu Kamis Jumat Sabtu Minggu 
Jam 
buka 
Jam 
tutup 
Jam 
buka 
Jam 
tutup 
Jam 
buka 
Jam 
tutup 
Jam 
buka 
Jam 
tutup 
Jam 
buka 
Jam 
tutup 
Jam 
buka 
Jam 
tutup 
Jam 
buka 
Jam 
tutup 
              
KARAKTERISTIK APOTEK 
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17. Berapakah perkiraan total jumlah pembeli obat (resep maupun non-resep) per bulan di apotek Bapak/Ibu? 
Mohon dicentang (). 
 Sampai dengan 200 orang 
 201 – 500 orang 
 501 – 1000 orang 
 1001 – 2000 orang 
 2001 – 4000 orang 
 Lebih dari 4000 orang 
 
18. Berapakah perkiraan jumlah pembeli Obat Antidiabetes Oral per bulan di apotek Bapak/Ibu? Mohon dicentang 
(). 
 Sampai dengan 20 orang 
 21 – 50 orang 
 51 – 100 orang 
 101 – 250 orang 
 251 – 500 orang 
 Lebih dari 500 orang 
 
19. Berapakah perkiraan jumlah pembeli Insulin per bulan di apotek Bapak/Ibu? Mohon dicentang (). 
 Sampai dengan 10 orang 
 11 – 25 orang 
 26 – 50 orang 
 51 – 100 orang 
 Lebih dari 100 orang 
 
 
 
TERIMA KASIH UNTUK WAKTU DAN PARTISIPASI BAPAK/IBU 
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Appendix 5       
Invitation letter for the pharmacist survey (second round)      
 
 
Kepada                    Surabaya, 8 Agustus 2011 
Yth. Bapak/Ibu Apoteker di Apotek 
Di Surabaya 
 
 
Dengan hormat, 
Bersama surat ini kami bermaksud mengundang Bapak/Ibu Apoteker di Apotek untuk turut 
serta dalam survei mengenai Layanan Diabetes. Survei ini diadakan oleh Curtin University, 
dan telah mendapatkan persetujuan IAI Cabang Surabaya (No. 001/SK/BPD-
IAI/SURABAYA/2010). Tujuannya adalah menggali peran potensial apoteker di apotek 
dalam memberikan Layanan Diabetes.  
 
Jenis Layanan Diabetes di apotek dapat bervariasi tergantung pada kesanggupan masing-
masing apotek, sehingga sangat penting untuk menjawab apa adanya.  
Kami juga ingin mengetahui harapan Bapak/Ibu mengenai Layanan Diabetes yang 
seharusnya diadakan di apotek.  
Jawaban Bapak/Ibu akan sangat bermanfaat dalam perencanaan layanan kefarmasian di 
apotek dan  bagi perkembangan profesi apoteker. 
 
Untuk itu, Kami mohon Bapak/Ibu berkenan mengisi kuesioner terlampir. Pengisian 
kuesioner akan memerlukan waktu sekitar 15 menit. Jawaban beserta identitas Bapak/Ibu 
akan kami rahasiakan dalam penyajian data. 
 
Kuesioner yang sudah diisi dengan lengkap, mohon dimasukkan kembali ke dalam amplop 
yang sama; dan akan kami ambil di Apotek tempat Bapak/Ibu bekerja pada tanggal 12 s/d 
17 September 2011.   
 
Sebagai tanda terima kasih atas partisipasi Bapak/Ibu, kami sertakan materi Seminar 
’Sosialisasi Peraturan Perundang-undangan’ yang diselenggarakan PIOLK Universitas 
Surabaya pada bulan lalu. Selain itu, kami akan memberikan Buku ’Peraturan Perundang-
undangan TERBARU di Bidang Pelayanan Kefarmasian di Apotek’ pada saat 
pengambilan kuesioner yang telah terisi lengkap. Kami percaya Bapak/Ibu bersedia 
memberikan masukan, karena perbaikan layanan kefarmasian sangat penting artinya bagi 
eksistensi profesi apoteker.  
 
Terima kasih atas perhatian dan partisipasi Bapak/Ibu. Semoga Tuhan membalas kebaikan 
Bapak/Ibu dengan rahmat dan berkah yang melimpah. 
 
Hormat kami, 
Signature 
Yosi Irawati Wibowo (Ms) 
PhD Student, School of Pharmacy, Curtin University 
Apoteker, Pusat Informasi Obat & Layanan Kefarmasian (PIOLK), Universitas Surabaya 
 
Professor Jeff Hughes 
Professor Bruce Sunderland 
Supervisors, School of Pharmacy, Curtin University 
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Appendix 6        
Patient questionnaire (English and Indonesian versions) 
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Patient Survey: 
Pharmacy-based Type 2 Diabetes Services  
 
This study is being conducted by Curtin University’s School of Pharmacy with approval from the Indonesian 
Pharmacist Association - Surabaya (No. 001/SK/BPD-IAI/2010). The aim of this study is to explore the potential roles 
of community pharmacists in providing care for Type 2 Diabetes patients.  
  
As part of our study, we would like to invite pharmacy patients with Type 2 Diabetes to complete a survey. It is your 
decision whether or not to take part in this survey. If you decide to take part, you will be asked to sign a consent 
form (below), and to complete the enclosed questionnaire. The questionnaire should take approximately 15 minutes 
to complete.  
 
We hope that you will participate in this study, as your answer will assist community pharmacists to help you in 
managing your Diabetes. Needs for diabetes services may vary between patients. Hence, we are interested to hear 
your honest response. All information provided will be treated as strictly confidential. Your information will be 
combined with that of others, and you will be de-identified in any publications arising from this study. Should you 
require any further information, please contact the project pharmacist or the investigators: 
Ms. Yosi Wibowo      Professor Jeff Hughes 
PhD student, School of Pharmacy, Curtin University         Professor Bruce Sunderland 
Pharmacist, Pusat Informasi Obat dan Layanan Kefarmasian,   Supervisors, School of Pharmacy, Curtin University 
Universitas Surabaya      Phone : +61 8 9266 7369 
Phone : 031-2981170      Email : J.D.Hughes@curtin.edu.au  
Email : yosi.wibowo@postgrad.curtin.edu.au      B.Sunderland@curtin.edu.au  
        
 
 
Thank you for participating in this study  
 
 
This study has been approved by the Curtin University Human Research Ethics Committee (Approval No PH-09-11). The Committee is comprised of members 
of the public, academics, lawyers, doctors and pastoral carers.  Its main role is to protect respondents. If needed, verification of approval can be obtained 
either by writing to the Curtin University Human Research Ethics Committee, c/- Office of Research and Development, Curtin University, GPO Box U1987, 
Perth, 6845 or by telephoning +61 8 9266 2784 or by emailing hrec@curtin.edu.au. 
Consent Form 
I consent to the collection and use of the data in the enclosed form based on the understanding of the nature of 
the study as outlined above. I understand that all data provided will be treated with the strictest confidence, and 
respondents will be de-identified in any publications arising from this research.  
Signature : _____________________ 
Name   : _____________________ 
Address : _____________________       Date : __/__/2011 
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1. Gender.Please tick ().   
 Male 
 Female 
 
2. Year of birth:  
 
 
3. Ethnicity. Please tick ().  
 Asian 
 Other (please specify): ______________ 
 
4. Please tick () your highest level of education: 
 No schooling 
 Primary school graduate  
 Junior high school graduate  
 Senior high school graduate  
 Diploma graduate  
 Bachelor degree graduate 
 Postgraduate degree graduate 
 
5. Please tick () your current employment status: 
 Working full-time (40 hours or more per week) 
 Working part-time (less than 40 hours per week) 
 Unemployed 
 Other (please specify):________________ 
 
6. Please tick () total combined income in your household (from all sources) per month: 
 Up to Rp. 2 millions 
 > Rp. 2 millions – 5 millions  
 > Rp. 5 millions – 10 millions  
 More than Rp. 10 millions 
 
7. Please tick () the health insurance plan(s) that you have:  
 Insurance plan where you or member of your family pays all of the plan premium 
 Insurance plan where the employer/institution pays all or part of the plan premium 
 I do not have an insurance plan, but I am eligible for insurance scheme for the poor (eg. Jamkesmas) 
 I have no insurance plans  
 
8. Are you a member of a diabetes organisation? Please tick ().  
 Yes  
 No 
 
1 9   
RESPONDENT DETAILS 
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DIABETES SERVICES 
 
9. Please rate your satisfaction regarding services at the PHARMACY (you visit most frequently) in assisting you 
with your Diabetes:  
 Very satisfied 
 Satisfied 
 Moderately satisfied 
 Slightly satisfied 
 Not at all satisfied 
 
10. Thinking about your visits to a PHARMACY, please indicate your response under Section (I) and (II). 
 
(I) 
Have you ever 
RECEIVED  
the following 
services:  
 (Circle one answer) 
(II) 
Do you think that  
PHARMACIES SHOULD PROVIDE  
the following services in assisting you 
with your Diabetes: 
(Circle one number) 
Definitely 
no 
Definitely 
yes 
A. TREATMENT ADMINISTRATION   
 The pharmacy prepares and delivers your medications  Yes                 No 1         2         3         4         5         6 
The pharmacy provides labels with instruction for use 
(eg. a label written ‘1 tablet 3 times daily’) Yes                 No 1         2         3         4         5         6 
B. EDUCATION   
The pharmacy provides information (verbal or written), including:   
• Information on what diabetes is Yes                 No 1         2         3         4         5         6 
• Information about treatment targets  
(eg. the desired blood sugar levels) 
Yes                 No 1         2         3         4         5         6 
• Information about medications for diabetes:   
-   how to take your medications  Yes                 No 1         2         3         4         5         6 
-   how to use insulin devices  Yes                 No 1         2         3         4         5         6 
-   how to store your medications Yes                 No 1         2         3         4         5         6 
-  special precautions to follow when using medications 
(eg. this medication should be taken with or soon after food to avoid 
risk of low blood sugar) 
Yes                 No 1         2         3         4         5         6 
-  common/important adverse effects  
(eg. after taking this medication, nausea may occur) Yes                 No 1         2         3         4         5         6 
• Information about appropriate exercise  Yes                 No 1         2         3         4         5         6 
• Information about healthy diet Yes                 No 1         2         3         4         5         6 
• Information on self-monitoring of blood sugar 
(eg. how to use blood sugar test devices, and interpret the results) 
Yes                 No 1         2         3         4         5         6 
• Information on how to prevent/treat emergency problems  
(eg. how to treat low blood sugar)  
Yes                 No 1         2         3         4         5         6 
• Information on how to prevent/treat diabetes complications  
(eg. how to prevent heart disease) Yes                 No 1         2         3         4         5         6 
• Information on the needs for regular medical monitoring  
(eg. heart, kidney, eye and foot examination) 
Yes                 No 1         2         3         4         5         6 
• Information on foot self-care 
eg. toenail trimming, examine for any trauma) 
Yes                 No 1         2         3         4         5         6 
• Information about smoking cessation Yes                 No 1         2         3         4         5         6 
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No. 10 (continued) (I) 
Have you ever 
RECEIVED the 
following 
services: 
(Circle one answer) 
(II) 
Do you think that  
PHARMACIES SHOULD PROVIDE  
the following services in assisting 
you with your Diabetes: 
 (Circle one number) 
Definitely 
no 
 Definitely 
yes 
C. MONITORING   
The pharmacy monitors compliance by:   
• Asking if you have regularly taken your medications for diabetes Yes                 No 1         2         3         4         5         6 
• Asking if you have followed your exercise plan Yes                 No 1         2         3         4         5         6 
• Asking if you have followed your diet plan Yes                 No 1         2         3         4         5         6 
• Asking if you have maintained plan for preventing/treating 
diabetes complications  
        (eg. have you regularly taken cholesterol drugs?) 
Yes                 No 1         2         3         4         5         6 
• Asking if you have followed scheduled medical monitoring  
(eg. heart, kidney, eye and foot examination) 
Yes                 No 1         2         3         4         5         6 
The pharmacy monitors treatment targets by:   
• Testing your blood sugar Yes                 No 1         2         3         4         5         6 
• Measuring your weight  Yes                 No 1         2         3         4         5         6 
• Measuring your blood pressure  Yes                 No 1         2         3         4         5         6 
• Checking your records on self-monitoring of blood sugar Yes                 No 1         2         3         4         5         6 
• Checking your results of laboratory tests  Yes                 No 1         2         3         4         5         6 
• Asking if you experience any adverse effects from your 
medications 
Yes                 No 1         2         3         4         5         6 
The pharmacy provides referrals (eg. to doctors/specialists) wherever 
appropriate Yes                 No 1         2         3         4         5         6 
 
11. In your opinion, what are the 5 most important services that SHOULD BE PROVIDED at PHARMACIES to assist 
you with your Diabetes (this may include services listed in Question 9)? 
(Try to be as specific as possible, eg. providing information about medications for diabetes) 
 
12. If pharmacies provide a consultation service to help with your diabetes, how much would you be willing to pay 
for the service (other than cost of medications and/or test kits)? Please tick (). 
 Nothing 
 Any payment less than Rp. 25,000 
  Rp. 25,000 – 50,000  
  More than Rp. 50,000 
1 
 
2 
 
3 
 
4 
 
5 
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DIABETES HISTORY 
 
 
13. In what year were you diagnosed with diabetes?   
 
14. Is your Diabetes being treated by:  
 (Tick one box on each line) 
modifying diet?  Yes  No 
routine exercise programme?   Yes  No 
medications taken by mouth (eg. tablets/capsules)?  Yes  No 
insulin injection?  Yes  No 
 
If you are on insulin, have you taken insulin since your diabetes treatment started?  
 Yes  
 No 
 
15. Have you ever received diabetes information?  
 Yes  
 No 
 
If Yes, where do you get the information from? 
(Tick   more than one box if necessary) 
 
 
 
16. Other health factors:  
a) Your height:    ___________ cm 
b) Your weight:   ___________ kg 
Do you smoke?                                             Yes                     No, previously smoked                        No, never smoked  
a) Do you have high cholesterol?          Yes  No   Don’t know 
b) Do you take medications to treat your high cholesterol?  Yes    No   Don’t know 
a) Do you have high blood pressure?               Yes    No   Don’t know 
b) Do you take medications to treat your high blood pressure?  Yes    No   Don’t know 
 
17. Do you suffer from: 
 (Tick  one box on each line) 
heart disease (i.e. chest pain, heart attack, or heart failure)?  Yes  No  Don’t know 
eye problems (i.e. blurred vision which is not correctable with glasses, 
vision blocked with patches, or sudden vision loss)?  Yes  No  Don’t know 
foot discomfort (i.e. burning/numbness/frequent tingling)?  Yes  No  Don’t know 
foot ulcers?  Yes  No  Don’t know 
kidney problems?  Yes  No  Don’t know 
    
 Doctor’s office 
 Pharmacy 
 Television 
 Internet 
 Newspaper 
 Others (please specify):_____________________ 
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18. How many times in the last month have you had high blood sugar reactions such as thirst, dry mouth and skin, 
increased sugar in the urine, less appetite, nausea, or fatigue? Please tick (). 
 0 times       
 1 – 3 times          
 4 – 6 times      
 6 – 12 times 
 More than 12 times 
 Don’t know 
 
19. How many times in the last month have you had low blood sugar reactions such as sweating, weakness, anxiety, 
trembling, hunger or headache? Please tick (). 
 0 times       
 1 – 3 times          
 4 – 6 times      
 6 – 12 times 
 More than 12 times 
 Don’t know 
 
20. How many times in the past 12 months have you had severe low blood sugar reactions such as passing out or 
needing immediate help to treat the reaction? Please tick (). 
 0 times       
 1 – 3 times          
 4 – 6 times      
 6 – 12 times 
 More than 12 times 
 Don’t know 
 
21. In the last week, did you test your blood sugar (i.e. when you need to take blood from your finger)?  
(if you were sick in the last week, try to remember the most recent 7 days when you were NOT sick) 
 Yes       
 No 
If Yes,  
a) On how many days in the last week did you test your blood sugar? 
____________days 
 
b) On days that you test your blood sugar, how many times per day did you test on average? 
___________ times 
 
 
 
DIABETES MONITORING 
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Note: Health professionals could be doctors, pharmacists, nurses or laboratory/health facility staff 
 
22. In the past three months, did any health professional check your: 
 
23. In the past 12 months, did any health professional check your: 
 (Tick one box on each line) 
cholesterol (when you need to give a blood sample to be tested)?  Yes  No  Don’t know 
kidney  (when you need to give a urine sample to be tested )?   Yes  No  Don’t know 
eye (when drops were put in your eyes and caused blurred vision for  
1-2 hours)?  Yes  No  Don’t know 
feet (when your feet were checked for any sores or irritation)?  Yes  No  Don’t know 
 
24. In the past 12 months, did any health professional check your blood for HbA1c? 
(HbA1c is a blood test that is done to monitor average sugar levels in the past 2-3 months. Please note that this test should be done in laboratory, hospital 
or doctor’s office; this is NOT a test that you can perform at home)  
 Yes     
 No          
 Don’t know 
 
If Yes, 
a) How many times have you had HbA1c checks in the past 12 months? 
(Tick one box) 
 
 
 
b) What was your last HbA1c value? 
(Tick one box) 
 
 
 
THANK YOU FOR YOUR TIME AND PARTICIPATION
 (Tick  one box on each line) 
blood sugar?  Yes  No  Don’t know 
blood pressure?  Yes  No  Don’t know 
weight?  Yes  No  Don’t know 
 1 time 
 2 – 4 times 
 More than 4 times 
 Don’t know 
 Less than 6.5%        
 6.5 – 8%                      
 More than 8% 
 Dont’t know 
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Survei Pasien: 
Layanan Diabetes Tipe 2 di Apotek  
 
 
School of Pharmacy, Curtin University, dengan persetujuan Ikatan Apoteker Indonesia cabang Surabaya (No. 
001/SK/BPD-IAI/SURABAYA/2010) akan melakukan penelitian untuk menggali kemungkinan peran apoteker di 
apotek dalam memberikan layanan bagi pasien Diabetes Tipe 2. 
Sebagai bagian dari penelitian ini, kami mengajak pasien apotek yang menderita Diabetes Tipe 2 untuk ikut serta 
dalam survei berikut. Bapak/Ibu dapat memutuskan untuk bersedia ataupun tidak bersedia berpartisipasi. Jika 
Bapak/Ibu bersedia berpartisipasi, silakan menandatangani lembar persetujuan di bawah ini, dan melengkapi 
kuesioner yang terlampir. Pengisian kuesioner ini akan memerlukan waktu sekitar 15 menit.  
Besar harapan kami bahwa Bapak/Ibu akan turut berpartisipasi, karena jawaban Bapak/Ibu akan menjadi masukan 
bagi apoteker di apotek dalam membantu menangani penyakit Diabetes Anda. Jenis layanan diabetes tergantung 
pada kebutuhan masing-masing Bapak/Ibu, sehingga sangatlah penting untuk menjawab apa adanya. Semua 
jawaban akan dirahasiakan. Jawaban Bapak/Ibu akan digabungkan dengan jawaban responden lain, dan identitas 
Bapak/Ibu tidak akan diketahui dalam laporan penelitian ini. Jika Bapak/Ibu mempunyai pertanyaan, silakan 
menghubungi apoteker di apotek ini atau peneliti: 
Ms. Yosi Wibowo      Professor Jeff Hughes 
PhD student, School of Pharmacy, Curtin University         Professor Bruce Sunderland 
Apoteker, Pusat Informasi Obat dan Layanan Kefarmasian,   Supervisors, School of Pharmacy, Curtin University 
Universitas Surabaya      Telepon : +61 8 9266 7369 
Telepon : 031-2981170      Email :  J.D.Hughes@curtin.edu.au  
Email : yosi.wibowo@postgrad.curtin.edu.au       B.Sunderland@curtin.edu.au  
   
       
 
Terima Kasih atas Partisipasi Bapak/Ibu 
 
Penelitian ini telah mendapat persetujuan dari Curtin University Human Research Ethics Committee (No. PH-09-011). Komite ini terdiri dari anggota 
masyarakat, akademisi, pengacara, dokter dan pemuka agama. Tugas utamanya adalah memberikan perlindungan bagi responden. Jika diperlukan 
verifikasi,  Bapak/Ibu dapat mengirimkan surat ke Curtin University Human Research Ethics Committee, c/- Office of Research and Development, Curtin 
University, GPO Box U1987, Perth, 6845 atau menelepon ke +61 8 9266 2784 atau mengirimkan email ke hrec@curtin.edu.au. 
Lembar Persetujuan 
Saya menyetujui pengambilan dan penggunaan data pada kuesioner terlampir setelah memahami karakteristik 
penelitian sebagaimana dijelaskan di atas. Saya memahami bahwa seluruh data akan dirahasiakan, dan identitas 
responden tidak akan diketahui dalam laporan penelitian ini.  
Tanda tangan : _____________________ 
Nama   : _____________________ 
Alamat  : _____________________      Tanggal  : __ - __ - 2011 
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1. Mohon dicentang (). Jenis Kelamin Bapak/Ibu: 
 Pria 
 Wanita 
 
2. Tahun kelahiran Bapak/Ibu:         
 
3. Mohon dicentang (). Etnis Bapak/Ibu: 
 Asia  
 Lainnya (mohon disebutkan): ______________ 
 
4. Mohon dicentang (). Tingkat pendidikan terakhir Bapak/Ibu: 
 Tidak sekolah 
 lulus SD 
 lulus SMP/sederajat  
 lulus SMA/sederajat 
 lulus Diploma/Akademi 
 lulus Sarjana (S1) 
 lulus Pasca-sarjana (S2/S3)  
 
5. Mohon dicentang (). Status pekerjaan Bapak/Ibu saat ini: 
 Bekerja penuh-waktu (40 jam atau lebih per minggu) 
 Bekerja paruh-waktu (kurang dari 40 jam per minggu) 
 Tidak bekerja 
 Lainnya (mohon disebutkan):________________ 
 
6. Mohon dicentang (). Pendapatan rumah tangga Bapak/Ibu (yaitu: total gaji suami-istri dan sumber penghasilan 
lain) per bulan: 
 Tidak lebih dari Rp. 2 juta 
 > Rp. 2 juta – 5 juta 
 > Rp. 5 juta – 10 juta  
 Lebih dari Rp. 10 juta 
 
7. Mohon dicentang (). Bentuk asuransi kesehatan yang Bapak/Ibu miliki saat ini:  
 Asuransi kesehatan yang seluruhnya dibayar sendiri oleh Bapak/Ibu atau keluarga 
 Asuransi kesehatan yang sebagian atau seluruhnya dibayarkan oleh perusahaan/institusi 
 Saya tidak memiliki asuransi kesehatan, tetapi saya dapat memperoleh Jaminan kesehatan untuk rakyat miskin 
(Jamkesmas atau yang sejenis) 
 Saya tidak memiliki asuransi kesehatan apapun 
 
8. Apakah Bapak/Ibu menjadi anggota perkumpulan diabetes (diabetes club)? Mohon dicentang (). 
 Ya 
 Tidak 
1 9   
DATA RESPONDEN 
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LAYANAN DIABETES 
9. Seberapa puas Bapak/Ibu terhadap layanan di APOTEK (yang paling sering dikunjungi) dalam membantu menangani 
Diabetes Anda? 
 Sangat puas 
 Puas 
 Cukup puas 
 Agak puas 
 Tidak puas   
10. Dengan memikirkan saat Bapak/Ibu mengunjungi APOTEK, mohon diberikan jawaban pada Bagian (I) dan  (II). 
 
(I) 
Apakah Anda  
PERNAH 
MENDAPATKAN 
layanan di bawah ini : 
(Lingkari satu jawaban) 
 
(II) 
Apakah menurut Anda (dalam 
rangka menangani Diabetes Anda),  
APOTEK SEHARUSNYA 
MENGADAKAN layanan di bawah ini: 
 (Lingkari satu angka) 
Tidak perlu 
diadakan 
Harus 
diadakan 
A. PEMBERIAN OBAT   
Apotek menyiapkan dan menyerahkan obat Ya             Tidak 1          2         3         4         5         6 
Apotek memberikan label tentang cara minum obat 
(misalnya: label  tertulis ’sehari 3x1 tablet’) Ya             Tidak 1          2         3         4         5         6 
B. EDUKASI   
Apotek memberikan penjelasan (secara lisan atau tulisan) berupa:   
• Informasi tentang apa itu penyakit diabetes Ya             Tidak 1          2         3         4         5         6 
• Informasi tentang target hasil pengobatan  
(misalnya: kadar gula darah yang seharusnya)  
Ya             Tidak 1          2         3         4         5         6 
• informasi tentang obat untuk diabetes:   
-  cara minum obat  Ya             Tidak 1          2         3         4         5         6 
-  cara pakai alat  untuk pemberian insulin  Ya             Tidak 1          2         3         4         5         6 
- cara penyimpanan obat Ya             Tidak 1          2         3         4         5         6 
-  hal yang perlu diperhatikan saat menggunakan obat  
(misalnya:  obat ini harus diminum dengan atau segera setelah 
makan untuk menghindari risiko gula darah rendah) 
Ya             Tidak 1          2         3         4         5         6 
-  efek samping obat yang umum/penting  
(misalnya: setelah minum obat  ini dapat menyebabkan mual) Ya             Tidak 1          2         3         4         5         6 
• Informasi bagaimana berolahraga secara tepat Ya             Tidak 1          2         3         4         5         6 
• Informasi bagaimana menjalankan pola makan sehat Ya             Tidak 1          2         3         4         5         6 
• Informasi bagaimana memeriksa gula darah sendiri 
(misalnya: cara penggunaan alat tes gula darah, dan arti hasil tes) Ya             Tidak 1          2         3         4         5         6 
• Informasi cara mencegah/mengobati kondisi darurat 
(misalnya: cara menangani  gula darah rendah)  Ya             Tidak 1          2         3         4         5         6 
• Informasi cara mencegah/mengobati komplikasi diabetes 
(misalnya: cara mencegah penyakit jantung) 
Ya             Tidak 1          2         3         4         5         6 
• Informasi agar melakukan pemeriksaan komplikasi (seperti: 
pemeriksaan jantung, ginjal, mata dan kaki) secara teratur  
Ya             Tidak 1          2         3         4         5         6 
• Informasi bagaimana merawat kaki sendiri  
(misalnya: merapikan kuku, memeriksa adanya luka di kaki ) 
Ya             Tidak 1          2         3         4         5         6 
• Informasi cara penghentian merokok Ya             Tidak 1          2         3         4         5         6 
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No.10 (lanjutan) (I) 
Apakah Anda 
PERNAH 
MENDAPATKAN 
layanan di bawah ini: 
(Lingkari satu jawaban) 
(II) 
Apakah menurut Anda (dalam 
rangka menangani Diabetes Anda),  
APOTEK SEHARUSNYA  
MENGADAKAN layanan di bawah ini: 
(Lingkari satu angka) 
Tidak perlu  
diadakan 
Harus 
diadakan 
C. PEMANTAUAN   
Apotek memantau kepatuhan dengan:   
• Menanyakan apakah obat untuk diabetes diminum teratur   Ya             Tidak 1          2         3         4         5         6 
• Menanyakan apakah telah mengikuti program olahraga Ya             Tidak 1          2         3         4         5         6 
• Menanyakan apakah telah mengikuti pengaturan pola makan Ya             Tidak 1          2         3         4         5         6 
• Menanyakan apakah telah mengikuti program untuk 
mencegah/mengobati komplikasi diabetes 
(misalnya: apakah telah minum obat kolesterol secara teratur?) 
Ya             Tidak 1          2         3         4         5         6 
• Menanyakan apakah pemeriksaan komplikasi (seperti: 
pemeriksaan jantung, ginjal, mata dan kaki) dilakukan teratur Ya             Tidak 1          2         3         4         5         6 
Apotek memantau target hasil pengobatan dengan:   
• Memeriksa gula darah Anda Ya             Tidak 1          2         3         4         5         6 
• Mengukur berat badan Anda  Ya             Tidak 1          2         3         4         5         6 
• Mengukur tekanan darah Anda  Ya             Tidak 1          2         3         4         5         6 
• Melihat catatan hasil 'pemeriksaan gula darah yang  Anda 
lakukan’ 
Ya             Tidak 1          2         3         4         5         6 
• Melihat hasil tes laboratorium Anda Ya             Tidak 1          2         3         4         5         6 
• Menanyakan adanya efek samping terkait pengobatan   Ya             Tidak 1          2         3         4         5         6 
Apotek merujuk Anda  (misalnya: ke dokter/spesialis) saat 
diperlukan Ya             Tidak 1          2         3         4         5         6 
 
11. Menurut Bapak/Ibu, manakah LIMA layanan terpenting yang HARUS ADA di APOTEK untuk membantu menangani 
Diabetes Anda (dapat termasuk layanan yang tecantum pada Pertanyaan No. 9)?  
(Mohon disebutkan layanannya secara spesifik, misalnya: pemberian informasi mengenai cara minum  obat untuk diabetes) 
1 
2 
3 
4 
5 
 
12. Jika apotek menyediakan layanan konsultasi untuk membantu menangani Diabetes Bapak/Ibu, berapakah 
Bapak/Ibu bersedia membayar untuk layanan tersebut (selain biaya obat dan/atau alat tes)? Mohon dicentang (). 
 Tanpa dipungut biaya  
 Pembayaran kurang dari Rp 25.000 
  Rp. 25.000 – 50.000  
  Lebih dari Rp. 50.000 
 261 
 
RIWAYAT DIABETES  
13. Tahun dinyatakan (didiagnosis dokter) menderita Diabetes:   
 
14. Apakah saat ini Diabetes Bapak/Ibu diobati dengan:  
 (Centang  satu jawaban pada tiap baris) 
pengaturan pola makan?  Ya  Tidak 
program olahraga rutin?   Ya  Tidak 
obat yang ditelan (misalnya: tablet/kapsul)?  Ya  Tidak 
suntikan Insulin?  Ya  Tidak 
 
Jika saat ini menggunakan suntikan Insulin, apakah Bapak/Ibu telah menggunakannya sejak pengobatan diabetes 
Bapak/Ibu dimulai sampai sekarang?                  
 Ya   
 Tidak  
15. Apakah Bapak/Ibu pernah mendapatkan informasi mengenai diabetes? 
  Ya  
 Tidak 
 
Jika Ya, darimana mendapatkan informasi tersebut? 
(Centang  lebih dari satu jawaban jika perlu) 
 
 
 
16. Faktor kesehatan yang lain: 
Tinggi badan Bapak/Ibu:               ___________ cm  
Berat badan Bapak/Ibu:                ____________kg    
Apakah Bapak/Ibu merokok?                        Ya         Dulu merokok, tapi sudah berhenti           Tidak pernah merokok 
a) Apakah Bapak/Ibu memiliki kolesterol tinggi?   Ya  Tidak  Tidak tahu 
b) Apakah saat ini Bapak/Ibu minum obat untuk kolesterol tinggi?  Ya  Tidak  Tidak tahu 
a) Apakah Bapak/Ibu memiliki tekanan darah tinggi?   Ya  Tidak  Tidak tahu 
b) Apakah saat ini Bapak/Ibu minum obat untuk tekanan darah tinggi?      Ya  Tidak  Tidak tahu 
         
17. Apakah Bapak/Ibu menderita: 
 (Centang  satu jawaban pada tiap baris) 
penyakit jantung (yaitu: nyeri dada, serangan jantung, atau gagal jantung)?  Ya  Tidak  Tidak tahu 
gangguan pada mata (yaitu: penglihatan kabur yang tidak terbantu dengan 
pakai kaca mata, terdapat bercak-bercak yang menghalangi penglihatan, atau 
kehilangan penglihatan secara mendadak)? 
 Ya  Tidak  Tidak tahu 
gangguan pada kaki (yaitu: rasa panas/mati rasa/sering kesemutan)?  Ya  Tidak  Tidak tahu 
borok pada kaki?  Ya  Tidak  Tidak tahu 
gangguan ginjal?  Ya  Tidak  Tidak tahu 
    
 Tempat praktek dokter 
 Apotek 
 Televisi 
 Internet 
 Surat kabar 
 Lainnya (mohon disebutkan):______________ 
 262 
 
 
 
18. Dalam bulan lalu, berapa kali Bapak/Ibu mengalami gejala akibat gula darah tinggi, seperti: merasa kehausan, mulut 
dan kulit kering, peningkatan gula dalam urin, nafsu makan berkurang, mual, atau kelelahan? Mohon dicentang (). 
 Tidak pernah       
 1 – 3 kali          
 4 – 6 kali       
 6 – 12 kali 
 Lebih dari 12 kali 
 Tidak tahu 
 
19. Dalam bulan lalu, berapa kali Bapak/Ibu mengalami gejala akibat gula darah rendah, seperti: berkeringat dingin, 
lemas, gelisah, gemetar, merasa kelaparan, atau sakit kepala? Mohon dicentang (). 
 Tidak pernah       
 1 – 3 kali          
 4 – 6 kali       
 6 – 12 kali 
 Lebih dari 12 kali 
 Tidak tahu 
 
20. Dalam 1 tahun terakhir, berapa kali Bapak/Ibu mengalami gejala yang parah akibat gula darah rendah, seperti: 
pingsan atau memerlukan bantuan segera untuk mengatasinya? Mohon dicentang (). 
 Tidak pernah       
 1 – 3 kali          
 4 – 6 kali       
 6 – 12 kali 
 Lebih dari 12 kali 
 Tidak tahu 
 
21. Dalam minggu lalu, apakah Bapak/Ibu melakukan tes gula darah (yaitu: dengan mengambil darah dari jari)?  
(Jika anda sakit dalam minggu lalu, cobalah mengingat 7 hari terakhir saat anda TIDAK sakit)  
 Ya       
 Tidak 
 Jika Ya,  
a) Dalam minggu lalu, pada hari apa saja Anda melakukan tes gula darah?            
(Centang  lebih dari satu jawaban jika perlu) 
 
 
 
 
b) Pada hari-hari dimana Anda melakukan tes gula darah, rata-rata berapa kali per hari Anda melakukannya?  
_______kali               
 
 Senin 
 Selasa 
 Rabu 
 Kamis 
 Jumat 
 Sabtu 
 Minggu 
PEMANTAUAN DIABETES  
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Catatan: Yang dimaksud tenaga kesehatan dibawah ini adalah dokter, apoteker, perawat atau petugas 
laboratorium/fasilitas kesehatan 
 
22. Dalam 3 bulan terakhir, apakah tenaga kesehatan memeriksa: 
 (Centang  satu jawaban pada tiap baris) 
gula darah Anda?  Ya  Tidak  Tidak tahu 
tekanan darah Anda?  Ya  Tidak  Tidak tahu 
berat badan Anda?  Ya  Tidak  Tidak tahu 
 
23. Dalam 1 tahun terakhir, apakah tenaga kesehatan memeriksa:  
 (Centang  satu jawaban pada tiap baris) 
kolesterol (yaitu: dengan mengambil sampel darah Anda untuk dites)?  Ya  Tidak  Tidak tahu 
ginjal  (yaitu: dengan mengambil sampel urin Anda untuk dites)?  Ya  Tidak  Tidak tahu 
mata (yaitu: dengan menetesi mata  Anda dengan suatu cairan yang dapat membuat 
pandangan kabur selama 1-2 jam)?  Ya  Tidak  Tidak tahu 
kaki (yaitu: dengan memeriksa adanya luka atau iritasi pada kaki Anda)?  Ya  Tidak  Tidak tahu 
 
24. Dalam 1 tahun terakhir, apakah tenaga kesehatan melakukan tes darah untuk memeriksa HbA1c Bapak/Ibu? 
(HbA1c adalah tes darah yang dilakukan untuk melihat rata-rata kadar gula selama 2-3 bulan terakhir. Tes ini hanya dapat dilakukan di laboratorium, rumah 
sakit atau tempat praktek dokter; ini BUKANLAH tes yang dapat dilakukan sendiri di rumah).  
 Ya     
 Tidak          
 Tidak tahu 
Jika Ya, 
a)  Berapa kali HbA1c Anda diperiksa dalam 1 tahun terakhir? 
(Centang  satu jawaban) 
 
 
 
b) Berapa nilai HbA1c Anda pada pemeriksaan terakhir? 
 (Centang  satu jawaban) 
 
 
 
 
TERIMA KASIH UNTUK WAKTU DAN PARTISIPASI BAPAK/IBU 
 1 kali 
 2 – 4 kali 
 Lebih dari 4 kali 
 Tidak tahu 
 Kurang dari 6,5%        
 6,5 – 8%                      
 Lebih dari 8% 
 Tidak tahu 
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Appendix 7     
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versions) 
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PARTICIPANT INFORMATION SHEET 
 
You are invited to participate in a study exploring pharmacy-based services for type-2 
diabetes patients in Indonesian setting.  This study is being conducted by Curtin University’s 
School of Pharmacy with the approval from the Indonesian Pharmacist Association – 
Surabaya (No. 001/SK/BPD-IAI/SURABAYA/2010).  
 
 
What is the purpose of the study?  
The purpose of the study is:  
1. To explore the current practice of doctors and pharmacists with respect to the 
management of type 2 diabetes in primary care. 
2. To explore doctors’ and pharmacists’ expectations of community pharmacists’ 
professional responsibilities with respect to management of type 2 diabetes.  
 
When and where will the study take place?  
Data for the study will be collected through your participation in an interview arranged at a 
time and place that suits your convenience.    
  
Who is being asked to take part and what will they do?  
We are interested in learning more about the current practice of diabetes care, and the 
potential role of community pharmacists in diabetes care. During the interview, you will be 
asked to describe your opinions on this topic. The interview will take one hour or less.  The 
interview will be tape-recorded to ensure the inclusion of all details.    
  
What are the risks and benefits of the study?  
Participation is voluntary. You are not required to answer any questions that you do not want 
to and participation or non-participation will not have any effect on your professional or 
personal life.  You have the right to withdraw from the study at any time with no adverse 
consequences.    
 
A potential benefit from your participation is the opportunity to air your views regarding the 
role of community pharmacists in diabetes care.  Your opinion will help shape the future 
development of the pharmacy profession as part of the diabetes team to deliver an integrated 
service.  
Study: Pharmacy-based Type 2 Diabetes Services 
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Is the study confidential?  
All of the data collected will be kept strictly confidential.  Your name will not be used at any 
stage of the research process. You will be given a unique study identifier code to ensure 
privacy, and the names of persons identified in interviews will be removed from the 
transcriptions. All data will be kept on a password-protected computer or a locked cabinet 
accessible only by the researchers. No information will be reported that would disclose any 
personal identity.  The final report may be submitted for publication in a peer-reviewed 
journal.    
 
Your participation is very important to the study and we hope that you will agree to take 
part.  Should you have any queries, please find our contact details are as follows: 
Ms. Yosi Wibowo       Professor Jeff Hughes 
PhD student, School of Pharmacy, Curtin University    Professor Bruce Sunderland 
Pharmacist, Pusat Informasi Obat & Layanan Kefarmasian   Supervisors, School of Pharmacy  
Universitas Surabaya        Curtin University 
Phone : 031- 298 1170      Phone : +61 8 9266 7369 
Email : yosi.wibowo@postrad.curtin.edu.au     Email : J.D.Hughes@curtin.edu.au 
              B.Sunderland@curtin.edu.au 
 
 
This study has been approved by the Curtin University Human Research Ethics Committee (Approval Number PH-03-12). 
The Committee is comprised of members of the public, academics, lawyers, doctors and pastoral carers. Its main role is to 
protect participants. If needed, verification of approval can be obtained either by writing to the Curtin University Human 
Research Ethics Committee, c/- Office of Research and Development, Curtin University, GPO Box U1987, Perth WA 6845 
or by telephoning +61 8 9266 2784 or by emailing hrec@curtin.edu.au 
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CONSENT FORM 
 
I have read the information sheet, I have had the nature of the study explained to me, and I 
agree to participate in the study described.  I understand that the interview will be tape-
recorded.  All questions have been answered to my satisfaction.    
  
I understand that any information I provide for the study will be kept confidential. All data 
will be securely stored. No information will be reported that would disclose any personal 
identity. 
  
I understand that my participation in this study is voluntary and that I have the right to 
withdraw at any time. 
 
 
 
Date: ____/____/____ (to be dated by participant)  
  
Signature of participant : ______________________ 
  
Name of participant  : ______________________  
  
  
Study: Pharmacy-based Type 2 Diabetes Services 
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LEMBAR INFORMASI UNTUK PARTISIPAN 
 
 
School of Pharmacy, Curtin University dengan persetujuan IAI Surabaya (001/SK/BPD-
IAI/SURABAYA/2010) meminta kesediaan Bapak/Ibu untuk berpartisipasi dalam penelitian 
mengenai layanan untuk pasien diabetes tipe 2 di apotek.  
 
 
Tujuan penelitian 
Penelitian ini bertujuan untuk: 
1. Mengetahui praktek layanan dokter dan apoteker untuk pasien diabetes tipe 2 rawat jalan 
2. Menggali harapan dokter dan apoteker terhadap peran apoteker di apotek dalam 
memberikan layanan diabetes tipe 2 rawat jalan 
 
Waktu dan tempat penelitian 
Pengumpulan data penelitian dilakukan melalui proses wawancara yang akan diatur pada 
waktu dan tempat yang disepakati. 
 
Target partisipan dan kewajiban partisipan 
Pada penelitian ini, kami tertarik untuk mengetahui praktek layanan diabetes yang ada saat 
ini, dan kemungkinan apoteker di apotek terlibat dalam layanan tersebut. Selama wawancara, 
Bapak/Ibu akan diajak berdiskusi mengenai topik ini. Wawancara akan berlangsung sekitar 1 
jam. Jalannya wawancara akan direkam supaya semua yang Bapak/Ibu katakan dapat tercatat 
dengan baik.  
 
Manfaat penelitian 
Dengan berpartisipasi dalam penelitian ini, Bapak/Ibu dapat menyuarakan pendapat 
Bapak/Ibu terkait peran apoteker  dalam layanan diabetes. Masukan ini bermanfaat untuk 
menentukan arah perkembangan profesi apoteker - sebagai bagian dari tim kesehatan - dalam 
memberikan layanan diabetes yang terintegrasi. 
Kami berharap Bapak/Ibu secara sukarela berpartisipasi dalam penelitian ini. Bapak/Ibu 
bebas menarik diri kapan saja tanpa dampak apapun.  
 
 
 
Layanan Diabetes Tipe 2 di Apotek 
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Kerahasiaan 
Semua informasi yang diperoleh akan dijaga kerahasiaannya. Identitas Bapak/Ibu tidak akan 
diketahui dalam proses penelitian ini, sebagai gantinya akan diberikan suatu kode 
identifikasi. Semua data akan disimpan dalam komputer yang ber-password atau dalam laci 
terkunci yang hanya dapat diakses oleh peneliti. Semua laporan terkait penelitian ini tidak  
akan mencantumkan identitas Bapak/Ibu.  
 
Besar harapan kami bahwa Bapak/Ibu bersedia berpartisipasi. Jika Bapak/Ibu mempunyai 
pertanyaan, silakan menghubungi peneliti: 
Ms. Yosi Wibowo       Professor Jeff Hughes 
PhD student, School of Pharmacy, Curtin University    Professor Bruce Sunderland 
Pharmacist, Pusat Informasi Obat & Layanan Kefarmasian   Supervisors, School of Pharmacy  
Universitas Surabaya        Curtin University 
Phone : 031- 298 1170      Phone : +61 8 9266 7369 
Email : yosi.wibowo@postrad.curtin.edu.au     Email : J.D.Hughes@curtin.edu.au 
              B.Sunderland@curtin.edu.au 
 
Penelitian ini telah disetujui oleh Curtin University Human Research Ethics Committee (No. PH-09-011). Komite ini terdiri 
dari anggota masyarakat, akademisi, pengacara, dokter dan pemuka agama. Tugas utamanya adalah memberikan 
perlindungan bagi responden. Jika diperlukan verifikasi,  Bapak/Ibu dapat mengirimkan surat ke Curtin University Human 
Research Ethics Committee, c/- Office of Research and Development, Curtin University, GPO Box U1987, Perth, 6845, atau 
menelepon ke +61 8 9266 2784, atau mengirimkan email ke hrec@curtin.edu.au. 
  270 
 
 
LEMBAR PERSETUJUAN 
 
 
Saya menyetujui untuk berpartisipasi dalam penelitian ini, setelah membaca lembar 
informasi dan memahami karakteristik penelitian ini. Saya memahami bahwa proses 
wawancara akan direkam. Semua pertanyaan saya terkait penelitian ini telah dijawab dengan 
memuaskan. 
Saya juga memahami bahwa seluruh data akan dijaga kerahasiaannya, dan disimpan di 
tempat yang aman. Laporan terkait penelitian ini tidak akan mencantumkan identitas pribadi. 
Saya memahami bahwa partisipasi saya bersifat sukarela, dan saya berhak mengundurkan 
diri kapanpun.  
 
 
Tanggal  : ____/____/____ (dilengkapi oleh partisipan) 
 
Tanda tangan partisipan : ______________________ 
  
Nama partisipan    : ______________________  
 
Layanan Diabetes Tipe 2 di Apotek 
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Appendix 8       
Demographic data form for the qualitative study 
 
 
 
Demograpic Data – Community Pharmacist 
 
 
Interview No. : __________________ 
Date   : ____/_____/________ 
Location  : ______________________________________________ 
Interviewer  : ___________________ 
 
 
Interviewee  :  ___________________ 
Pharmacy   : ___________________ 
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Respondent details 
Gender  : __________________________ 
Age  : __________________________ 
Position : ___________________________ 
Years of work experience: _____________________________ 
 
Pharmacy characteristics 
Setting 
- Location   : ______________________________ 
- Within doctor clinic   : Yes / No 
- Private counselling area/room : Yes / No 
Ownership : ______________________________ 
Opening hours 
Monday Tuesday Wednesday Thursday Friday Saturday Sunday 
       
 
Staffing 
Pharmacy Staff Working hours 
Pharmacist manager  
Pharmacist A  
Pharmacist B  
  
  
  
 
Total no. of customers: ______________________/month 
No. of customers dispensed oral antidiabetic medications: ____________________/month 
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Demograpic Data – Doctor 
 
 
 
Interview No.  : __________________ 
Date   : ____/_____/________ 
Location  : ______________________________________________ 
Interviewer  : ___________________ 
 
 
Interviewee  :  ___________________ 
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Respondent details 
Gender   : __________________________ 
Age   : __________________________ 
Level   : __________________________ 
Years of work experience : __________________________ 
 
Clinic characteristics 
Setting 
- Location : ____________________________ 
- With on-site pharmacy :  Yes / No 
- Others  :  _______________________________ 
 
Opening hours 
Monday Tuesday Wednesday Thursday Friday Saturday Sunday 
       
 
Staffing 
Clinic staff Working hours 
  
  
  
  
  
 
No. of type 2 diabetes patients: __________________/month 
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Appendix 9       
Interview guides for the qualitative study 
 
 
Interview Guide – Community Pharmacist 
 
 
Opening 
 
The marked increase of type 2 diabetes patients in Indonesia will place pressure on health 
care workers to ensure optimal diabetes management. In this situation, there is a need to 
make better use of health care resources in the community, including community 
pharmacies. 
 
 
Current practice (process of services) 
 
1. WHAT- When a patient with type -2 diabetes visits your pharmacy, please describe 
services provided. 
 
• Probe/challenge them on each point in the generic model of care, starting with:  
o Treatment administration 
o Education/counselling 
o Initial assessment (provide the definition) 
o Treatment plan (provide the definition) 
o Monitoring/review (provide the definition) 
• PROBE: Patients is newly diagnosed or has longstanding disease – vary? 
• PROBE: Patient with and without insurance – differences?  
 
 
2. HOW - For each service, could you tell me how you run it (details of the process)?  
 
• PROBE: personnel and resources  
 (If there is any documents (e.g. reports, protocols, etc.), ask permission to review it) 
 
 
3. What has been your overall experience when providing the service? 
 
• PROBE: Barriers/facilitators – is there any difficulty/driving force in providing the 
service?  
• PROBE: Customer feedback 
• PROBE: Charges 
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Views on community pharmacists’ roles 
 
The marked increase of type 2 diabetes patients will place pressure on health care workers to 
ensure optimal diabetes management. This provides challenges to pharmacy profession to be 
actively involved in the diabetes team.  
 
 
4. What do you think that community pharmacists SHOULD do for type-2 diabetes 
patients? 
 
• Probe/challenge them on each point in the generic model of care 
o Treatment administration 
o Education/counselling 
o Initial assessment  
o Treatment plan 
o Monitoring /review 
• (If they mention services beyond dispensing) PROBE: Why do you think this service 
is important? 
• (If they mention no services should be provided - except for dispensing medications) 
PROBE: what things made you think that community pharmacists should only do 
dispensing? 
• (If the services mentioned haven’t done – check point 2) PROBE: Barriers – what 
things made it difficult for you to provide the services? 
 
 
In Closing  
 
5. Our project is about the role of community pharmacists with respect to diabetes care.  
Does anything else come to mind that I haven’t asked you about?  
 
 
THANK YOU FOR YOUR PARTICIPATION 
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 Interview Guide – Doctor 
 
 
Opening 
 
The marked increase of type 2 diabetes patients in Indonesia will place pressure on health 
care workers to ensure optimal diabetes management. In this situation, there is a need to 
make better use of health care resources. 
 
 
Current practice (process of services) 
 
1. WHAT - When a patient with type -2 diabetes visits your clinic, please describe a typical 
consultation/assessment provided. 
 
• Probe/challenge them on each point in the generic model of care 
o Initial assessment  
o Treatment plan 
o Education/counselling 
o Monitoring/review 
• PROBE: Patient is newly diagnosed or has longstanding disease -vary? 
• PROBE: Patient with and without insurance – differences?  
 
 
2. HOW - For each service, could you tell me how you run it (details of the process)?  
 
• PROBE: personnel and resources  
(If there is any documents (e.g. reports, protocols, etc.), ask permission to review it) 
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Views on community pharmacists’ roles 
  
The marked increase of type 2 diabetes patients in Indonesia will place pressure on health 
care workers to ensure optimal diabetes management. In this situation, there is a need to 
make better use of health care resources in the community. In other countries such as 
Australia, community pharmacists have a more active role within diabetes team, such as: 
repeat medications (i.e. doctors prescribe medications that allow patients to refill their 
medication for certain times where pharmacists ensure their diabetes control), patient 
education/counselling, and monitoring (e.g. blood glucose level, blood pressure, weight).  
 
 
3. What would you like community pharmacists to do in helping your type-2 diabetes 
patients? 
 
• Probe/challenge them on each point in the generic model of care, starting with:  
o Treatment Administration (how about repeat medications?) 
o Education/Counselling 
Then: 
o Assessment (provide examples) 
o Treatment Plan (provide examples) 
o Monitoring/review (provide examples) 
•   (If they mention some extended services) PROBE: Why do you think this service is 
important to be provided in the pharmacy? 
• (If they mention no services should be provided - except for dispensing medications) 
PROBE: what things made you think that community pharmacists should only do 
dispensing? 
• (We previously did surveys among patients and pharmacists, and we found areas 
other than dispensing that pharmacists could be involved, such as monitoring, and 
counselling) PROBE: What do you think about that? 
 
 
In Closing  
 
4. Our project is about the role of community pharmacists with respect to diabetes care.  
Does anything else come to mind that I haven’t asked you about?  
 
 
 
 
THANK YOU FOR YOUR PARTICIPATION 
